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SUMMARY 
 
The aim of this research was to investigate the effect of novel cytokine antagonists, 
tumour necrosis factor-alpha antagonist (Etanercept) and interleukin-1 antagonist 
(Anakinra), and interleukin-10 anti-inflammatory cytokine on the inflammatory 
response at the site of peripheral nerve injury, in order to establish their potential 
contribution on nerve regeneration and determine their potential effect on the reduction 
or prevention of neuropathic pain.   
The outcome measures of functional nerve recovery were assessed using a 
combination of electrophysiology to determine the rate of axon regeneration, 
immunohistochemistry to study immune cell immunoreactivity and their related pain 
markers expression, and analysis of gait coordination to determine nerve function.  In 
addition, axonal tracing was used to quantity regenerated nerve fibres following nerve 
conduit repair.  The results showed that the peripheral application of interleukin-1 
antagonist and combination treatment of interleukin-10 and tumour necrosis factor-
alpha antagonist at the time of nerve repair was significantly effective in 
downregulating macrophage immunoreactivity at the site of nerve injury and repair. 
Application also decreased expression of GFAP and IBA-1 positive glial cells in the 
spinal cord.  Results showed that interleukin-1 antagonist or tumour necrosis factor-
alpha antagonist, as single therapies did not appear to significantly improve the 
regenerative potential of injured axons after nerve repair.  However, application of a 
combined therapy of tumour necrosis factor-alpha antagonist and interleukin-10 
greatly improved recovery, possibly due to reduced immune response and scar tissue 
formation.  Following poly-caprolactone nerve conduit repair, axonal tracing revealed 
that regenerating axons took a more uniform path in the regeneration process, 
following treatment with tumour necrosis factor-alpha antagonist, when compared with 
the sterile water treatment, where many axons displayed a disorganized pattern of 
regeneration.  However, no significant difference in nerve function recovery was 
observed between the two groups.  The findings contained in this work provide new 
insights into the role of inflammatory cytokines on functional nerve recovery and the 
development of neuropathic pain after peripheral nerve injury. These agents 
demonstrate potential as therapeutic strategies for the treatment of peripheral nerve 
injures. 
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1.1 Introduction 
Injury to the peripheral nerves is a major health problem worldwide (Kouyoumdjian, 
2006).  It is associated with significant functional loss as a result of sensory and/ or 
motor impairment (Fawcett and Keynes, 1990; Wojtkiewicz et al., 2015). These injuries 
can also lead to the development of neuropathic pain. Common aetiologies of 
peripheral nerve damage include; penetrating injury, crush, stretch or ischaemic 
injuries (Campbell, 2008).  Development of neuropathic pain following a nerve injury 
may also have social consequences and cause longstanding disability (Wojtkiewicz et 
al., 2015).  The incidence of peripheral nerve injury is estimated as 300,000 persons 
per year in the developed countries (Mohanna et al., 2003).  According to the Health 
and Social Care Information Centre of England, 72783 operations involving release 
and/ or repair of different peripheral nerves were reported in March 2015 (Health 
episode statistics for England, 2014 and 2015). 
The functional recovery of injured neuronal axons is dependent on the type of injury, 
site, and distance over which the axons must regenerate to cross the gap between the 
nerve segments (Rodríguez et al., 2004).  The understanding of the complex 
sequence of events that commences within the axons in response to peripheral nerve 
injury has increased significantly, promoting the clinician with knowledge of the role of 
neurobiology to enhance axonal regeneration after repair.  The response of peripheral 
nerves to traumatic injury starts with degradation of the myelin sheath within the distal 
segment.  This is followed by axonal regeneration at the proximal segment (Navarro 
et al., 2007).  Sometimes the proximal segment continues to regrow resulting in a 
disorganized mass composed of neuronal fibres and fibrous connective tissue which 
is typically known as a traumatic neuroma.  These neuromas are often associated with 
paraesthesia or chronic neuropathic pain (Foltán et al., 2008). 
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Despite the potential capability of peripheral nerves to regenerate, the functional 
outcome is often poor because of the formation of scar tissue in the injured nerve, 
which impedes the growth of regenerated nerve even after meticulous repair (Atkins 
et al., 2007). 
Over the past hundred years, the outcome following the management of peripheral 
nerve injury has been of concern, and significant research has been undertaken into 
the repair methods to improve functional recovery, and attenuate the development of 
neuropathic pain.  Several techniques exist within the literature to repair injured 
peripheral nerves.  These techniques include; direct anastomosis of the cut ends with 
sutures, or by the use of nerve grafting materials to bridge the gap distance between 
the segments (Navarro et al., 2007).  Despite these advances in surgical repair the 
outcome is often unpredictable and many patients are left with permanent disability.  
There are several factors such as age, length of the gap, and time of repair which may 
influence the outcome after nerve repair.  Therefore, future modification in surgical 
repair solely, is unlikely to considerably improve the outcome after peripheral nerve 
injury and the return to normal function.   
At present, there is invaluable data and ongoing research focusing on the modulation 
of neurobiology during neuronal regeneration.  The investigations in this thesis were 
undertaken to elucidate the effect of cytokines or their antagonists on neuronal 
regeneration and the potential development of neuropathic pain (Atkins et al., 2007; 
Ngeow et al., 2011).   
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1.2 Biological features of the spinal nerves, cranial nerves and the spinal cord 
In response to nerve injury, a cascade of events happens in the central and peripheral 
nervous systems which affects nerve regeneration and recovery.  Therefore, to 
increase the understanding and clarity of this thesis the biological features of the spinal 
nerves, spinal cord, glial cells and the cranial nerves will be briefly described in this 
section. 
1.2.1 The functional unit of the nervous system 
The neurone is the basic cellular and functional unit of the nervous system (Fitzgerald 
et al., 2012).  The neurone is responsible for the transmission and conduction of 
electrical changes as nerve impulses (Figure 1.1).  Neurones consist of an axon, and 
a single cell body (soma) (Crossman and Neary, 2015).  The axon is a protracted 
process of the neurone whose cell body (soma) is located in the dorsal root ganglion 
(DRG) and carries the impulses away from the soma to the axon end terminals (Kerns, 
2008).  The size of the cell body varies in location and function, and is found to 
correlate with length of the axon proportionally (Crossman and Neary, 2015).  The cell 
body exhibits short branching processes known as dendrites which conduct nerve 
impulses from adjacent nerve cells inward toward the cell body.  The components of 
the cytoplasm (axoplasm) of the neurone cell body are similar to most other cells and 
include a centrally located nucleus and other surrounding structures.  The Golgi 
apparatus and mitochondria are microscopically marked cellular organelles within the 
cell body.  Other distinctive cellular inclusions are known as Nissl bodies or substance 
which represents an endoplasmic reticulum and its related ribosomes (Crossman and 
Neary, 2015).  The axoplasm also contains intracellular organelles such as 
microtubules and neurofilaments which play an important part during the process of 
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nerve regeneration by promoting the axoplasmic transport mechanism (Topp and 
Boyd, 2012).   
A synapse is the site of communication between terminal axons of one neurone and 
dendrites of another (Crossman and Neary, 2015).  “There are synaptic connections 
between neurones in the central nervous system and in the autonomic ganglia, but not 
in the DRG” (Kerns, 2008).  Transmission of information or electrical changes are 
processed by the release of specific chemical mediators from the presynaptic 
membrane of the nerve cell, which then act on postsynaptic membrane receptors 
(Crossman and Neary, 2015). 
Most peripheral nerve axons are myelinated and surrounded by a concentric myelin 
sheath layer, produced by a Schwann cell (Kerns, 2008).  The thickness of the myelin 
sheath is directly related to the axon diameter.  The span of axonal membrane that is 
covered by each Schwann cell is called an internode (Topp and Boyd, 2012).  These 
sheath layers are lipid rich plasma membranes and confer increased rates of 
transmission and conduction of nerve impulses.  The space between the Schwann 
cells is known as node of Ranvier, where ion channels are present, and are 
responsible for continuous propagation of electrical impulses at the subsequent node 
of Ranvier (Kerns, 2008; Topp and Boyd, 2012). 
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Figure 1.1:  Diagram illustrates the anatomy of the neurone cell.  
(Figure reproduced with permission from John Wiley and Sons and 
Copyright Clearance Centre). 
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1.2.2 Anatomical and physiological features of the nerve cell 
Anatomical features of the nerve cell 
The peripheral nervous system is comprised of nerves and their root and branches, 
that allow communication with the brain and spinal cord, with the body parts, including 
the extremities, skeletal muscles and the viscera (Crossman and Neary, 2015).  These 
nerves branch out from the brain and spinal cord and are directed towards targeted 
receptor or effector cells.   
The nerve cell contains bundles of fibres; sensory, motor or mixed, which are 
surrounded by a specialized connective tissue layers; including the epineurium, 
endoneurium and perineurium (Figure 1.2).  Each bundle of nerve cell fibres is known 
as a fascicle.  Within a fascicle each single axon is surrounded by endoneurium 
connective tissue which contains fibroblasts their collagen fibres and extracellular 
matrix (Kerns, 2008).  A fascicle is surrounded by the perineurium.  The perineurium 
consist of multiple epithelial-like perineurial cell layers that encircle the nerve axons 
into fascicles which provide additional mechanical strength to the nerve trunk (Topp 
and Boyd, 2012).  In addition, this connective tissue layer acts as a diffusion barrier 
which prevents the passage of irritant substances to the exposed axons within the 
endoneurium (Flores et al., 2000; Kerns, 2008).  The epineurium encloses the 
fascicles together and represents approximately 50 % of the thickness of the 
peripheral nerves trunk (Flores et al., 2000).  This connective tissue layer protects and 
maintains continuity of the fascicles and their accompanying blood vessels (Flores et 
al., 2000).   
A peripheral nerve is infiltrated by a complex network of external and internal blood 
supply within the epineurium and the endoneurium connective tissue layer to ensure 
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uninterrupted blood flow along the course of the nerve trunk. The blood vessels are 
relatively permeable and capillaries exist only in the endoneurium (Flores et al., 2000). 
The capillaries form a continuous endoneurial-capillary pattern that possess tight 
junctions, regulating the endoneurial environment by maintaining the endoneurial fluid 
pressure at 2-3mmHg, which counter balances the endoneurial oncotic pressure (Topp 
and Boyd, 2012). 
Nerve fibres primarily come in three different diameters which reflects their conduction 
velocity, and target receptors (Osbourne, 2007).  Type A fibres and their subtypes (α, 
β, γ and δ) are heavily myelinated, the largest in diameter (up to 20 μm), and have the 
highest conduction rate of electrical impulses.  Type B fibres are less myelinated and 
have a diameter up to 3 μm, and these are autonomic fibres.  Type C fibres 
(nociceptive fibres) are unmyelinated and have the smallest diameter of all nerve fibres 
(less than 2 μm) (Osbourne, 2007). 
Myelination of the nerve fibres enhances the electrical impulse conduction during an 
action potential (Topp and Boyd, 2012).  In large myelinated nerve fibres the 
conduction velocity is fast in comparison to less myelinated fibres which conduct at a 
slower rate (Topp and Boyd, 2012).  Heavily myelinated fibres are associated with the 
transmission of motor and proprioceptive impulses whereas less myelinated and 
unmyelinated fibres convey sensory signals. 
Physiology of the nerve cell 
In the peripheral nervous system, the neurones create, amplify and propagate 
electrical impulses along their axon terminals These impulses are called action 
potentials (Topp and Boyd, 2012). 
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Figure 1.2: Diagram illustrates the organization of connective tissues 
surrounding nerve fibres. a) Fascicles surrounded by perineurium (p) 
which embedded in a loose connective tissue, the epineurium (epi) - the 
outer layers of the epineurium are condensed into a sheath. b) and c) 
illustrate the appearance of unmyelinated and myelinated fibres 
respectively. Schw: Schwann cell; my: myelin sheath; ax: axon; nR: node 
of Ranvier.  (Figure reproduced with permission from Elsevier and 
Copyright Clearance Centre). 
  
 
 
 
10 
 
 
An action potential in the nerve cell largely occurs in response to alterations in 
potassium and sodium ion gradients across the cell membrane in response to tissue 
damage or mechanical stimulation in the nociceptive fibres and proprioceptive fibres, 
respectively.  At rest the neurone’s cell body maintains its intracellular membrane 
potential at -70 mV by retaining higher concentration of potassium (K+) ions as 
opposed to low concentration of sodium ions (Na+) (Topp and Boyd, 2012).  During 
excitation, sodium channels open and allow an influx of Na+ ions to produce an action 
potential by raising the membrane potential to a threshold potential of -50 mV causing 
membrane depolarization.  Afterwards, previously opened sodium channels become 
inactive and potassium channels open to repolarize the membrane to its resting 
potential state and generate a new action potential at another site (Topp and Boyd, 
2012). 
In addition to the electric impulse conduction along the axons of peripheral nerves, 
there is also the continuous movement of intracellular organelles and neurotrophic 
substances that are crucial for neurone regeneration and growth.  This movement is 
known as bidirectional axoplasmic flow and may flow in a forward direction 
(anterograde) away from the cell body to the dendrites, using kinesin molecules 
(ATPase) (Topp and Boyd, 2012), or in a backward direction (retrograde), from the 
dendrites towards the cell body, utilizing dynein/dynactine complexs (Lloyd, 2012).  
The axon cytoskeleton is made up of microtubules, neurofilaments and microfilament 
proteins, play a role in axonal transport, and also movement of mediators and 
provision of neurotrophic factors is necessary for nerve cell survival (Lloyd, 2012).  
Disruption of the cytoskeletal proteins, necessary for axoplasmic transport, has a 
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detrimental effect on neurone cell integrity, this affecting the growth and maintenance 
of nerve fibres.  
1.2.3 The spinal nerves 
There are 31 pairs of spinal nerves that emerge from the dorsal and ventral spinal 
roots.  These nerves comprise motor and sensory nerve fibres to and from all parts of 
the body (Decosterd and Woolf, 2000; Köbbert and Thanos, 2000; Rigaud et al., 2008; 
Watson et al., 2009).  Spinal nerves exit the vertebral column through the intervertebral 
foramina.  Each spinal nerve comprises somatic and visceral fibres.  The 
somatosensory fibres are peripheral processes of the dorsal root ganglion (DRG) 
neurons that carry sensory information from the subcutaneous tissues, skin and joints. 
In addition, the somatomotor fibres are axons of ventral horn neurons which carry 
motor impulses to the skeletal muscles.  The visceral afferent fibres are composed of 
peripheral processes of DRG neurons which convey sensation from the visceral 
organs of the body.  
Of importance to this work, sciatic nerve will only be described in this section.  Equally, 
mouse and rat sciatic nerve was used as model of peripheral nerve injury in this 
research work.  Currently, the use of sciatic nerve as model of peripheral neuropathy 
is gaining a greater interest (Decosterd and Woolf, 2000; Köbbert and Thanos, 2000; 
Rigaud et al., 2008).  From anatomical point of view the sciatic nerve crosses lower 
limb at level of mid-thigh and carry mixed nerve fibres (sensory, somatic a and 
autonomic motor fibres) that originates from the lumbar segments at regions 4-6 of the 
spinal cord and its associated DRG cells (Figure 1.3).  Although, several injury models 
were descried, sciatic nerve transection model is considered reliable due to its 
relevance to human peripheral neuropathy (Decosterd and Woolf, 2000; Köbbert and 
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Thanos, 2000; Rigaud et al., 2008).  In addition, other important factors that were 
considered for the selection of sciatic nerve because of its larges size and relative 
ease of access which facilitate the nerve dissection and exposure.   Moreover, the 
mouse model offers some advantages which include availability of several transgenic 
stains, relative ease of handling, and cost-effectiveness in domiciliary care. 
 
 
  
Figure 1.3: Diagram of the sciatic nerve and corresponding dorsal root 
ganglions projection in the lumbar regions 4-6.  Figure reproduced with 
permission from Wolters Kluwer Health, Inc and Copyright Clearance 
Centre. 
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1.2.4 The spinal cord 
The spinal cord is an important structure that link the brain with the body which process 
the motor and sensory signals from the body to the brain (Watson et al., 2009).  The 
spinal cord divided into four regions; cervical, thoracic, lumbar and sacral, each of 
which is comprised of several segments.  Of importance to this work, Lumbar 
segment-4 (L4) of the spinal cord will only be described.  Transversely, L-4 region of 
the spinal cord resembles a “butterfly” shape and contains the white matter which 
surround the central gray matter where most of spinal neuronal cell bodies with 
sensory and motor neurons are located (Watson et al., 2009) (Figure 1.4).  The mid 
region of the butterfly represents intermediate gray commissure which crosses the 
midline below the white commissure.  The gray matter mainly contains the cell bodies 
of neurons and glia and is divided into four main horns; dorsal, lateral and ventral 
horns. The horns of gray matter divide the white matter into three columns (funiculi): 
dorsal, lateral and ventral (Watson et al., 2009).  The boundary between the lateral 
and ventral columns is not distinct. 
The dorsal horn is found at all spinal cord levels and contains the sensory nuclei that 
receive and process incoming somatosensory information toward the midbrain and 
diencephalon.  The intermediate and the lateral horns comprise autonomic neurons 
innervating visceral and pelvic organs (Watson et al., 2009).  The ventral horn 
comprises motor neurons that innervate skeletal muscle.  The ventral root axons join 
with the peripheral processes of DRG cells to form mixed afferent and efferent spinal 
nerves, which merge to form peripheral nerves.  A large group of axons that are in 
these areas called a funiculus.  Smaller bundles of axons, which share common 
features within a funiculus are called fasciculus (Watson et al., 2009).  
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Spinal gray matter reveals microscopic layers of nuclei that are distributed within the 
spinal cord which exhibits a pattern of lamination (Figure 1.5).  Cytoarchitecture of 
each lamina is composed of various sizes or shapes of neurons which is related the 
function of the corresponding nuclear groups (Watson et al., 2009).  Briefly, laminae I 
to IV are concerned with nociceptive sensation which comprise the dorsal horn, 
whereas laminae V and VI are concerned primarily with proprioceptive sensations. 
Lamina VII is equivalent to the intermediate zone and acts as a relay between muscle 
Figure 1.4: Transverse section of the spinal cord under light microscope 
illustrates anatomical organization of the Lumbar region (L4) of the spinal cord. 
DH: dorsal horn, GM: gray matter, IGC: intermediate gray commissure, LF: 
lateral funiculi, LH: lateral horn, VF: ventral funiculi, VH: ventral horn, WC: 
white commissure, WM: white matter, *: image background. 
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spindle to midbrain and cerebellum, and laminae VIII and IX comprise the ventral horn 
and contain mainly motor neurons that innervates skeletal muscle.  Lamina X 
surrounds the central canal and contains neuroglia cells (Watson et al., 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Diagram illustrates cytoarchitectonic organization of lamina in the 
spinal cord sections of lumbar region-4 in the rodents.  Lamina I: fine rim of 
posteromarginal nucleus of dorsal horn; Lamina II: substantia gelatinosa 
proper; Laminae III and IV: nucleus proprius; Lamina V: Neck of the dorsal 
horn; Lamina VI: Base of the dorsal horn; Lamina VII: intermediomedial 
nucleus Lamina VIII: motor interneurons; Lamina IX: mediolateral part of the 
ventral horn; motor neurons; IM: intermedio-medial nucleus; Liss: Lissauer's 
tract.  (Figure reproduced with permission from John Wiley and Sons and 
Copyright Clearance Centre).    
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The human spinal cord is a tubular structure that comprises a bundle of fibre that 
corresponds to the spinal dorsal and ventral nerve roots on each side (Decosterd and 
Woolf, 2000; Köbbert and Thanos, 2000; Rigaud et al., 2008; Watson et al., 2009).  
The dorsal root of a spinal nerve contains sensory fibres whereas, the ventral root 
which comprise the motor fibres.  Each dorsal root exhibit an ovoid swelling known as 
the dorsal root ganglion (DRG) located close to the junction of the dorsal and ventral 
roots.  The cells of DRG are primary sensory neurons being described as pseudo-
unipolar neurons with a single axon (Decosterd and Woolf, 2000; Köbbert and Thanos, 
2000; Rigaud et al., 2008; Watson et al., 2009).  The sympathetic fibres entering the 
DRG and regulate the sympathetic outflow to the corresponding DRG. It has been 
suggested that disruption of the DRG cells function resulting from peripheral nerve 
injury play important role in neuropathic pain development (Navarro et al., 2007). 
 
1.2.5 Glial cells 
In the central nervous system (CNS) glial cells is play supportive role by surrounding 
neurons and maintain haemostasis and provide insulation between them (De Bock et 
al., 1843; Aldskogius and Kozlova,1998; Kurosinski and Götz, 2002; Crossman and 
Neary, 2015) (Figure 1.6). Glial cells are the most abundant cell types in the central 
nervous system and spinal cord. There are three types of glial cells, namely, 
astrocytes, oligodendrocytes, and microglial cells. Following peripheral nerve injury 
microglia and astrocytes activation were considered to play a role in development of 
neuropathic pain (De Bock et al. 1843; Aldskogius and Kozlova,1998; Kurosinski and 
Götz, 2002; Crossman and Neary, 2015).    
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Astrocytes, represent 40-50 % of all glial cells which are restricted to synaptic 
terminals, have elaborate local processes that give these cells a star-like shape (De 
Bock et al., 1843; Aldskogius and Kozlova,1998; Kurosinski and Götz,2002; Crossman 
and Neary, 2015).  Their major function is to maintain neuron synaptic junction 
haemostasis that provide an appropriate chemical environment for neuronal signaling. 
In close association with neurons, astrocytes enwrap synaptic terminals and make 
extensive contacts with endothelial cells from the capillaries.  Moreover, astrocytes 
are interconnected with one another by gap junctions (De Bock et al., 1843; Aldskogius 
and Kozlova,1998; Kurosinski and Götz, 2002). 
Oligodendrocytes, which are also restricted to the central nervous system, lay down a 
laminated, lipid-rich wrapping called myelin around some, but not all, axons.  Myelin 
has important effects on the speed of action potential conduction (De Bock et al., 1843; 
Aldskogius and Kozlova,1998; Kurosinski and Götz, 2002). 
In the central nervous system, microglia are macrophage-like cells that serve a 
phagocytic function and primarily acts as scavenger cells that remove cellular debris 
in normal and pathological state.  Microglia make up about 5-10 % of the total glial cell 
in the CNS and spinal cord and primarily derived from resident microglia or 
macrophage infiltrates the injured area from the circulation (De Bock et al., 1843; 
Aldskogius and Kozlova,1998; Kurosinski and Götz, 2002; Crossman and Neary, 
2015). 
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Figure 1.6: Diagram illustrates Glial cells under physiologic make contacts with 
neurons and capillaries and exchanges nutrients between the blood supply 
and the active neuron.  Glial cells, astrocyte, regulate neuron haemostasis by 
encircling presynaptic and postsynaptic terminals which help integrate 
neurotransmitter inputs and release their own transmitters that act on adjacent 
neurons.  (Figure reproduced with Elsevier and Copyright Clearance Centre).    
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1.2.6 The cranial nerves  
Cranial nerves emerge directly from the anterior aspect of the brain stem and process 
different aspects of the body function that are important for daily activities such as 
motor functions including chewing and swallowing, and, in addition, responsible for 
sensation of the skin of face, teeth and intraoral mucous membranes (Craven, 2010; 
Crossman and Neary, 2015).  These functions are of great importance in relation to 
the dentistry and in providing care for patients with dental problems. 
There are 12 pairs of cranial nerves which leave the cranial cavity through foramina 
or fissures towards their intended target or tissues (Craven, 2010; Crossman and 
Neary, 2015) (Figure 1.7).  These nerves are designated in roman numbers as follows; 
I (olfactory), II (optic), III (oculomotor), IV (trochlear), V (trigeminal), VI (abducens), VII 
(facial), VIII (vestibulo-cochlear), IX (glossopharyngeal), X (vagus), XI (accessory) and 
XII (hypoglossal). The trigeminal nerve will only be described in relevance to this work. 
The trigeminal nerve (fifth cranial nerve) comprise three divisions; the ophthalmic, 
maxillary and mandibular. It is the largest cranial nerve, and made up of mixed nerve 
fibres, comprising sensory and motor fibres (Craven, 2010; Crossman and Neary, 
2015) (Figure 1.8). 
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Figure 1.7. Superficial origins of the cranial nerves (Figure reproduced with 
Elsevier and Copyright Clearance Centre).    
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The nerve emerges from the anterolateral aspect of the pons as two roots; sensory 
and motor root which crosses the upper border of the petrous temporal bone just 
lateral to the petrous apex, where they enter the middle cranial fossa and expands into 
the trigeminal ganglion from where the three divisions emerge (Craven, 2010; 
Crossman and Neary, 2015).  The ophthalmic nerve being the most medial while, the 
largest division, the mandibular nerve being the most lateral. The motor branch runs 
separately, beneath the ganglion, before joining the mandibular nerve within the 
foramen ovale.  The motor nerve fibres only present in the mandibular division 
Figure 1.8:  Illustration of the trigeminal nerve branches; ophthalmic, maxillary 
and mandibular nerve branches in face and mouth. 
22 
 
whereas, the ophthalmic or maxillary nerves are exclusively carries sensory fibres to 
the oral and facial region (Craven, 2010; Crossman and Neary, 2015). 
 
In the lateral wall of the cavernous sinus, the ophthalmic nerve gives three branches 
(frontal, lacrimal and nasociliary), all of which cross the superior orbital fissure to enter 
the orbit cavity (Craven, 2010; Crossman and Neary, 2015).  However, the maxillary 
nerve exit through the foramen rotundum to enter the pterygopalatine fossa and gives 
three branches (anterior, middle and posterior superior nerves).  Moreover, the 
sensory fibres of the maxillary nerve are distributed to the skin of the upper part of the 
face, the mucous lining of the nasal cavity and paranasal sinuses, the meninges within 
the cranial cavity, the anterior and lateral aspects of the scalp, the roots of all the 
maxillary and mandibular teeth and their gum (Craven, 2010; Crossman and Neary, 
2015). 
The mandibular nerve exit through the foramen ovale to enter the infratemporal fossa. 
The motor fibres in the mandibular nerve are distributed to the muscles of mastication, 
tensor tympani, mylohyoid and tensor veli palatine.  The sensory fibres of the 
mandibular nerve are distributed to the skin of the lower part of face, floor of the oral 
cavity including the anterior two-thirds of the tongue, the roots of all mandibular teeth, 
and their gum (Craven, 2010; Crossman and Neary, 2015). 
The terminal branches of the trigeminal nerve divisions are at greater risk of damage 
during various dental treatment or intraoral surgical procedures or as consequence to 
orofacial traumatic injuries.  Injuries to the trigeminal nerve branches usually present 
as loss or disturbance in taste and/or sensation (Craven, 2010; Crossman and Neary, 
2015). 
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1.3 Peripheral nerve injuries 
1.3.1 Epidemiology of peripheral nerve injuries 
A peripheral nerve injury is described as damage to the motor and sensory nerves that 
lie outside the brain or spinal cord (Navarro et al., 2007).  Peripheral nerves can be 
damaged by various mechanism such as neurodegenerative diseases, chemical 
toxins or mechanical trauma. Only nerve injuries caused by mechanical and iatrogenic 
trauma are considered here. 
 
1.3.1.1 Traumatic injury to peripheral nerves- aetiology, incidence and recovery 
in different extremities and nerves 
Peripheral nerve injury is a global problem and can result in significant disability and 
incapacity and affect general wellbeing (Eser et al., 2009; Wojtkiewicz et al., 2015).  
Peripheral nerve injuries encompass a large spectrum of neurological deficits and its 
symptoms can include weakness, altered sensation, loss of function and chronic pain 
(Martins et al., 2013).  “Neuropathic pain is characterized in humans by spontaneous 
pain, and/ or evoked pain resulting from hypersensitivity to normally painful stimuli 
(hyperalgesia) or non-painful stimuli (allodynia)” (Djouhri et al., 2012).    
The incidence and aetiological factors of traumatic peripheral nerve injuries reported 
in the literature are varied according to periods of peacetime or conflict (Martins et al., 
2013).  In general, most of the knowledge and experience about peripheral nerve 
injuries was developed during times of war (Seiler and Payne, 1999; Rodríguez et al., 
2004; Campbell, 2008).  The first report of the causalgia syndrome of the extremities 
was described in the American Civil War.  This syndrome characterized by a burning 
pain and sensation, was caused by partial nerve injury (Seiler and Payne, 1999; Evans, 
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2001).  The treatment approach of limb injuries at that time was based on the severity 
of the injury, where a simple suture was advocated for mild injury but amputation 
reserved for more severe injuries. 
During peacetime the incidence and the aetiological spectrum of peripheral nerve 
injuries reflects the country's development (Eser et al., 2009).  In developed countries, 
peripheral nerve injury frequently results from sports, occupational accidents and road 
traffic accidents (Robinson, 2000; Campbell, 2008).   
Peripheral nerve injuries may result in significant physical and psychological morbidity 
and economic burden if not managed efficiently, particularly in an individual of working 
age (Martins et al., 2013).  In spite of differences across the study population, there 
are consistent reports of a higher incidence of peripheral nerve injuries associated with 
the upper limbs (more than 70 %), and the most affected nerves are the ulnar, radial 
and brachial plexus (Robinson, 2000; Kouyoumdjian, 2006; Eser et al., 2009).  For 
lower limbs the most frequently injured peripheral nerves are the peroneal or sciatic 
nerves (Robinson, 2000; Kouyoumdjian, 2006; Eser et al., 2009; Ciaramitaro et al., 
2010).  
Nerves of the upper and lower extremities can be damaged in various ways, including 
nerve compression, laceration or complete transection (Dahlin, 2008; Campbell, 2008). 
In addition, stretch-related damage is the most common type of injury of peripheral 
nerves of upper and lower extremities, especially in motor vehicle accidents, whereas 
laceration by sharp objects represents about 30 % of severe nerve injuries.  
Compression related damage of the extremities, is another type of nerve injury which 
may involve structural deformation as well as ischemia (insufficient blood supply) 
(Campbell, 2008).  In general, compression related damage shows better regeneration 
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capacity than a transection injury due to the nature of the transection insult and the 
significant anatomical disruption of axons or nerve trunk (Seiler and Payne, 1999). 
Therefore, early management of these transection injuries can result in improved 
recovery, to some extent, of the lost function, and as a result, it is crucial the 
pathophysiological consequences of these injuries are understood in order to define 
an acceptable management strategy to improve the functional recovery of this 
disabling condition (Martins et al., 2013; Wojtkiewicz et al., 2015). 
1.3.1.2 Traumatic injury to cranial nerves- aetiology, incidence and recovery with 
different nerves  
Injury to the nerves of the jaws and face in relation to dentistry has only been 
appreciated in the last three centuries (Pogrel et al., 2011).  However, the 
consequences of damage to the peripheral branches of trigeminal nerve on patient 
wellbeing is well documented. 
The mechanism of recovery following trigeminal nerve injury is complex, in part due to 
it being the largest cranial sensory nerve, representing approximately 40 % of the 
sensory cortex of the human brain (Renton and Yilmaz, 2012).  The most commonly 
injured nerve branches are the inferior alveolar and lingual nerves.  The sensory 
dysfunction of these nerves is more likely to be permanent when the injury is severe 
and if there is delay between the time of injury and assessment of the patient (Renton 
and Yilmaz, 2012). 
It is well established that damage to the mandibular branch of the trigeminal nerve is 
amongst the most debilitating injuries in the field of oral surgery.  Altered sensation 
and pain in the oral and maxillofacial region may interfere with eating, drinking, 
speaking, tooth brushing, and shaving (Renton and Yilmaz, 2012).  Subsequently, 
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injury to the mandibular nerve, may lead to the patient experiencing a reduced quality 
of life, psychological distress, and social disabilities.   
1.3.1.3 Sequelae following different major surgical interventions- trauma, 
fractures, orthognathic surgery 
Damage to the mandibular nerve branches, the inferior-alveolar and lingual nerves, 
may also follow orthognathic surgery, as well as a result from maxillofacial traumatic 
injuries and/or their surgical interventions (Bagheri et al., 2009).   
Facial fractures often run in lines of weakness, which include sites in close 
approximation with nerve foraminae such as the mandibular parasymphysis and 
maxillary fracture sites (i.e., mental, infraorbital), or can cross the line of weakness, 
such as in the third molar region, directly involving the inferior-alveolar nerve trunk 
(Bagheri et al., 2009).  However, the precise mechanism of trigeminal nerve damage 
is often uncertain, and injury may result from nerve compression either by displaced 
bone fragments or soft tissue oedema, or from traction of a displaced fracture, and 
crushing, avulsion, or even partial or total nerve transection from fractured bone edges 
(Bagheri et al., 2009).  The overall prevalence of neurosensory disturbances 
associated with the inferior-alveolar nerve before surgical interventions in post-
traumatic injuries ranges from 46 % to 58.5 % for fracture lines involving the angle and 
body of the mandible (Bagheri et al., 2009).  However, exaggeration of pre-existing 
neurosensory disturbances is often observed after surgical repair especially in these 
fractures.  In the majority of cases, the sensory deficit is temporary, but sometimes it 
is persistent (7.7%) (Bagheri et al., 2009).  At the time of fracture repair, the nerve 
fibres may undergo further damage by additional traction and/or compression while 
the fracture sites are being reduced and stabilised.  Moreover, unintentional and 
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misapplication of surgical technique, such as placement of fixation screws near or 
through the mandibular canal can cause nerve injury (Bagheri et al., 2009). 
Facial deformity due to abnormal growth or discrepancies in jaw alignment is a well-
known concern among young adult patient across the world.  Corrections of 
discrepancies in jaw relationships involve either single or two jaw surgery.  The sagittal 
split ramus osteotomy is the operation of choice for correction of abnormalities in body 
and ramus of the mandible.  The procedure is versatile and reliable but neurosensory 
disturbances are common due to close approximation of osteotomy lines with lingual 
and inferior-alveolar nerves (Bagheri et al., 2010).  Majority of postoperative 
neurosensory disturbances reported are transient and resolve without need for 
intervention.  The incidence of persistent neurosensory disturbances of the inferior-
alveolar nerve after orthognathic surgery is approximately 12.8 % (Colella et al., 2007), 
whereas the reported incidence of lingual neurosensory dysfunction ranges from 9.3 % 
to 19.4 % (Bagheri et al., 2010).  Potential recovery of the inferior-alveolar sensory 
function has been documented to be improved within the first 3 months when 
compared to the lingual nerve and this may be due to natural protection offered by the 
mandibular bony canal (Bagheri et al., 2010). 
1.3.1.4 Sequelae following different minor surgical interventions- lower wisdom 
teeth removal, local anaesthesia injection injuries, implants and root canal 
treatment 
Injury to the peripheral branches of the trigeminal nerve can result from minor surgical 
procedure or even mandibular block anaesthesia in the oral and maxillofacial region 
(Bagheri et al., 2009).  The surgical removal of wisdom teeth (lower third molars) is a 
commonly performed procedures undertaken to treat pathology related to the 
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impacted teeth such as pericoronitis, caries, and odontogenic cysts (Renton and 
Yilmaz, 2012).  The overall complication rate relating neurosensory dysfunction of the 
lingual and inferior-alveolar nerves after lower third molar surgery varies widely from 
0.2 % –22 %, depending to a certain extent, on the surgical technique used (Robinson 
et al., 2000). 
Injury of inferior-alveolar nerve following endodontic treatment is rare complication but 
may lead to longstanding altered sensation which adversely affect the patient’s quality 
of life (Grötz et al.,1998; Rosen, 2014; Rosen,2017).  It has been suggested that the 
possible mechanism of injury of inferior-alveolar nerve when performing endodontic 
treatments occurs due to either mechanical compression, or chemical neurotoxicity 
following mechanical tooth preparation, and/or overextension of filling material and 
irrigants solutions into the mandibular nerve canal (Grötz et al.1998; Rosen, 2014; 
Rosen,2017).  Also, it been suggested that injury of inferior-alveolar nerve following 
endodontic surgical procedures is a rare but considered a serious complication due to 
direct injury to the nerve during surgery and may lead to long-term sensory disturbance 
(Grötz et al.1998; Rosen, 2014; Rosen,2017). 
Nerve injury following implant placement in the mandible especially posterior region is 
serious complications (Alhassani and AlGhamdi, 2010; Juodzbalys et al. 2013).  The 
prevalence of injury to the inferior-alveolar nerve (IAN) or the lingual nerve has been 
reported range between 3-40 % with an average of 13 % during dental implant 
placement or bone drilling (Alhassani and AlGhamdi, 2010; Juodzbalys et al., 2013). 
Other less frequent causes that has been reported such as flap retraction and 
compression of the mental nerve which could resulting in altered sensation of lower 
lip (Alhassani and AlGhamdi, 2010; Juodzbalys et al., 2013). 
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Trigeminal nerve injury also is a rare complication of regional anaesthesia especially 
in dentistry (Hillerup and Jensen, 2006).  As neurosensory dysfunction after 
mandibular nerve blocks are so uncommon, it is difficult to attain consistent figures 
about their incidence.  Furthermore, it is difficult to identify nerve injury that is caused 
by trauma to the nerve during injection when compared with those related to the 
neurotoxicity of the local anaesthetic solutions (Hillerup and Jensen, 2006). 
Local anaesthetic agents are the most commonly used drugs for pain control in clinical 
dentistry (Yapp et al., 2011).  It is commonly known that all local anaesthetic agents 
after injections are followed by complete recovery and return to normal nerve function 
and activity within a few hours.  Local anaesthetic agents, like other medicines, have 
the potential to be unsafe, with adverse effects that can range from mild dizziness to 
serious reactions such as cardiac and respiratory depression.  Amide local anaesthetic 
agents are commonly used in dentistry, and are considered as the safest local 
anaesthetic agent due to their rapid metabolism into inactive metabolites which in turn 
decreases the risk of systemic toxicity and over dosage (Yapp et al., 2011).  However, 
in relation to local effects a few studies have reported a persistent deficit in sensation 
(paraesthesia) when articaine has been used as opposed to lidocaine (Hogan, 2008; 
Haas, 2006; Hillerup and Jensen, 2006).  The estimated prevalence of temporary 
inferior-alveolar and lingual nerve neurosensory dysfunction after mandibular block 
anaesthesia ranged from 0.15–0.54 % whereas permanent impairment has been 
reported between 0.0001– 0.01 % in USA (Hillerup and Jensen, 2006).  In contrast to 
this observation other studies on articaine safety had compared articaine to other local 
anaesthetic (lidocaine) agents and have shown low numbers of adverse or toxic 
reactions associated with this agent.  Furthermore, there is much controversy about 
the mechanism or theories of persistent sensation deficit related to the site of injection.  
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Firstly, hydrostatic pressure from injection of the solution (Hogan, 2008), direct 
mechanical injury from the anaesthetic needle and lastly chemical injury from the local 
anaesthetic agent (Haas, 2006).  An investigation of possible mechanisms of chemical 
injury or neurotoxicity has been directly related to the duration as well as the increased 
concentrations of the local anaesthetic solutions (Hogan, 2008).  Furthermore, in an 
animal study model, different solution concentrations (2% versus 4%) of articaine 
injected into rat sciatic nerves resulted in a concentration dependent reduction of 
sciatic nerve conduction.  Whilst numbers of myelinated axons were not affected, 
myelin sheath thickness as well as the mean cross-sectional axonal area was 
significantly reduced (Hillerup et al., 2011). 
1.3.1.5 The effect of nerve injury on patient quality of life- peripheral and cranial 
nerves 
Injuries to peripheral and cranial nerves are of significance as they hinder recovery of 
normal daily functions and carry a high risk of the developing neuropathic pain.  Most 
of damage-induced pain is most probably related to severe nerve injuries (neurotmesis 
or axonotmesis), whilst neuropraxia as a result of peripheral nerve injury (Ciaramitaro 
et al., 2010).  These consequences of nerve injury have brought to the surgeon’s 
attention the need for a greater understanding of the patients' perception due to this 
damage, especially when they suffer permanent disability (Sandstedt and Sörensen, 
1995).   
A long-term adaptation of the neurosensory dysfunction associated with these injuries 
will have direct effects on the patient physical and psychological wellbeing (Pogrel et 
al., 2011).  It is generally understood that the majority of patients with long term oral 
neurosensory disturbance (paraesthesia or dysaesthesia) tend to have severe 
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symptoms and greater socio-psychological consequences (Sandstedt and Sörensen, 
1995).  Therefore, when defining treatment approaches often results in total recovery 
with permanent problem for patients with peripheral nerve injury it is vital to determine 
the extent of nerve tissue damage by thorough assessment of nerve function. 
1.3.2 Classification of peripheral nerve injuries 
An accurate description and understanding of the types of nerve injury are essential 
to determine the underlying condition of the damaged nerve at the time of nerve repair.  
As a result, an introduction to a classification of the degree and mechanism of injury 
following nerve damage to predict the clinical outcomes after surgical exploration is 
needed.  The most widely accepted classification systems of nerve injuries were first 
introduced by Seddon in 1942 and later modified by Sunderland in 1951 (Figure 1.9). 
1.3.2.1 Seddon's classification system 
Seddon divided nerve injuries into three categories namely; neuropraxia, axonotmesis 
and neurotmesis (Figure 1.9).  Seddon's proposed classification system detected the 
degree of severity, and the capacity of spontaneous recovery of the injured nerve 
fibres (Zuniga and Radwan, 2013). 
Neuropraxia  
This is the mildest grade of nerve injury which involves transient and reversible 
conduction block of electrical nerve impulses (Zuniga and Radwan, 2013).  
Neuropraxia usually occurs due to either local ischemia or focal demyelination of the 
myelin layer of the axon (Kerns, 2008) and causes transient functional loss (Burnett 
and Zager, 2004).  The axon membrane is intact, although the action potential is 
blocked temporarily at the region of damage.  The likelihood of full recovery after 
neuropraxia is good and usually occurs within weeks to months (Robinson, 2000). 
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Figure 1.9:  Classifications of peripheral nerve injury.  (Figure reproduced with 
permission from Neurosurgical focus). 
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Axonotmesis 
Axonotmesis includes a moderate degree of severity in which there is disruption of the 
myelin sheath and axon membrane.  This degree of nerve injury is most commonly 
caused by crush injuries or severe compression (Kerns, 2008; Zuniga and Radwan, 
2013). The axon still has some continuity retained as both perineurium and epineurium 
are still intact.  At this stage, Wallerian degeneration arises within the degenerated 
part of the axon distal to injury.  The prognosis following axonotmesis is variable, and 
recovery may take several months (Kerns, 2008; Zuniga and Radwan, 2013). 
Neurotmesis  
This is the severe type of nerve injury in which the whole nerve trunk is completely 
sectioned (Zuniga and Radwan, 2013).  This degree of nerve damage is commonly 
seen after lacerations especially following surgical procedures.  In neurotmesis, the 
axon membrane, myelin sheath layer, endoneurium, perineurium and epineurium are 
disrupted.  As a result, Wallerian degeneration begins, but the prognosis for functional 
recovery is poor and requires surgical intervention (Zuniga and Radwan, 2013). 
1.3.2.2 Sunderland’s classification system 
Sunderland modified the classification system described by Seddon into five degrees 
of injury according to severity (Figure 1.10).  This system is based on the histological 
changes, and the extent of tissue damage within nerve trunk occurring after the injury 
(Zuniga and Radwan, 2013).  Additional Grade of nerve injury to Sunderland grading 
scheme has been described as sixth grade of nerve injury (Chhabra et al.2014).  
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First-Degree Injury   
The first-degree injury of Sunderland corresponds to Seddon's neuropraxia in which 
there is transient disruption of transmission of nerve signals at the injured site 
(Sunderland, 1990).  Similar, to neurapraxia this degree of injury is commonly caused 
by compression or ischemia.  The axon membrane integrity is preserved and has 
relatively rapid degree of functional recovery.  The cell body (soma) of the axon is 
intact (Robinson, 2000).  Although minor changes within the myelin sheath layer occur, 
there is no Wallerian degeneration, and any histopathological changes are mild 
(Burnett and Zager, 2004). 
Second -Degree Injury 
A second-degree injury corresponds to axonotmesis category of Seddon's 
classification in which there is complete disruption of axon membrane continuity and 
myelin layer (Kerns, 2008).  Subsequently, Wallerian reaction occurs distal to the site 
of the injury (Sunderland, 1990).  In pathological terms, conduction of electrical nerve 
signals distal to the injury site reduces within 24-72 hours after the injury.  Despite the 
loss of axon continuity, the endoneurial connective tissue layer remain intact to 
maintain the regenerating fibres within its original sheath.  This however, ensures 
undisturbed regeneration and full recovery (Sunderland, 1990; Burnett and Zager, 
2004).  Although rate of axonal growth is approximately 1 mm per day, full recovery of 
function usually takes several months longer than the first degree (Kerns, 2008). 
Third-Degree Injury  
Nerve injury of the third degree of Sunderland classification ensues when there is 
complete axon membrane disruption (similar to axonotmesis) but damage involves the 
endoneurium layer only (Sunderland, 1990; Zuniga and Radwan, 2013).  The extent 
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of damage of endoneurium (intra-fascicular) could be either partial or complete 
(Sunderland, 1990).  In this type of injury, the perineurium which maintains the 
fascicular structure of the whole nerve trunk is preserved.  Here, the degree of 
Wallerian degeneration distally is severe and as a result some neuronal cell bodies 
are lost which decrease the number of sprouting fibres (Kerns, 2008).  At the site of 
injury and distally, the axon membrane and its myelin sheath degrades within hours to 
days in a response to the injury (Wallerian degeneration).  At the proximal stump, the 
cell body response exhibits a series of histomorphological changes known as 
chromatolysis which reflects a shift in axon function, from being neurotransmission to 
synthesis for regeneration (Kerns, 2008).  Lastly, intraneural fibrosis (scar tissue) can 
result from the consequent inflammatory reaction, haemorrhage, oedema, and 
ischemia, impede the axonal regeneration. Recovery usually is possible, but 
substantially delayed.  
Fourth-Degree Injury  
In this type of nerve injury, all connective tissue layers of the nerve are destroyed 
except the epineurium (Sunderland, 1990; Zuniga and Radwan, 2013).  This type of 
nerve injury involves disruption of the fascicular structure of the nerve fibres and 
causes functional loss.  At this stage the nerve trunk is still in continuity, except at the 
injury site where intraneural scar and neuroma are formed.  The neuroma consists of 
a disorganized mass of regenerating axons contained within fibrous tissue.  The 
degree of damage proximal to the site of injury is more severe than in third-degree 
injuries resulting in the death of a significant proportion of nerve cells and as a result 
fewer misdirected axons survive to regenerate (Sunderland, 1990).  Functional 
recovery is not possible without surgical interventions (Robinson, 2000).  This type of 
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injury requires surgical dissection of the involved segment and an appropriate nerve 
repair. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10:  Classification of nerve injury based on the extent of 
histological changes within the neurone. (Figure reproduced with 
permission from Springer and Copyright Clearance Centre). 
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Fifth-Degree Injury  
This is a severe nerve injury which has the greatest nerve tissue damage and complete 
loss of function due to transection of the entire nerve trunk (Robinson, 2000; Zuniga 
and Radwan, 2013).  Similar to Seddon’s, neurotmesis, the transected ends of the 
nerve fibre may remain disconnected, or may be joined by scar-tissue or neuroma.  
Spontaneous regeneration to cross the gap is limited, and full functional recovery 
remains restricted due to retrograde effects of the injury, and misdirected axons.  The 
likelihoods of beneficial recovery are significantly enhanced by an appropriate surgical 
repair (Robinson, 2000; Zuniga and Radwan, 2013). 
It is well established from the previous classifications, that the capacity of damaged 
neurones to regenerate to its pre-injury condition is likely dependent upon the extent 
of tissue damage and amount of continuity remaining within the nerve trunk following 
injury.  In general, neurapraxia have the greatest chance of spontaneous regeneration 
than axonotmesis or neurotmesis.  In the milder injury the prognosis is more 
favourable because Schwann cells and supporting structures that surround the nerve 
fibres are intact. 
Sixth-Degree Injury 
This is a mixed type of nerve injury which represent a complex pattern of tissue 
damage (Chhabra et al.2014).  In this degree of the injury involve various layers across 
the nerve and usually follow the penetrating trauma of the nerves. The recovery 
potential is variable and depends upon the degree of tissue damage. The treatment of 
this type of injury usually range from a simple nerve repair to a complex nerve graft, 
or transfer (Chhabra et al.2014). 
 
38 
 
1.3.3 Pathophysiology of peripheral nerve injury 
Injury to a peripheral nerve provokes a reaction that incorporates a sequence of 
biological alterations in the neurone cell body and its associated axon which responds 
in a distinct way to the damage process.  The effects of injury involve the constituents 
of the neurone cell (Figure 1.11). 
1.3.3.1 Wallerian degeneration of injured neurone cell 
Investigation of the degeneration process of peripheral nerve fibres in response to 
injury is still evolving since its first description by ʻ Waller in 1850ʼ (Navarro et al., 2007).  
Once nerve damage occurs, degeneration is initially detected within 24 hours, and 
lasts approximately two weeks following separation of the nerve segments from the 
cell body (Navarro et al., 2007). 
 Response of distal Schwann cells-axons to injury 
In the peripheral nervous system, almost 90 % of nucleated neural cells present either 
as ʻ myelinating and non-myelinating Schwann cellsʼ (Gaudet et al., 2011).  Myelinating 
Schwann cells produce a myelin sheath membrane which surrounds either motor or 
sensory single large diameter nerve fibres.  While the small-diameter unmyelinated 
axons are loosely enclosed by non-myelinatingʼ Schwann cells (Gaudet et al., 2011).   
Soon after injury, Schwann cells respond to the damage process first by division, then 
proliferation followed by subsequent cessation of myelin sheath formation (Gaudet et 
al., 2011).  Both forms of reactive Schwann cells, reach peak proliferation around 4 
days after injury and then there is a decreasing rate of division for up to 2 or 3 weeks 
(Navarro et al., 2007; Gaudet et al., 2011).  Schwann cells respond to the damage 
process by rapidly dividing into daughter cells and subsequently up-regulating gene 
expression for molecules to support the degeneration and regeneration processes 
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(Osbourne, 2007).  After injury Schwann cells are rapidly denervated by detachment 
of myelin sheaths, as a result of activation of ErbB2, tyrosine kinase receptor (Navarro 
et al., 2007).  After division of Schwann cells and initial degradation of myelin sheaths, 
Schwann cells migrate to form strands within the tube of the basal lamina and these 
are termed bands of Büngner, to help guide the path of sprouting axons (Stoll and 
Müller, 1999). 
During Wallerian degeneration, Schwann cell proliferation primarily occurs following 
loss of contact between the Schwann cell-axonal union, and later by a production of 
interleukin-1, cytokine (IL-1) and Tumour necrosis factor-alpha (TNF-α) that are 
released from infiltrating macrophages to induce axon disintegration (Ide, 1996).  The 
reaction of the distal nerve segment to injury has been investigated in preclinical 
studies of peripheral nerve injury, and the axons initially swell, followed by the 
disintegration of its myelin sheath, until complete degeneration of the axon terminals 
occurs, with the clearance of the cytoplasmic debris taking place (Johnson et al., 2005).  
This process is known as anterograde degeneration of Wallerian type that occurs 
distal to the site of nerve injury and is facilitated by the activation of the ʽaxonal 
proteases systemʼ (Myers et al., 2006).  Following injury to a peripheral nerve, distally 
degenerated materials are removed by the reciprocal activity of denervated Schwann 
cells and recruited macrophages, which serve to create a local environment that 
favours neuronal axonal regeneration (Rodríguez et al., 2004). 
It has been recognized that, following nerve injury the degeneration process is a slow 
process and severed axon segments that remain intact can conduct action potentials 
for a few days following a peripheral nerve injury (lag phase; approximately 24-48 
hours) (Gaudet et al., 2011).  
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Figure 1.11: Diagram illustrates the degenerative and regenerative events 
of the neurone cell after peripheral nerve injury.  A: normal neurone cell, B: 
nerve injury and Wallerian degeneration, C: axonal regeneration, D: 
reconnection of axon and end-targets organ.  (Figure reproduced with 
permission from John Wiley and Sons and Copyright Clearance Centre). 
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Response of the cell body and proximal segment to injury 
As previously mentioned the most detectable early changes are associated with distal 
segment degeneration, with the destruction of the axon and its myelin sheath, and 
subsequent clearance by macrophages (Kerns, 2008).  Furthermore, it is well 
recognized that extensive damage also occurs in the proximal portion of the injured 
axon, which could extend backwards from the site of injury to the first node of Ranvier 
(Johnson et al., 2005).  Proximal changes (retrograde) may occur immediately at the 
first node of Ranvier next to the site of injury and show a considerable structural 
change within the soma (Johnson et al., 2005).  Changes within the neurone cell body 
involve the removal of protein synthesizing organelles by action of the lysosomes and 
are associated with a subsequent increases in the production of cytoplasmic RNA 
(Johnson et al., 2005).  
After axon injury, the soma usually exhibits profound alterations in structure, 
metabolism, and its physiological activity (phenotypic) (Grafstein, 1975).  Typically, the 
phenotypic changes are first recognized by hypertrophy of the cell body, movement of 
the nucleus to the periphery of the body, and finally the dissolution of basophilic Nissl 
substance (ribosome clusters) from the cytoplasm “chromatolysis” (Grafstein, 1975).  
Collectively, chromatolysis of the soma and disorganization of the ribosome clusters 
are associated with an anabolic reaction which incorporates various metabolic 
alterations and appear soon after injury, corresponding with the initial stage of 
Wallerian degeneration (Fu and Gordon, 1997; Navarro et al., 2007).  Metabolic 
changes include increased cytoplasmic RNA synthesis and increased cellular protein 
content while neurotransmitters and cytoskeleton proteins production is reduced 
(Navarro et al., 2007).  A shift in the neuronal state from transmission to synthesis is 
essential for regeneration and survival (Kerns, 2008).  Axonal transport plays a pivotal 
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role in intracellular movement of cellular contents such as proteins, RNA, and 
organelles from the axon to the soma and vice versa.  One to 2 days after injury, there 
is a reduction in transport of transmitter-associated proteins in the neurone, but 
following axonal outgrowth initiation, there may be an increase in the amount and/or 
the rate of axonal transported protein materials (Grafstein, 1975).  Meanwhile, re-
establishing axonal transport does occur when changes in RNA and protein 
metabolism take place in response to an increased demand of the cell body to supply 
materials necessary for support and maintenance of the sprouting axons (Grafstein, 
1975).  The proximal segment response to injury has been assessed in animal based 
studies and histologically reveal a reduction in the diameter and the count of nerve 
fibres, demyelination and reduction of nerve conduction velocity in electrophysiological 
studies (Gunasekera et al., 2011). Furthermore, there may be a reduced expression 
of transcription molecules essential for regeneration such as   Jun N-terminal kinase 
(JNK, c-Jun), and growth associated pretient-43 (GAP-43), and in some cases, 
neurone cells may undergo apoptosis and death as a consequence of the injury (Kerns, 
2008). 
Degenerative changes at the site of injury 
Two to 3 days following injury, recruitment of haematogenous macrophages into the 
degenerating axon segment are thought to be directed by cytokines that are secreted 
by reactive Schwann cells such as monocyte chemoattractant protein 1 (MCP1) 
(Tofaris et al., 2002).  In Wallerian degeneration, recruitment of non-neural cells such 
as macrophages is considered imperative in the process of regeneration in injured 
nerves (Gaudet et al., 2011).  During the early phase of Wallerian degeneration, 
resident macrophages within the endoneurium, are considered prime responders to 
injury before the infiltration of circulating macrophages.  The macrophages express 
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major histocompatibility molecules and complement receptor 3 and their recruitment 
is enhanced by the production of immune triggering substances such as antibodies 
and disruption of the blood-nerve barrier, within 48 hours of the injury (Gaudet et al., 
2011). 
It has been suggested that Schwann cells express toll-like receptors (TLRs) that act 
as a first line defence mechanism in the host immune response by activating different 
signalling cascades including transcription factors and cytokine expression both of 
which are important in the regeneration process of damaged peripheral nerves.  TLR1 
is highly upregulated after injury, and degenerated axons release endogenous TLR 
ligands which bind to TLRs expressed on the surface of Schwann cells, provoking an 
inflammatory reaction, essential for stimulating axon regeneration (Gaudet et al., 
2011).  Furthermore, Schwann cells produce essential trophic factors that support the 
progress of axon growth as well as cytokines and chemokines production to recruit 
other immune cells into the injured neurone to intensify the inflammatory reaction 
(Gaudet et al., 2011). 
TNF-α, a pro-inflammatory cytokine, is also implicated in the regulation of macrophage 
infiltration at sites of peripheral nerve injury (Liefner et al., 2000).  Liefner et al. (2000) 
explored the function of TNF-α during Wallerian degeneration by tracking the course 
of macrophages after nerve injury in control and TNF-α deficient mice.  Their results 
revealed Wallerian degeneration and macrophage infiltration was not affected in the 
control group, while in TNF-α deficient mice macrophage, recruitment was impaired 
but without disruption of their myelin phagocytic activity. 
Circulating macrophages enter the distal nerve stump between days 4 to 7 after injury 
and clear the axon and myelin debris within two weeks (Stoll and Müller, 1999).  The 
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final stages of Wallerian degeneration exhibit distinct changes which include reduction 
of nerve fibre diameter and atrophy of the fascicles with subsequent shrinkage of the 
nerve trunk.  This amount to a reduction of between 50 % to 60 % of the cross-
sectional fascicular area (Sunderland, 1990).  In third-degree injuries, the retraction of 
the separated nerve ends causes intra-fascicular damage proceeded by significant 
local reaction because of the elastic nature of the endoneurium connective tissue layer 
(Burnett and Zager, 2004).  These injuries also lead to vascular damage which is 
followed by haemorrhage and oedema, which cause a severe inflammatory response.  
This reaction is followed by a proliferation of fibroblasts, and the formation of fibrous 
scar tissue which forms a disorganized growth (neuroma) of the injured segment.  By 
5 to 8 weeks, the process of Wallerian degeneration is usually completed, and only 
fragments of Schwann cells remain inside the endoneurial tube (Burnett and Zager, 
2004). 
1.3.3.2 Regeneration and healing of damaged neurone cell 
Following peripheral nerve injury, nerve cell state switches from synthesis and 
transmitting to regeneration, inducing a differential regulation of various cell 
constituents which regulate pathways that are responsible for either neurone survival 
or death (Figure 1.12) (Navarro et al., 2007).  
Regenerative changes of the cell body and proximal segment 
Regeneration and sprouting of severed axons involves the production and supply of 
trophic factors that are provided by infiltrating macrophages and reactive Schwann 
cells, and from the local environment within the degenerated distal nerve segment 
(Rodríguez et al., 2004).  Following peripheral nerve injury, myelin sheet removal by 
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Schwann cells and macrophages help down-regulate regeneration-inhibiting factors 
including glycoprotein (Navarro et al., 2007). 
In severe types of peripheral nerve injury, axonal regeneration begins when Wallerian 
degeneration has regressed, but in mild nerve injuries the degeneration and 
regeneration processes occurs simultaneously (Burnett and Zager, 2004).  The period 
of nerve regeneration and healing may persist for several months following injury. 
However, the earliest signs of regeneration observed in the nerve cell body is the 
reversal of chromatolysis, centralisation of the nucleus and subsequent restoration of 
the metabolic functions towards transmission state (Burnett and Zager, 2004). 
It has been reported that between approximately 10-30 % of sensory neurone fibres 
of DRG undergo apoptosis after injury of the sciatic nerve (Navarro et al., 2007).  
Neuronal cell death has been attributed to several factors including age, severity, and 
proximity of injury to the neurone’s cell body (Navarro et al., 2007).  It has been well 
recognized that after injury the reactive Schwann cells and infiltrating macrophages 
reciprocally release nerve growth factor (NGF).  This trophic factor is conveyed to the 
neurone cell body by means of fast active transport to support the regeneration of the 
neurone (Myers et al., 2006).   
In peripheral nerve injury, the presence of an intact endoneurium of the axon on either 
side of the injury region is imperative for successful reconnection of the nerve 
segments (Johnson et al., 2005).  This state of regeneration is complemented by the 
division, proliferation and arrangement of Schwann cells which will seal the gap within 
the existing basal lamina-endoneurial tube (Johnson et al., 2005).  In the peripheral 
nervous system, the endoneurium of both myelinated and non-myelinated nerve fibres 
is continuously covered by basal lamina which act as a natural nerve conduit following 
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denervation of Schwann cells (Ide, 1996).  In this respect, the role of Schwann cell-
basal lamina in axon regeneration aids the healing process after moderate type of 
nerve injury when compared to neurotmesis by acting as a ˝pseudo-conduit̏̏̏̏ . (Johnson 
et al., 2005). 
 
 
 
 
 
 
 
 
 
  
 
 
A 
B 
C 
Figure 1.12:  Diagram illustrates the regeneration process of severed 
axons.  A: initial axon sprouting, B: growth cone and basal lamina-
endoneurial tube formation, C: successful neurone cell regeneration and 
reconnection of end-targets organ.  (Figure reproduced with permission 
from John Wiley and Sons and Copyright Clearance Centre). 
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Axon regrowth is initiated at the first node of Ranvier where the bands of Büngner of 
Schwann cells extend from the proximal axon segment into the distal stump to reach 
its target organs (Ide, 1996).  The rate of axon growth initially is slow, but 2 to 3 days 
following injury, a length of about 2-3 mm per day can be achieved (Navarro et al., 
2007). Schwann cells and basal lamina have been considered to play an important 
role in axonal regeneration by providing an essential source of trophic factors.  
Additionally, Schwann cell-basal lamina tubes also provides a favourable growth 
environment by serving as platforms for regenerating axons (Ide, 1996).   
Upon successful regrowth, the regenerating axon and its associated Schwann cells 
form the growth cone within the endoneurial tube which extend toward the distal 
degenerated segment (Johnson et al., 2005).  The tip of the axon growth cone exhibits 
specialized guiding actin filaments (filo-podia) that adhere to the Schwann cell-basal 
lamina and are responsible for regulating the sprouts pathways (Burnett and Zager, 
2004). 
The growth process sometimes continues over a prolonged period of time even if 
functional recovery is unlikely and form abnormal growth (Johnson et al., 2005).  The 
lack of appropriate guidance during regeneration, causes sprouting axons to make a 
tortuous path, with the formation of an abnormal mass or neuroma that is composed 
of a mixture of immature axons and fibrous connective tissue (Navarro et al., 2007).  
Myelination by Schwann cells will resume when the axon successfully establishes 
reinnervation of its intended targets (Johnson et al., 2005).  It has been shown that 
Schwann cells also express laminin, cell adhesion molecule, on the plasma membrane 
surface, to enhance axon regeneration within the growth cone (Ide 1996; Gaudet et 
al., 2011).  Laminin is upregulated after injury and acts directly on the Schwann cell 
basal lamina and its associated axon by binding integrin receptors to promote 
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adhesion to the actin cytoskeleton network within the growth cone (Gaudet et al., 2011).  
In peripheral nerve injury, however, the blockage of laminin subunit has been shown 
to inhibit the regeneration of the axons (Gaudet et al., 2011). 
Regenerative changes of the injury site and distal segment 
It has been postulated that intracellular signals that are responsible for initiation of the 
regeneration process act at differential time periods which follows a sequence of 
actions to support and maintain the sprouting and healing of the severed axons 
(Navarro et al., 2007).  In acute states, reactive Schwann cells upregulate gene 
expression of the trophic factors, and GAP-43, which are delivered to the axon growth 
cone over a period of several days after injury to promote axonal ingrowth (Fawcett 
and Keynes, 1990; Hall, 2001).  However, expression of these factors is reduced upon 
successful reinnervation and Schwann cells revert their interaction with the axon (Hall, 
2001).  
Following peripheral nerve injury, opening of the voltage-gated ions channels with a 
rapid influx of calcium and sodium ions within the axoplasm causes a hyper-excitability 
state, and this generates action potentials that are transmitted to reach the cell body.  
As a result, this electrical response promotes inflow of calcium ions which activates 
mitogen-activated protein kinase (MAPK) and subsequent release of glutamate and 
brain-derived neurotrophic factor (BDNF) centrally (Navarro et al., 2007).  These 
protein kinase cascades participate in the retrograde axoplasmic transport which help 
support and maintain the regeneration process. 
Schwann cells express NGF and NGF receptors on their surfaces which guide 
sprouting axons within the basal lamina tubes.  However, upregulation of NGF–TrkA 
signalling has been linked with the development of neuropathic pain (Myers et al., 
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2006).  In addition, macrophages release IL-1, a cytokine that promotes expression of 
NGF in Schwann cells to stimulate the process of regeneration (Brown et al., 1991). 
It has long been recognized that abnormal regeneration and subsequent impairment 
of functional recovery may occur due to failed selectivity of sensory and motor 
sprouting axons to establish appropriate target reinnervation (Navarro et al., 2007).  
As a result, this impaired maturation leads to reduction of the axon diameter, and 
ultimately neuron atrophy.   
Successful regeneration of the severed axons depends on the intrinsic capacity of 
neurone cells to withstand the effect of injury and ability to change from transmitter to 
regenerative state (Navarro et al., 2007).  In severe nerve injury however, the intense 
inflammatory reaction, fibroblast proliferation and subsequent fibrous scar formation 
complicate the regeneration process of severed axons, resulting in the formation of 
neuroma (Osbourne, 2007).  
1.3.3.3 Expression of cell-signalling molecules and factors  
It is generally agreed that axon damage after nerve injury creates intracellular signals 
that are responsible for the activation of a number of signalling cascades of several 
gene expressions within the neurone that may lead to either cell body death or survival 
and subsequent regeneration (Navarro et al., 2007).  In response to injury, the neurone 
also relies on neurotrophic support for survival and maintenance of its regeneration.  
As previously mentioned, degeneration of the distal nerve segment is considered to 
act as a suitable permissive environment for growth of severed axons by providing 
essential neurotrophic factors (Ide, 1996).  Among these neurotrophic factors are 
neurotrophins (BDNF and NGF), and pro-inflammatory cytokines (TGF-β, IL, IL6, LIF). 
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Expression of neurotrophic factors in peripheral nerve injury 
In uninjured neurones, trophic factors are produced in the end-target organs, and 
carried to the cell body by way of retrograde axonal transport (Ide, 1996).  It has been 
proposed that interruption of such established harmonious interactions of axons with 
the cell body by injury causes Schwann cell activation, and subsequently, the 
production of NGF and BDNF which spread diffusely in a gradient manner around 
sprouting axons (Ide, 1996).  Therefore, a reduced expression of trophic factors 
reaching the cell body due to axonal disruption is considered a molecular signal which 
triggers the regeneration process in peripheral nerve injury (Burnett and Zager, 2004). 
NGF is considered a key neurotrophic factor which play a major role in peripheral 
nerve regeneration and the growth process (Burnett and Zager, 2004).  NGF’s role in 
promoting sensory axons regeneration has been of great interest for many years 
(Kelleher et al., 2016).  NGF produced locally by Schwann cells and fibroblasts at an 
injury site, binds to receptors on the Schwann cell surface.  Following peripheral nerve 
injury levels of NGF mRNA and protein increase, whereas in an intact nerve, Schwann 
cells expression of NGF-mRNA is low in comparison.  The up-regulation of NGF by 
Schwann cells after injury is thought to be regulated by IL-1 released from 
macrophages infiltrating the nerve injury site (Ide, 1996).  Subsequently if macrophage 
recruitment fails, myelin sheath clearance will be considerably delayed, along with a 
reduction of levels of NGF synthesis by Schwann cells, resulting in compromised 
sensory axon regeneration (Ide, 1996).  A study by Brown et al. (1991) using the 
delayed axonal breakdown C57B1/OIa mice model, linked with slow recruitment of 
macrophages, reported low levels of mRNA for both NGF and its receptor that 
impaired the regeneration of sensory, but not motor fibres.  These data provide 
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evidence that macrophage recruitment in peripheral nerve injury is essential for NGF 
synthesis and promoting axon regeneration (Brown et al., 1991). 
BDNF and NGF regulate sensory neurone functions in both the central and peripheral 
nervous system (Meyer et al., 1992).  Under normal physiological conditions NGF is 
produced by end-target tissues, whereas BDNF is synthesized in the CNS by glial cells 
and peripheral nerves.  NGF and BDNF are expressed at low levels in the Schwann 
cells of normal intact peripheral nerves.  However, several days after a peripheral 
nerve injury, expression levels of BDNF mRNA increase above the normal, reaching 
a maximum after several weeks (Meyer et al., 1992).  In contrast the level of NGF 
mRNA, shows a biphasic expression, increasing rapidly after 6 hours and reaching a 
maximum 3-4 days after injury (Ide, 1996).  These observations support the work of 
Brown et al.  (1991) that suggest prolonged NGF mRNA upregulation is related to IL-
1 release from macrophages at site of injury.   
Expression of neuroinflammatory cytokines in peripheral nerve injury 
Transforming growth factor beta (TGF-β) is a protein molecule that belongs to the 
complex cytokine family that are involved in regulating several physiological functions 
in embryogenesis, angiogenesis and wound healing (O’Kane and Ferguson, 1997). 
TGF-β subgroups comprises 5 isoforms (TGF-β1-5) of which, TGF-β-1, -2 and -3 are 
expressed in mammals and exert differential cellular effects.  The diverse levels of 
expression of TGF-β during the wound healing process reflects different biological 
effects.  Serin-threonine kinase is considered to be the transducing signal that 
activates TGF-β which binds to specific receptors R1 and R2 (O’Kane and Ferguson, 
1997).  
52 
 
TGF-β1 has been recognised to play an important role in the wound healing process 
by regulating collagen production, fibroplasia and downregulation of protease enzyme 
(O’Kane and Ferguson, 1997).  TGF-β1 is also a strong chemotactic molecule for 
many inflammatory cells such as fibroblasts and is also responsible for mediating 
expression of other TGF-β types (O’Kane and Ferguson, 1997).  TGF-β1 is expressed 
in all tissues and cells while TGF-β2 is found mostly in saliva, amniotic fluid, and breast 
milk.  However, TGF-β3 is scarce in both body fluids and tissues (O’Kane and 
Ferguson, 1997).  
Fibrosis and scar formation, both of which hinder the healing process, have been 
attributed to the upregulated levels of TGF-β-1 and -2, while the expression of TGF-β-
3 associated with reduced scar formation at the site of nerve injury (Ferguson and 
O’Kane, 2004; Atkins et al., 2006).  Moreover, TGF-β-1 upregulation has been 
implicated in scarring of the epineurium due to collagen type-1 deposition that is 
produced by infiltration of fibroblasts at the site of injury (Nath et al., 1998; Atkins et 
al., 2006).  In injured sciatic nerves, exogenous application of anti-TGF-β antibodies 
was associated with a reduction of fibroblast recruitment and, subsequently a 
reduction in overall transduction signals for collagen deposition and this reduces scar 
tissue formation (Nath et al., 1998). 
IL-1 protein is a pro-inflammatory cytokine expressed by macrophages in the 
peripheral nervous system (Thacker et al., 2007).  Immediately after nerve injury 
mRNA levels of IL-1 are elevated and persists at higher levels for several days 
(Thacker et al., 2007).  In addition, IL-1 is considered to play important role in nerve 
regeneration, by stimulating the synthesis of NGF by activating Schwann cell 
production (Ide, 1996).   
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LIF and IL-6 are two other important pro-inflammatory cytokines, that are upregulated 
following nerve injury (Tofaris et al., 2002).  The source of LIF is still not known but 
“autocrine circuits” regulated by Schwann cells have been attributed to play a part in 
macrophage recruitment.  After injury, Schwann cell and microglial cells play a role in 
orchestration of the cellular responses and regeneration of damaged neurons by 
producing IL-6 (Galiano, M et al. 2001; Tofaris, G.K et al.2002).  IL-6 indirectly regulate 
LIF, and MCP-1 pathways, which regulate entry of macrophages and lymphocytes to 
the injured nerves (Galiano, M et al. 2001; Tofaris, G.K et al.2002). 
1.3.4 Neuropathic pain development in response to peripheral nerve injury 
The expression patterns of specific regulatory factors such as pro-inflammatory 
cytokines or alteration of ion channels and glial activation have been implicated in the 
increased nociception of neurones following peripheral nerve injury and associated 
neuropathic pain. (Navarro et al., 2007, Mika et al., 2008).  
Role of sodium and potassium ion channels in the development of neuropathic 
pain 
Nerve injury can alter the excitation patterns of sodium and potassium ion channels 
following an increase in their density along the axoplasm, by focal accumulation of 
vesicles containing ion channel proteins which are predominately found in neuroma 
tissues (Rasband et al. 2001; Navarro et al., 2007; Theile and Cummins, 2011).  It has 
been proposed that the DRG of primary sensory neurones potentiate the development 
of neuropathic pain by upregulation of some ion channels (Na v1.3, K v1.1, K v1.3) 
while the expression of other channels (Na v1.1, Na v1.2, K v1.2, K v2.1) are reduced 
(Navarro et al., 2007).  Following nerve injury, the altered electrical excitation of DRG 
and maintenance of hyper excitable severed afferent fibres has been attributed to 
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changes in the expression pattern of sodium and potassium ion channels (Rasband 
et al. 2001; Navarro et al., 2007; Theile and Cummins, 2011) (Table 1.1). 
 
 
 
 
Table 1.1: Ion channels implicated in neuropathic pain following peripheral nerve injury 
Ion channels subtype Tissue expression Role in pain 
Sodium ion channels Na v1.1 CNS, PNS Neuropathic pain 
Na v1.2 CNS, embryonic PNS Neuropathic and 
inflammatory pain 
Na v1.3 CNS, embryonic PNS Neuropathic and 
inflammatory pain 
Na v1.7 PNS; sympathetic and 
sensory neurones 
Neuropathic; 
inflammatory pain 
Na v1.8 PNS; small diameters 
peripheral neurones 
Neuropathic; 
inflammatory pain; 
mediate tingling 
sensation 
Na v1.9 PNS inflammatory pain 
Potassium ion 
channels 
K v1.1 
and 1.4 
PNS; small diameter 
neurones 
Acute nociception 
K v1.2 
and 1.3 
PNS; Large diameter 
neurones 
Mechanoreception and 
proprioception 
K v9.1 Large diameter 
myelinated spinal 
neurones 
Initiate ectopic electrical 
activity 
CNS: central nervous system; PNS: peripheral nervous system 
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Sodium ion channels play a key role in the propagation of noxious signals along nerve 
fibres towards CNS, and recent research has implicated some sodium ion channels 
with specific types of neuropathic pain in human and transgenic mice (Liu and Wood, 
2011; Bird et al., 2013).  Increased expression of Na v1.8 channels have been 
described in human lingual nerve neuromas and correlated significantly with tingling 
sensation following iatrogenic trauma of the lingual nerve during the surgical extraction 
of lower wisdom teeth (Bird et al., 2013).  Moreover, neurones excitability which 
enhance neuropathic pain state following peripheral nerve injury has been reduced by 
blockage of these channels (Liu and Wood, 2011).  In humans, the expression of 
sodium ion channels is variable.  Sodium channels that are preferentially expressed 
in the peripheral nervous system include Na v1.7, 1.8 and 1.9.  Na v1.7 channels are 
expressed in sympathetic and sensory neurones, whereas Nav1.8 presents only in 
small diameter peripheral sensory neurones (Navarro et al., 2007; Liu and Wood, 
2011).  It has been shown that Na v1.8 channels have the ability to retain and transmit 
nociception of cold temperature while Na v1.9 channels are implicated in the increased 
sensitivity of inflammatory pain.  In damaged neurones expression of Na v1.8 mRNA 
and protein is reduced following peripheral nerve injury (Liu and Wood, 2011).  This 
may be in response to the production of neuro-inflammatory cytokines during the 
degeneration process (Dib-Hajj et al., 2010).  
Ruangsri et al. (2011) studied the expression of Na v1.8 mRNA in the sciatic nerve 
entrapment (SNE) model of painful neuropathy in rats.  Na v1.8 shRNA vector 
(cationized gelatine/plasmid DNA polyplex) was injected subcutaneously into the rat 
hind paw.  After 3–4 days Na v1.8 shRNA attenuated the SNE-induced pain behaviour 
and continued over 4–6 days before returning to its basic levels.  In pain behavioural 
testing knockdown of Na v1.8 mRNA showed alleviation only in the injured nerve, but 
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not in the DRG, possibly due to unaffected transcription of the Scn10a gene encoding 
Na v1.8 (Ruangsri et al., 2011).  Based on these results it would appear peripheral 
inhibition of Na v1.8 expression decreases mechanical allodynia and thermal 
hyperalgesia.  The authors concluded that painful neuropathy is caused by the 
upregulation of Na v1.8 and axonal accumulation of Na v1.8 mRNA protein following 
nerve injury (Ruangsri et al., 2011). 
The nociceptive pathway contributing to the hyper excitability state in myelinated 
sensory neurones still remains unknown (Tsantoulas et al., 2012).  K v9.1 a potassium 
channel is selectively expressed in large-diameter myelinated sensory neurones 
following spinal nerve transection (L5), and its down regulation after injury has been 
correlated with the initiation of ectopic electrical activity and neuropathic pain 
development (Tsantoulas et al., 2012).  
 
Role of immune mediators and immune cells in development of neuropathic 
pain 
After disruption of the neurone membrane, the local environments in Wallerian 
degeneration, and release of inflammatory cytokines are believed to alter the neurone 
cell function which can sensitise nociceptive fibres to noxious stimuli (Zuo et al., 2003).  
Resident endoneurial mast cells are considered the prime initiator of natural immunity 
following peripheral nerve injury (Thacker et al., 2007).  However, infiltration of mast 
cells at the site of nerve injury is usually followed by their degranulation and 
subsequent production of histamine and protease enzymes (Thacker et al., 2007).  It 
has been shown that neural histamine receptors are expressed at high levels in sciatic 
nerve crush injury models where histamine mediators induce pain by sensitising 
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nociceptive nerve fibres to non-noxious stimuli thus initiating the development of 
neuropathic pain (Thacker et al., 2007).  Hence, the activation of mast cells in injured 
peripheral nerves to play a key in initiating an inflammatory response which later leads 
to the development of neuropathic pain (Zuo et al., 2003).  However, mast cell 
stabilisation with sodium cromoglycate has been shown to reduce infiltration of 
neutrophils and monocyte to the injury region, and suppressed the development of 
hyperalgesia.  Moreover, blocking of histamine action by application of anti-histamine 
receptors drugs has been shown to alleviate pain-related behaviours (Zuo et al., 2003).   
Neutrophils are the second dominant immune cells in innate immunity that invade 
nerve tissue within a short period of time after injury where they exert their phagocytic 
activity and release inflammatory mediators after degranulation (Thacker et al., 2007).  
Neutrophils are considered to be another major source for various pro-inflammatory 
cytokines (IL-1 and TNF-α) and chemokine (IL-8) production which enhance 
neutrophils to express endothelial adhesion molecules, and subsequently enhance 
degranulation of themselves and produce cytotoxic substance (Thacker et al., 2007).   
Intact nerves normally are devoid of neutrophils but, after injury a significant number 
of neutrophils invade the site of damage in the endoneurium (Perkins and Tracey, 
2000).  Perkins and Tracey (2000) investigated neutrophil distribution and their 
contribution to hyperalgesia in a ligation injury model of a rat’s sciatic nerve.  The study 
involved administration of a neutrophil cytotoxic antibody, and their results indicated 
that a greater number of neutrophils infiltrated the endoneurium at the site of injury 
when compared to the sham-nerve, which coincided with the development of acute 
hyperalgesia up to 7 days post-injury.  Neutrophil depletion at the time of nerve 
damage was associated with significant attenuation of hyperalgesia but, late depletion 
of the cells did not relieve chronic hyperalgesia.  Authors advocated that neutrophil 
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recruitment at the site of nerve injury plays a significant part in the development of 
neuropathic pain in peripheral nerve injury (Perkins and Tracey, 2000). 
Lymphocytes; T cells and natural killer cells play role in the development of 
neuropathic pain following peripheral nerve injury (Moalem and Yu, 2004; Thacker et 
al., 2007). They infiltrate the site of nerve injury and their upregulation has been shown 
to associated to be with thermal and mechanical allodynia/ hyperalgesia in several 
rodent models of nerve injury (Moalem and Yu, 2004; Thacker et al., 2007).  The T- 
Lymphocytes cell divided into Type 1 and Type 2 according to its cytokine expression 
profile. Type 1 helper T cells produce proinflammatory cytokines (IFN-γ and TNF-α) 
which increases nociception while, Type 2 helper T cells produce anti-inflammatory 
cytokines (IL-10) associated with a modest reduction of pain sensitivity following nerve 
injury (Moalem and Yu, 2004; Thacker et al., 2007). 
Role of glial cells in development of neuropathic pain 
It has been generally agreed that peripheral nerve injury is associated with an 
increased density and infiltration of microglial cells in the sensory regions of the 
superficial and deep laminae I and II of the spinal dorsal horn region (Eriksson et 
al.,1993; Taves et al., 2013) (see chapter 1; section 1.2.4; Figure 1.5).  Several 
immunohistochemical studies using specific microglial markers to investigate cellular 
immunoreactivity in different sensory territories in response to peripheral nerve injuries 
have been undertaken.  These studies highlight the specific response of microglial 
cells in the dorsal horn after nerve injury which are characterized by their proliferation 
and upregulation of OX-42 pan- microglial markers.  In addition, signals responsible 
for microglial cells reaction are suggested to act quickly, which convey sensory 
information to the corresponding sensory ganglionic cell bodies and then onward to 
central projection neurones (Eriksson et al.,1993; Taves et al., 2013).  It is also 
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proposed that the time course for the response of microglial reaction in sensory 
projection zones is similar in damaged axons that travel either in sensory or motor 
pathways.  
Within the CNS microglia represents approximately 10–20 % of all resident cells and 
their distribution largely homogenous in different regions, including the spinal cord 
(Taves et al., 2013). In their typical resting state microglia exhibit a ramified shape with 
fine radiating processes (Figure 1.13).  However, after nerve injury their morphology 
changes and is described as an amoeboid shape in which the cells stoma becomes 
large and their projecting processes prolonged and less ramified (Eriksson et al., 1993).   
 
 
 
 
 
 
Figure 1.13: Sections of spinal cord after immunohistocal staining with antibody Iba-1 
microglial marker showing three different morphological phenotypes of microglial cells. 
A: The ramified microglia: normal-appearing body with long, thin and radially projecting 
processes (Blue arrow). B and C: Spinal cords following peripheral nerve injury and 
repair showing hypertrophied microglia: enlarged body with shorter, thicker processes 
(Yellow arrows), D: Showing amoeboid microglia:  bigger and densely stained body 
with much fewer processes (Grey arrow). Scale bar = 25 µm. 
 
60 
 
Neural plasticity and pain hypersensitivity in spinal neurones due to peripheral and 
central sensitization is widely believed to be mediated by the activity of glial cells 
(Scholz and Woolf, 2007; Mika et al., 2013).   
The sensory input that contributes to the chronic pain state in the spinal cord dorsal 
horn largely rely on lamina I and II neurones which receive input from primary afferents 
neurons and convey nociceptive information to projection neurons that ascend to the 
brain (Mika et al., 2013; Taves et al., 2013).  It is believed that following peripheral 
nerve injury, spinal neurons undergo marked plasticity, and as a result leads to hyper 
excitability of the projections neurons within the dorsal horn which then induce chronic 
pain states (Scholz and Woolf, 2007; Mika et al., 2013). 
In several preclinical models of peripheral neuropathies microglial cell activation in the 
dorsal horn after nerve injury, is typically marked by increased proliferation, increased 
infiltration, and alterations of their morphology (amoeboid active state) (Scholz and 
Woolf, 2007; Mika et al., 2013; Taves et al., 2013).  Furthermore, microglial reaction 
is also characterized by the production and secretion of a range of pro-inflammatory 
cytokines that potentially trigger initiation of excitability of injured and non-injured 
nerves and result in maintenance of increased pain hypersensitivity.  Beggs and Salter 
(2007) investigated the distribution pattern of spinal microglial activation in response 
to peripheral nerve injury.  Their analysis showed a significant increase in microglial 
counts and the majority of sensory zones mapped to peripherally damaged primary 
afferent nerve fibres.  However, some microglial cell reactivity was also seen in the 
sensory projections of the intact nerve within the spinal cord.  Consequently, the 
authors proposed that this contributes to neuronal excitability and enhance nociceptive 
transmission which underlie neuropathic pain behaviours following nerve injury (Beggs 
and Salter, 2007). 
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Immunohistochemical studies by Eriksson et al. (1993) examined the microglial 
response in sensory areas of the spinal dorsal horn after sectioning of the sciatic nerve. 
Both the qualitative and quantitative analysis of images showed high microglial 
immunoreactivity with upregulation of OX-42 marker after 24 hours of sciatic nerve 
injury in the deep laminae of the dorsal horn with less activity of microglia in the 
superficial laminae in the L4 region.  Thereafter, expression levels of OX-42 peaked 
at day seven, which then declined slowly over different survival periods when animals 
were culled.  Qualitative image analysis in L1 and L4 regions showed similar patterns 
of distribution of small cells with extensive branching throughout the spinal cord 
immediately after injury which indicates rapid microglial cell response to sciatic nerve 
injury (Eriksson et al., 1993). 
There is also growing evidence that Mitogen activated protein kinases (MAPKs), a 
protein kinase, play an essential role in chronic pain processing by acting through a 
variety of coordinated intracellular signal transduction mechanism which mediate 
cellular responses that allow cells to respond to multiple and divergent inputs. (White 
et al., 2011; Hansen and Malcangio, 2013).  Therefore, the process of activation of the 
JNK.  c-JNK (JNK) pathway is the major pathway via spinal astrocytes has the 
potential to contribute to chronic pain states through phosphorylation of several 
substrates, including transcription factors, and proteins, and thus directly affects a 
broad range of cellular responses (White et al., 2011; Hansen and Malcangio, 2013).  
However, it is acknowledged that the JNK pathway in included in a large number of 
cellular activities including that relating to pain. 
Given the findings from the peripheral nerve injury models reviewed, clearly, targeting 
immune inflammatory profile would be logical approaches to prevent neuropathic pain 
development (Sommer et al., 1999; Schäfers et al., 2001; Nadeau et al., 2011).  Early 
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evidence from preclinical trials also suggests that some of the agents used to reduce 
inflammation on the basis of its potent anti-inflammatory action show promising results, 
but the necessary use of special equipment or implantation of pumps subcutaneously 
for continuous drug delivery showed no advantage over single administration 
(Sommer and Kress, 2004, George et al., 2004).  Moreover, these agents also raised 
concerns in relation to the suppression of the immune-inflammation process at the site 
of nerve injury which may impair regeneration following repair in the peripheral nerve 
or spinal cord. 
Role of inflammatory cytokines in in development of neuropathic pain 
Pro-inflammatory cytokines (TNF-α, IL-1, and IL-6) and anti-inflammatory IL-10 that 
are produced and released by the different immune cells following peripheral nerve 
injury are considered the key regulatory molecules of initiation and maintenance of 
neuropathic pain (Thacker et al., 2007).  However, the mechanism of action of these 
cytokine molecules in peripheral nerve injury is still not fully understood and it has 
been proposed that cytokines alter the physiological coordination’s of neurone cells 
either by direct action on primary sensory fibres, or indirectly by activation of signalling 
cascades in neuro-immune pathways (Thacker et al., 2007).  
IL-1 is a potent pro-inflammatory cytokine that is released from macrophages and 
Schwann cells following peripheral nerve injury (Dinarello, 1988).  IL-1 mRNA is 
significantly upregulated following nerve injury and is recognised to be strongly 
associated with pain-related behaviours in peripheral neuropathy (Marchand et al., 
2005).  The mechanism of action of IL-1 is not fully understood but postulated to be 
linked to the complex signalling pathways that cause direct excitation of nociceptive 
nerve fibres and increase their response to painful stimuli following release of 
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inflammatory mediators (nitric oxide, COX2 and prostaglandins) in peripheral nerve 
injury (Marchand et al., 2005).  Furthermore, peripheral administration of IL-1 has been 
acknowledged to play a vital role in sensitization of polymodal receptors to painful 
stimuli which contribute to the development of cutaneous hyperalgesia (Fukuoka et al., 
1994).  Moreover, in vivo studies have demonstrated a reduction of pain-associated 
behaviours and attenuation of hyperalgesia following application of IL-1 receptor 
antagonist (IL-1ra) in neuropathy model of rodent sciatic nerves (Sommer et al., 1999; 
Schäfers et al., 2001). 
It has been suggested that injury-induced neuropathic pain attributed to changes in 
TNF-α protein levels may be related to the local inflammatory reaction induced by 
injury around the nerve (George et al., 2004).  George et al. (2004) used enzyme-
linked immunoassay and immunohistochemistry to monitor changes of TNF-α protein 
level in a crush injury model.  Data from their study showed a rapid rise in TNF-α levels 
with a two-fold increase after 12 hours, which remained elevated on day 3 and then 
returned to a baseline value 14 day after injury.  Immunohistochemistry studies 
revealed, after 3 days, strong TNF-α -immunoreactivity in all epineurial macrophages 
and fewer endoneurium macrophages.  Pain behavioural analysis revealed transient 
by reduced sensitivity to painful stimuli such as heat (hypoalgesia) and mechanical 
stimuli (hypoesthesia) followed by development of heat hyperalgesia and mechanical 
allodynia by day 10 after injury.  However, they assumed that, the early and transient 
increase of TNF-α protein level may correspond with the onset of pain-associated 
behaviour in nerve injury (George et al., 2004).  
Following peripheral nerve injury, TNF-α is rapidly upregulated and is believed to 
promote axonal degeneration, macrophage recruitment, and induce ectopic neuronal 
activity during Wallerian degeneration by binding and triggering two tumour necrosis 
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factor-α receptors TNFRs (George et al., 2005).  Immunohistochemistry studies have 
reported the expression of TNFR1 and TNFR2 on normal Schwann cells, and along 
nerve axons and in DRG neurones following injury.  The TNFR1 binds favourably to 
soluble TNF-α whereas TNFR2 binds to membrane-bound TNF-α molecules, and both 
elicit different effects (George et al., 2005).  George et al. (2005) studied the differential 
level of TNFR1 and TNFR2 protein using ELISA following chronic constriction or crush 
injury of mice sciatic nerves.  TNF-α protein levels peaked early and transiently after 
injury.  However, TNF-α receptors were detected at a low level in uninjured nerves or 
sham-controls.  TNFR1 level increased 2-fold on days 3 and 7 after injury whereas, 
TNFR2 was expressed at high levels from day 1 and increased 7- fold on days 3 and 
7 after injury.  These data indicate that endoneurial TNF-α receptors proteins are 
differentially regulated during peripheral nerve injury.  The authors speculated that the 
increased TNFR1 level paralleled to the development of pain-related behaviour at 
early stage of nerve injury. In addition, TNFR2 levels remained elevated for 4 weeks 
after injury which corresponds to the period of nerve regeneration, and it is proposed 
that TNFR2 could act as an endogenous TNF antagonist (George et al., 2005). 
IL-10 is a major anti-inflammatory cytokine that is produced by a variety of immune 
cells including T-lymphocytes, macrophages and natural killer cells (de Waal Malefyt 
et al., 1992; Wagner et al., 1998).  In humans, IL-10 is produced by type II T helper 
cells (Th2) (de Waal Malefyt et al., 1992).  It is considered to be a strong inhibitory 
cytokine molecule that has auto regulatory effects by down regulating the class II major 
histocompatibility (MHC) antigens reaction, which inhibit macrophage antigen 
presentation that are mediated by Interferon-γ, TNF-α and IL-1 (de Waal Malefyt et al., 
1992).  
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Immediately after nerve injury, expression of IL-10 increases rapidly and remains 
elevated for up to 4 weeks, which may reduce inflammatory cytokine release by 
immune cells (Taskinen et al., 2000).  However, Wagner et al. (1998) proposed that 
IL-10 may be implicated in suppression of intracellular signalling involved in the pro-
inflammatory cytokine production pathway by macrophages, and moreover, its 
peripheral administration at the site of injury would potentially reduce endogenous 
TNF-α protein expression and subsequently prevent development of neuropathic pain. 
Their experiment involved intraneurial injection of IL-10 (250 ng) in a CCI model of 
neuropathy in rat sciatic nerves and shown to exert significant anti-inflammatory and 
analgesic effects by attenuating thermal hyperalgesia and reducing macrophage 
immune reactivity, thus suggesting IL-10 diminishes the inflammatory response and 
nociception of sensory neurones by interfering with TNF-α expression after nerve 
injury.   
It has been suggested that ectopic electrical activity contributes to the onset of 
neuropathic pain through upregulation of sodium ion channels and TNF-α protein in 
DRG neurones in peripheral nerve injuries (Shen et al., 2013).  Shen et al (2013) 
identified expression of IL-10 receptor 1 (IL-10R1) in DRG neurones and proposed its 
role in blocking sodium channels activity could prevent neurone excitation and 
alleviate neuropathic pain.  The experiment involved spinal ligation (L5) model of nerve 
injury and intrathecal injection of recombinant rat IL-10 (500 ng).  Their results showed 
diminished excitation of DRG neurones and subsequent relief of mechanical allodynia 
seven days after spinal ligation.  In vitro study using recombinant rat IL-10 (200 pg/ml), 
applied to cultured neurone tissues demonstrated reduction of levels of Nav1.6 and 
Na v1.8, while TNF-α application up-regulated level of Na v1.6 and Na v1.8 in DRG 
neurones. 
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Immune modulation and the targeting of pro-inflammatory cytokines by the application 
of neutralized antibodies and receptor blockers at time of nerve repair may influence 
signalling regulatory molecules that are responsible for development of neuropathic 
pain. 
1.4 Therapeutic approaches to enhance regeneration and functional recovery           
of peripheral nerves after injury 
Over the past decade, scientific research has provided substantial knowledge 
regarding the degeneration and consequent regeneration process of peripheral nerves 
in response to injury, but much still remains unknown about the complex interaction 
between the immune and neuronal systems. Recent research has focussed on 
promoting the regeneration of severed nerves by targeting specific signalling cascades 
without compromising other important stages of the healing process, critical for nerve 
repair (Vidal et al., 2013).  After injury, the intrinsic capacity of damaged axons to 
regrow and attain functional recovery is completely dependent on the site and type of 
injury, and distance over which the axon must regenerate to cross the injury site 
(Rodríguez et al., 2004).  Once nerve damage is established, the severity and type of 
injury will determine the necessity for surgical nerve repair, and the outcome of 
recovery of nerve function.  In severe types of injury (neurotmesis), axons have a 
restricted ability to grow and cross the distance of the injury site.  Furthermore, if the 
damaged nerve is left untreated or its repair delayed, neuroma formation will occur 
(Rodríguez et al., 2004). 
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Numerous emerging strategies have been proposed to enhance functional 
regeneration and recovery of severed axons (Rodríguez et al., 2004).  These 
strategies include; surgical repair and nerve grafting procedures, biologically 
engineered materials (conduits), and more recently locally applied therapeutic agents 
(Rodríguez et al., 2004).  The principal objective of surgical procedures is to achieve 
reinnervation of intended targets by guiding regenerating axons into the distal segment 
without further damage to the residual intact fibres at the site of nerve injury (De 
Albornoz et al., 2011).  The success of surgical repair of damaged nerve tissue has 
been attributed to the type of injury and the proper alignments of nerve fibres at the 
time of repair (Stefano et al., 2013).  Epineurial suturing is the most widely preferred 
method and permits axon regeneration by approximating individual fascicle of nerve 
fibres.  This method involves direct end to end repair when there is a short gap and 
both segments of severed nerve can be approximated without undue tension 
(Rodríguez et al., 2004).  If the nerve defect is too long and does not permit tissue 
repair, an autologous nerve graft can be used.  This type of nerve grafting procedure 
is infrequently used due to the restricted availability and morbidity associated with 
donor nerve tissue (Stefano et al., 2013).  Over the last decade, due to the inherent 
complications that are associated with nerve grafts, research has focussed on 
developing novel biologically engineered tissues or materials that could functionally 
substitute autogenous nerve (Johnson et al., 2005).  Conduits are synthetic tube-like 
channels designed to guide sprouting axons from the regenerating proximal segment 
to their intended targets and prevent infiltration of fibrous tissue which impedes nerve 
regeneration (Johnson et al., 2005).  Advances in tissue engineering research has 
been dedicated to produce conduits with biological properties that are similar to natural 
healing environments, without compromising the regeneration process of axons 
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(Stefano et al., 2013).  A conduit should act as a suitable environment for regeneration 
by combining biocompatibility and appropriate scaffolding for axon extension and 
promotion of Schwann cell adhesion and proliferation.  It has been documented that 
nerve regeneration through non-degradable conduit materials elicit chronic 
inflammatory reaction, but recent tissue engineering introducing a biodegradable 
conduit based materials such as collagen, poly-glycolic acid, poly-lactic acid, or 
polyesters which would degrade within reasonable time along with the regeneration 
process (Li et al., 2014). 
As previously discussed, peripheral nerve injury that produces retrograde 
degeneration extending backwards to involve the corresponding cell body are usually 
associated with a delayed regeneration process, and recovery may be slow and often 
incomplete (De Albornoz et al., 2011).  Therefore, various conservative treatment 
modalities have been advocated in addition to the surgical repair, such as electrical 
nerve stimulation and laser phototherapy to promote the functional recovery.  
Applications of low frequency electrical stimulation at the time of nerve repair have the 
potential to stimulate rapid nerve regeneration, and preliminary data have shown that 
improvements in muscle innervation and increased axonal sprouting occur when this 
therapy is combined with physical exercise in animal models (De Albornoz et al., 2011).  
Recently, laser phototherapy application of low intensity has been proposed to 
enhance recovery of repaired nerves and reduce muscle atrophy.  Considered a non-
invasive approach with few side effects, this treatment approach is still evolving and 
its role in promoting nerve regeneration is undetermined due to a variation in reported 
outcomes, and the lack of high quality clinical trials (De Albornoz et al., 2011). 
After an injury the success of functional nerve regeneration is complex and depends 
on the local environments that surround the regenerating axons (Vidal et al., 2013).  
69 
 
Axon growth may be prevented due to the presence of inhibiting factors or due to scar 
formation that arises secondary to the intense inflammatory reaction after injury.  
Consequently, the immune-inflammatory reaction initiates the production of 
inflammatory cytokines that exert inhibitory and stimulatory effects mediated through 
several intracellular signalling pathways which permits them to regulate various 
cellular activities during the healing process of regenerating axons (Vidal et al., 2013).  
Therefore, one therapeutic strategy involves different experimental modes of drug 
delivery after nerve repair to enhance the functional regeneration and accelerate 
recovery of nerve function.   
1.4.1 The role of artificially engineered materials (conduit) implantation in 
peripheral nerve injury 
Over the past few years, the interest of nerve conduit guidance (NCG) has increased 
as an alternative procedure to the standard nerve repair which obviates the need for 
nerve graft in many cases of nerve injury, with promising results (Wood and Mackinnon, 
2015).  During nerve repair, tensionless reconstructing of the defect due to tissue loss 
is not always possible (Johnson et al., 2005; Wood and Mackinnon 2015).  Hence, 
conduit bridging material provides structural support to guide axonal regeneration.  An 
ideal NCG will bridge the gap and simulate nerve architecture as naturally as possible. 
In addition, these new replacement materials could be utilised to carry therapeutic 
agents to increase neuron survival and improve nerve growth (Allodi et al., 2012; 
Wood and Mackinnon, 2015).  NCG can provide tubular guidance which help nerve 
tissue regeneration within the gap between proximal and distal nerve stumps.  Within 
this tubular structure the fibrin clots also act as the initial intrinsic platform that supports 
the surface ingrowth of the Schwann cells (Allodi et al., 2012). 
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Regeneration of damaged nerve fibres is often incomplete whether using autograft or 
conduits (Johnson et al., 2005).  This suboptimal outcome has been attributed to cell 
body apoptosis, fibrosis, or inherent delay in growth of axons to the distal segment.  
Therefore, to enhance axonal regeneration several experiments have investigated the 
application of anti-inflammatory cytokines to overcome this problem with the use of 
synthetic or natural repair in peripheral nerve injury (Johnson et al., 2005; Allodi et al., 
2012). 
Currently, the technology relating to nerve tissue engineering aims to produce a novel 
NCG that can promote neural regrowth and protect regenerating axons (Johnson et 
al., 2005; Nan et al., 2012; Wood and Mackinnon 2015).  In addition, the biological 
and physiochemical properties have been experimentally investigated to support cells 
adhesions and preserve the viability of neuronal cells. 
There are several types of NCG materials that have been globally licenced for repair 
of peripheral nerve injury including biological and synthetic nerve guidance (Johnson 
and Soucacos, 2008; Nan et al., 2012).  The synthetic NCG is based on polymer 
substances and this type include lactate polymer, polyethylene and silicone polymer 
whereas the biological alternatives included arterial and, veins grafts and autologous 
collagen.  These options for peripheral nerve repair are based on their ability to support 
direct axon growth from the regenerating segment and provide an essential permissive 
growth environment and prevent fibrous tissue invasion (Johnson et al., 2005; Wood 
and Mackinnon, 2015).  As a result, several studies on nerve conduit materials have 
addressed several important factors such as biocompatibility (degradation rate and 
cells viability), mechanical properties, (thickness wall and intraluminal support), 
flexibility and ease of manipulation (Nan et al., 2012).  NCG based- biodegradable 
polymer also provides the advantage of slow degradation rate and, this avoid removal 
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once functional regeneration and recovery has been established (Deumens et al., 
2010). 
The following section will review poly-glycolic acid (PGA), poly-ethylene glycol (PEG) 
and poly-caprolactone (PCL) use as NCG in field of peripheral nerve repair. 
Several preclinical studies have been conducted investigating synthetic biodegradable 
polymer materials in animal models of peripheral nerve injury.  More recently, 
researchers have been focusing on the manipulation of the internal environment of 
NCG which is believed to have a profound effect on the neuronal regeneration process 
(Johnson and Soucacos, 2008; Wood and Mackinnon, 2015).  Pateman et al. (2015) 
assessed poly-acrylate ethylene glycol (PEG) biocompatibility when produced as a 3-
dimensional structure by microstereolithography.  In their study, thy-1-YFP transgenic 
mice were used for expression of fluorescent proteins that can enable axon labelling 
and assessment of axons regeneration across the site of nerve injury and repair.  In 
mice the right common fibular nerves were cut to create a 3 mm gap and then repaired 
with either PEG conduit (diameter 1 mm, length 5 mmm and wall thickness 250 μm) 
or nerve graft.  The animals were then allowed to recover for three weeks (Pateman 
et al., 2015). 
In both repair groups, axons had frequent disorganised pattern of growth at the join of 
the proximal segment with the graft or PEG conduit when compared to the distal edge. 
Furthermore, their result did not show any differences in axonal sprouting between the 
repair groups, and low values of axonal sprouting at distal end in the PEG conduit 
repair group was reported.  Consequently, the authors proposed this method was 
associated with reduced disruption and similar recovery in function to the graft repair 
group (Pateman et al., 2015).  Although no formal testing of nerve function 
(electrophysiology or gait assessment) or pain behavioural assessment was 
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performed due to difficulties related to the size and position of the common fibular 
nerve. 
Biodegradability of PCL material provides the advantage of acting as a temporary 
bridging scaffold which gradual degrade and prevents fibrosis and is less likely to 
cause chronic inflammatory reaction (Johnson and Soucacos, 2008; Wood and 
Mackinnon, 2015).  For repair of short defects, biodegradable NCG are considered 
more advantageous on this effect to be better recovery of nerve function with less 
morbidity those associated with standard repair techniques.  Bertleff et al. (2005) 
conducted a multicentre randomized trial to compare the recovery of sensory function 
following traumatic hand injuries using a biodegradable PCL and direct suturing of 
hand nerves in patients with different nerve injury (mainly ulnar or radial digital nerves).  
Seventeen patients received PCL conduits to repair gaps of 8 mm or more and both 
nerve endings were sutured into the conduit.  In addition, 13 patients had undergone 
direct end-to-end repair.  Assessment of sensory function was undertaken at 3, 6, 9, 
and 12 months after repair by using a computer-assisted force transducer (non-
invasive static measures) and 2-point discrimination methods. Recovery of sensation 
in the nerve guide group was considered at least as good as in the control group and, 
thus PCL conduit were considered suitable for the repair of nerve defects up to 20 mm 
without tension during implantation. 
Another randomised laboratory study conducted by Shin et al. (2009) evaluated the 
functional and histomorphological outcome following implantation of 1.5 mm conduit 
consisting of three synthetic materials (collagen, PCL and PGA) and nerve autograft 
in repairing a 10 mm defect of the sciatic nerve in a rodent model.  After nerve injury 
a recovery period of 12 weeks electromyographic measurements did not show a 
significant difference in compound muscle action potentials, or the percentage of axon 
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count measurements between the autograft and PCL conduit repairs as compared to 
another conduits repair.  In addition, there were no differences in the mean internal 
nerve fibre area, or mean myelin thickness of all experimental groups.  At 12-weeks 
their result showed that PCL and collagen conduits remained structurally stable with 
optimum results, whereas PGA conduits had the lowest compound muscle action and 
degraded quickly.  They established that PCL conduits can be used to repair 10mm 
sciatic nerve defects with improved functional outcome similar to the autograft repair, 
when compared to the other synthetic conduit guidance materials (Shin et al., 2009).  
They also, observed that thick walled-conduit impedes regeneration due to 
compression on regenerating fibres while thin walled conduit had tendency to collapse 
due to weak internal structures (Johnson and Soucacos, 2008; Shin et al., 2009; 
Pateman et al., 2015).  Therefore, it has been suggested that NCG needs to be thin 
as feasibly permit but requires some form of mechanical structural support. 
Several studies have shown that PCL conduits had improved biological and 
mechanical properties that would support neuronal axon regeneration and could 
replace the standard autograft methods for nerve defect repair following nerve injury.  
Den Dunnen et al. (1996) evaluated nerve regeneration following repair of a 10 mm 
gap either using a biodegradable PCL conduit (12 mm length) or an autologous nerve 
graft.  Nerve regeneration was assessed using light microscopy, and morphometric 
analysis.  In the PCL group recovery of sensation was determined by performing reflex 
withdrawal stimulation at week four and six stimulation of the proximal and distal part 
of the operated paw as compared to autograft repair and was shown to be improved 
and recovered further.  After 10 weeks, their result revealed that average number of 
myelinated nerve fibres in the PCL repair were twice as large when compared with 
autograft repair group.  In addition, the recovery pattern of the myelinated nerve fibres 
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was faster in the PCL repair group across short gap defect.  The authors proposed 
that nerve regeneration across gap of 10 mm inside the nerve conduit using a 
biodegradable PCL was faster and qualitatively better than autologous nerve grafts. 
It is important to choose a conduit with optimal internal diameter that does not 
compromise regeneration of nerve fibres.  The internal diameter should provide 
enough space to facilitate insertion of the nerve segments without compression, but 
not too large which could stimulate fibrous tissue formation (Bertleff et al., 2005; 
Johnson and Soucacos, 2008; Shin et al., 2009; Reid et al., 2013; Pateman et al., 
2015).  Reid et al. (2013) conducted histomorphological and immunohistochemical 
assessment of long-term nerve regeneration in 10 mm gap model of rat sciatic nerve 
injury repaired with PCL conduits (diameter 1.6 mm & length14 mm) and autologous 
nerve graft.  After eighteen weeks of recovery, there were no adverse reactions 
observed.  The histological evaluation  did not show a significant difference in the 
pattern or distribution of myelinated fibres between the repair groups and in addition, 
results revealed similar numbers of axons in the distal stumps and equivalent re-
innervation rate of end organ muscle and skin.  Based on their findings the authors 
support the potential use of synthetic biodegradable PCL nerve conduit in clinical 
nerve repair practice.  
1.4.2 Novel targeting of pro-inflammatory cytokines in peripheral nerve injury 
Pro-inflammatory cytokines that are produced after injury may act on sensory nerve 
fibres to generate central sensitization through increased ectopic neuronal activity by 
the interaction of peripheral injury environment and glial cells, which will lead to an 
increase in neurones excitability and subsequent initiation of neuropathic pain (Ren 
and Torres, 2009).  The following section will focus on the targeting of pro-
inflammatory cytokines (IL-1, TGF-β, and TNF-α) by the application of neutralising 
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anti-bodies and receptor blockers after nerve repair.  In addition, this section will also 
consider the effect of IL-10, anti-inflammatory cytokine, on nerve regeneration 
following injury. 
1.4.2.1 Application of antibodies to IL-1 cytokine in peripheral nerve injury 
IL-1 is a potent pro-inflammatory cytokine that is upregulated during the inflammatory 
stage of Wallerian degeneration (Ren and Torres, 2009). There is substantial evidence 
that IL-1 is implicated in the development of neuropathic pain following peripheral 
nerve injury (Sommer et al., 2001; Ren and Torres, 2009).   In addition, IL-1 is thought 
to be the main inflammatory cytokine in the interaction between glia and neurones 
following nerve injury and blocking the action of its IL-1 receptor 1 has been associated 
with a reduction in the development of pain-related behaviours (Sommer et al., 2001; 
Ren and Torres, 2009).      In a chronic constriction injury of the sciatic nerve, Schäfers 
et al. (2001) investigated the effect of combined epineurial application of neutralized 
antibodies to TNF receptor and IL-1R1 and compared that with single antibody therapy 
to TNF and IL-1R1, on attenuating the pain related behaviours in an animal model.  
Data from their study showed that application of combined regime significantly 
reduced the thermal hyperalgesia and withdrawal reflexes of the animals when 
compared to anti-TNF single therapy which were injected once intraoperatively, at day 
4 and 7 post-injury.  In contrast, daily application of anti-IL-1R1 showed continuous 
effect on attenuating thermal threshold when observed during the experiment.  
Additionally, immunohistochemical analysis showed comparable levels of expression 
of TNF and IL-1 protein at day 10 postoperatively across the groups.  The authors 
proposed that the combined therapeutic approach acted synergistically in reducing 
pain related behaviour (Schäfers et al., 2001).   
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Sommer et al. (1999) in a chronic constriction injury model on the sciatic nerve in rats 
investigated the effect of epineurial application of anti-IL-1R1 on thermal and 
mechanical hyperalgesia.  Pain behavioural analysis revealed that although they were 
treated at moderate and high doses showed significant reduction of both pain 
behavioural compared to sham mice groups.  In contrast, thresholds of paw withdrawal 
reflexes to mechanical stimuli was not different to the sham groups at low daily dose 
of anti-IL-1R1.  Immunohistochemical analysis also found that this dose-dependent 
reduction of neuropathic pain was associated with reduced TNF-α immune reactivity 
and low infiltration of macrophages at the site of injury across all the experimental 
groups.  The authors speculated that IL-1 induces neuropathic pain by an alternate 
pathway through activation of bradykinin receptors and prostaglandins, or mediated 
hyperalgesia through the production of NGF (Sommer et al., 1999). 
Sweitzer et al. (2001) investigated the effects of intrathecal administration of IL-1 
receptor antagonist and TNF-α antagonist on attenuating mechanical allodynia in the 
spinal nerve (L5) transection injury model.  Preoperative injection of TNF-α antagonist 
was found to attenuate mechanical allodynia when compared to the IL-1 receptor 
antagonist.  However, a combination of both therapies significantly reduced 
mechanical allodynia even at low doses.  Immunohistochemical analysis and ELISA 
did not reveal any significant differences in protein expression of IL-1 and TNF-α in 
any of the experimental groups.  Furthermore, treatment did not have any effect on 
glia or astrocyte activity.  The findings of the previous studies were consistent with 
those of Winkelstein et al. (2001) on exploring the effects of intrathecal administration 
of IL-1 receptor antagonist and TNF-α antagonist on neuropathic pain.  Their pain 
behavioural analysis demonstrated similar findings in both central and peripheral 
nerve injury models.  The levels of various cytokines expressed and degree of 
77 
 
microglia activity were identical across all the groups investigated.  In peripheral spinal 
section model, the treatment protocol had a significant effect on mechanical allodynia 
when compared to spinal (L5) nerve root ligation injury.  From these observations 
central blocked of IL-1 mediates its anti-allodynic effects believed to be related to down 
regulation of pro-inflammatory cytokines rather than inhibiting glial excitation (Sweitzer 
et al., 2001). 
The introduction and development of transgenic and knockout mice models has 
provided an alternative approach to study regeneration of injured peripheral nerves 
(Rodríguez et al., 2004).  It has been shown that knockout IL-1R1 and TNFR1 mice 
are associated with reduced invasion of neutrophils and macrophages as well as 
reduced mechanical hyperalgesia and impaired regeneration of peripheral nerves 
after injury, when compared to wild mice (Nadeau et al., 2011).  Nociception 
(hyperalgesia) to mechanical stimuli was reinstated, however, after peripheral injection 
of either recombinant IL-1 or TNF at the site of sciatic nerve ligation.  Furthermore, 
depletion of neutrophils with anti-LY6G significantly decreased hyperalgesia after 
nerve injury but axon regeneration and recovery was unaffected, which may introduce 
new insight of only targeting inflammatory cells that mediate initiation of neuropathic 
pain rather than blocking the entire pro-inflammatory cytokine profile which might be 
critical for axonal regeneration (Nadeau et al., 2011). 
1.4.2.2 Application of antibodies to TNF-α cytokine in peripheral nerve injury 
TNF-α is the second most important pro-inflammatory cytokine upregulated following 
peripheral nerve injury (George et al., 2005).  It is believed that TNF-α expression 
induces ectopic neuronal activity following axon damage and subsequently initiates 
neuropathic pain by triggering specific receptors TNFR1 and TNFR2 (George et al., 
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2005).  Tumour necrosis factor antagonist (Etanercept) has been extensively studied 
in other medical fields and used in the treatment of autoimmune conditions such as 
rheumatoid arthritis (Kato et al., 2009).   
It has been postulated that local application of Etanercept might be associated with 
the suppression of pro-inflammatory cytokines that mediate the initiation of 
neuropathic pain by binding to transmembrane TNF isoforms within the endoneurium 
after sciatic nerve injury (Kato et al., 2009).  Kato et al. (2009) examined the distribution 
and binding specificity of locally administered Etanercept in the crush sciatic model of 
nerve injury.  Immunohistochemical analysis using TNF specific antibody (Anti-IgG) 
showed Etanercept-IgG immunoreactivity in the endoneurium of damaged nerves 
after 1 hour and TNF was highly expressed in Schwann cells and macrophages.  Pain 
behavioural analysis following the peripheral application of Etanercept showed 
reduced mechanical hyperalgesia and withdrawal threshold, leading the authors to 
speculate that Etanercept had great potential as a targeted therapy in treating 
neuropathic pain following nerve injury (Kato et al., 2009).  In another study, Kato et 
al. (2010) used the crush sciatic model of nerve injury to investigate the effect of central 
(intraperitoneal) and peripheral (epineurial) application of Etanercept on axonal 
regeneration and expression of growth–related proteins.  They observed that 
immediate Etanercept injection enhanced the rate of sensory axon regeneration and 
expression of GAP-43 detected in ipsilateral DRG of sensory and motor neurones.  
Histological quantification of axons by light microscope also showed a significant 
increase the number of regenerating axons within the distal segment and an increased 
accumulation of Etanercept was also detected in GAP-43-positive immunoreactivity 
nerve fibres in the proximal nerve segments.  They concluded that the immediate 
79 
 
application of Etanercept helps to maintain and support the rate of growth, and 
regeneration process in crushed axons (Kato et al., 2010).  
Sommer et al. (2001) explored the effects of systemic administration of Etanercept 
with different dose regime on reducing hyperalgesia following peripheral nerve injury.  
Their study revealed that Etanercept can reduce thermal and mechanical hyperalgesia 
following constriction injury of mice sciatic nerves (Sommer et al., 2001).  
Immunohistochemical and histomorphological examination of the sciatic nerve tissues 
did not reveal any diverse changes within the groups during the degeneration and 
regeneration processes or in the magnitude of macrophage invasion, which rule out 
impairments of nerve regeneration by Etanercept therapy.  However, pain behavioural 
analysis showed significant effect following the local application of Etanercept on 
mechanical hyperalgesia when compared to intraperitoneal treatment.  The findings 
of Sommer et al. (2001) are support the previous studies by Kato et al., 2009; Kato et 
al., 2010, and suggest that Etanercept has the potential to reduce hyperalgesia and 
neuropathic pain through inhibition of TNF-α activity either prophylactically or 
therapeutically.  
1.4.2.3 Application of scar-reducing agents in peripheral nerve injury 
Scar formation following a severe type of nerve injury (neurotmesis) is common and 
acts as a mechanical obstacle that impedes axonal regeneration and promotes the 
development of neuroma formation at the site of injury (Atkins et al., 2007).  
Experimental manipulation of fibrous tissue formation throughout the process of 
wound healing at the site of peripheral nerve injury in rodents has led to the proposal 
of an alternate therapeutic approach to enhance the functional regeneration by 
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exogenous application of scar reducing agents such as the potent anti-inflammatory 
mediator (IL-10) or antibodies to TGF-β. 
TGF-β isoforms are pro-peptide molecules that contain amino acid chains and a pro-
protein region termed the Latency Associated Peptide (LAP) which has “asparagine 
linked mannose-6-phosphate oligosaccharides” (M6P receptor) (O’Kane and 
Ferguson, 1997).  TGF- β1 and TGF- β2 isoforms specifically bind to M6P receptors 
on corboxyhydate chain of TGF-β.  As a result, exogenous administration of M6P has 
been suggested as a novel approach in reducing scar formation by competitive 
inhibition of TGF-β isoforms at the M-6-P receptor (O’Kane and Ferguson, 1997).  
Moreover, peripheral administration of combined anti-TGF-β antibodies has been 
shown to reduce scar formation at the site of injury (Nath et al., 1998). 
Atkins and colleagues (2006) investigated the outcome of applying antibodies to both 
TGF- β1 and TGF- β2 at the time of sciatic nerve repair in rats.  However, after 7 
weeks’ recovery results revealed that animals that had received antibodies to TGF- β 
at the time of sciatic nerve repair demonstrated reduced levels of collagen which was 
not significantly different to controls.  Electrophysiological testing in the M6P treated 
group revealed slow conduction velocities and significantly lower compound action 
potential ratio when compared to repair alone, suggesting a lower proportion of 
regenerating axon had traversed the repair site.  Quantification of myelinated and non-
myelinated nerve fibres demonstrated considerably higher fibres count on either side 
of nerve repair group and those with antibodies to TGF- β, but this was not statistically 
significant between the groups when compared to controls.  The authors reported that 
neutralization of TGF- β at the time of nerve repair reduced intraneural fibrosis but this 
approach proved neither to promote axon regeneration or reduced increase of 
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neuronal sprouting (Atkins et al., 2006).  However, they did propose that the optimum 
stage for administration of this therapeutic agent is either at or shortly after nerve repair. 
An additional study by Ngeow et al. (2011a) conducted histomorphometric 
quantification of neuronal structures, in order to detect any variations at the site of 
nerve repair after the application of M6P.  Together electron and light microscopic 
analysis did not show any significant difference in myelinated axons diameter across 
the repair site in repair groups when compared to sham animals.  In contrast, axonal 
density and the cross-sectional area of myelinated axons were reduced distal to the 
repair site in the repair groups when compared to controls.  Moreover, the proportion 
of non-myelinated to myelinated axons was comparable in both repair and sham 
groups, and the authors proposed that M6P did not interrupt the myelination process 
by Schwann cells.  Furthermore, Schwann cell proliferation was associated with 
increased remak bundle counts and axonal density distal to the repaired site (Ngeow 
et al., 2011a).  Another study Ngeow et al. (2011b) explored the effects of M6P, 
triamcinolone and IL-10 application, at the time of nerve repair.  After administration 
of 600 mM of M6P, electrophysiological analysis showed that sprouting axons attained 
higher compound action potential modulus ratios and faster conduction velocities, 
suggesting higher percentages of nerve fibres had regenerated successfully, 
particularly lager diameter fibres.  Gait testing also displayed larger paw print area in 
the M6P treated group at 3 weeks, indicating better early functional recovery, which 
plateaued 12 weeks after repair.  In addition, collagen levels were significantly higher 
in all repair group, but not in sham controls.  Their results indicated that intraneural 
scar levels after M6P application were lower than controls, but this was not statistically 
significant.  They proposed that the M6P increased rate of axon regeneration at the 
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early stage of regeneration is attributed to scar remodelling at the site of nerve repair 
(Ngeow et al., 2011b). 
Another study, Harding et al. (2014) investigated the effect of M6P application on the 
rate of axonal regeneration following a nerve graft procedure.  They developed a 
technique of visually quantifying the number of individual regenerating axons across 
a repair site using a strain of transgenic thy-1-YFP-H mice.  The image analysis data 
revealed more sprouting with M6P and vehicle treated groups when compared to 
controls, which was clear to see as the axons entered the proximal part of the tissue 
graft.  The authors illustrated that approximately 75 % of axons present at 3.5 mm 
intervals were accurately followed back to the reference line (start point of axon 
regeneration).  Furthermore, visual quantification shown that the M6P treated group 
had a lower sprouting index when compared to vehicle treated graft, but there was no 
significant difference between the groups.  In repair groups, however, the sprouting 
index rates were stable at 0.5 mm and 1 mm distance from the reference line, and 
then continued to decline at an equivalent rate between the remaining intervals.  This 
study revealed that M6P had influenced the early response of regeneration which was 
specified by an increased sprouting index and the way axons quickly crossed the 
repair site (Harding et al., 2014). 
Wound healing is considered a complex process which involves a sequence of events 
including haemostasis, inflammation and granulation tissue proliferation and 
subsequent fibrosis and scar formation (Morris et al., 2014).  In wound healing, the 
production of pro-inflammatory cytokines by immune cells such as macrophages have 
been implicated in the recruitment of inflammatory cells.  In turn, these produce more 
pro-inflammatory cytokines and as a consequence intensify the inflammatory reaction 
and stimulate scar formation (Morris et al., 2014).  IL-10 is highly expressed in amniotic 
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fluids and fetal tissue and has been postulated to play an important part in the 
decrease of pro-inflammatory cytokines production and the inflammatory response 
and as a result in a healing with minimum scar formation (Morris et al., 2014). 
Atkins et al. (2007) studied the effect of exogenous administration of IL-10 and TGF-
β3 on functional regeneration after sectioning of the sciatic nerve in C57 black mice.  
After 6 weeks’ post-injury mice which received TGF-β3 showed elevated collagen 
levels and did not enhance the regeneration of repaired nerves in comparison to sham 
groups.  Conversely, mice groups received low doses of IL-10 revealed higher 
compound action potential as in control groups proposing that many sprouting 
myelinated axons had successfully spanned the injury site.  Moreover, the level of 
collagen types I and III were also reduced in IL-10 treated mice (low dose) and controls.  
They clarified that low doses of IL-10 could be effective in reducing the fibrous tissue 
formation and improve regeneration of severed nerve fibres, but long-term evaluation 
of outcome is required.  Furthermore, adjusting and implementing an appropriate 
therapeutic regimes and mode of drug delivery is an important aspect for the 
regeneration of nerve fibres (Atkins et al., 2007).  
Another study by Sakalidou et al. (2011) investigated the effect of IL-10 application on 
intraneural scar reduction and functional nerve regeneration after end to side 
anastomosis of peroneal nerve and the tibial nerve in rats.  After eight weeks’ of 
recovery the peroneal functional index and electrophysiological testing did not reveal 
any differences between the groups.  Moreover, histomorphological analysis of nerve 
sections of IL-10 treated groups showed significant higher myelination, reduced scar 
formation and reduced collagen levels when compared to repair alone.  In support of 
previous work by Atkins et al. (2007), they also predicted that unsuccessful functional 
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recovery might be attributed to the short term follow up of the experiment protocol 
(Sakalidou et al., 2011).  
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1.5 Research hypothesis 
Modulating cytokine signalling pathways peripherally either by anti-inflammatory 
cytokines or anti-scaring agents at the time of nerve repair will decrease macrophage 
immunoreactivity and glial cells activation, reduce neuropathic pain, and improve 
functional recovery. 
1.6 Aims and objectives 
Aims 
The overall aims of these studies were to investigate the effects of peripherally applied 
novel cytokine antagonists and anti-scarring agents on inflammation, and establish 
their contribution to the reduction or prevention of neuropathic pain, and effect on 
nerve regeneration.  In addition; the study aims to investigate the effect of poly-
carprolactone conduit implantations on enhancing the functional nerve regeneration.  
Objectives: The main objectives of these studies were to: 
1. Determine the effect of anti-inflammatory cytokine on macrophage infiltration at 
the site of nerve injury and repair, and on glial cells activation in the dorsal and 
ventral horns of the spinal cord using immunohistochemical techniques and 
image analysis.  
2.  To study the effect of novel anti-inflammatory cytokine or anti-scaring agents 
on axonal regeneration following peripheral nerve injury and repair by 
conducting electrophysiology recording and analysis of gait movement.  
3. Utilise transgenic YFP-H mouse strain to investigate the effect of poly-
carprolactone conduit on nerve regeneration following artificial nerve repair by 
axon tracing technique. 
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CHAPTER 2 
Materials and methods 
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2.1 Introduction 
All procedures were carried out at the University of Sheffield, in accordance with the 
UK Home Office Animals (Scientific Procedure) Act 1986.  All experimental protocols 
were approved by the University of Sheffield Biological Services and performed in 
accordance with Project Licence 70/8194.    
2.2 Research methodology 
2.2.1 Animal husbandry and surgical set up 
Experimental animals 
Animals used in this research were bred and supplied by an approved UK Home Office 
facility (Charles River, UK).  All animals were housed in plastic cages with unlimited 
access to water and food.  The room temperature was maintained between 19-21 °C 
with a twelve-hour light/dark cycle.  Animals were allowed to acclimatise for one week 
before undergoing any surgery.  Immediately following surgery, during the 
postoperative recovery period, animals were housed in single cages to reduce any 
incidents or injury from cage mates.  
Surgical procedures were performed under aseptic conditions, all instruments 
autoclaved and hibitane (5 %) used to disinfect the surgical area.  In the first 
experiment (Chapter 3) Sprague Dawley rats (males) were used to attain the primary 
result of the research.  However, in the other experiments (Chapter 4 and 5) C57-
black/ 6 mice were used. 
In this work additional sham group from previous work in the Oral neuroscience group 
is included to explain difference between treatment groups under the investigation.  
Sterile water is considered as negative control and sham not included initially due to 
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the ethical issue in accordance with the UK Home Office Animals (Scientific Procedure) 
Act 1986.   
2.2.2 Anti-inflammatory agent preparation and delivery 
Preparation of anti-inflammatory cytokine agents used in this research is presented in 
table 2.1.  For the preparation of cytokines antagonist agents, sterile water is used and 
as a negative control.  Normal saline was not used because it is a hypotonic solution 
and can be painful on injection.  Also, it can cause tissue damage and cells lysis if 
injected into the tissue (Svendsen et al. 2005). 
For drug administration, a micro-dialysis needle gauge 34 (outer diameter 0.164 mm 
and internal diameter 0.1 mm, World Precision Instruments [Microfill]) attached to a 
length of polyethylene tube (outer diameter 0.60 mm and internal diameter 0.28 mm, 
INSTECH) connected to a 0.5 ml insulin syringe and needle was used to deliver the 
agent at specified increments described below (Figure 2.1).  All treatments received 
by animals were randomised and investigators performing the experiments and 
analysis were blinded. 
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Table 2.1: Anti-inflammatory cytokines agents applied in sciatic nerve injury and 
repair experiments. 
 
 
 
 
 
Drug name Source  Formulation Reconstitution Dose given per 
100μl 
Total 
volume   
IL-1 receptor 
antagonist 
(Kineret ® 
[Anakinra])  
Sobi 100 mg/1 ml 
pre-filled 
syringes 
Not applicable 10 mg/100 μl  100 μl 
 
Combination 
of 
Recombinant 
Human IL-10 
Protein and 
TNF-α 
antagonist 
(Etanercept) 
R&D 
Systems 
217-IL-
005/CF 
Pfizer 
5 μg solution 
in vials 
 
25 mg 
powder 
12.5 μl IL-10 + 
237.5 μl PBS + 0.75 
mg/powder of pre-
weighed Etanercept 
+250 µl sterile 
water 
125 ng IL-10 
+ 0.15 mg 
Etanercept/ 
100 μl 
100 μl 
TNF-α 
antagonist 
(Etanercept) 
Pfizer 25 mg 
powder 
0.75 mg/powder of 
pre-weighed 
Etanercept +500 µl 
sterile water 
0.15 mg/100 µl 100 μl 
Sterile water  Dechra 100 ml 
 sterile water 
Not applicable 0.1 ml/100 µl 100 μl 
90 
 
 
 
 
 
2.2.3 Sciatic nerve injury and repair model and administration of anti-
inflammatory agent 
Animals (Sprague Dawley rats [Males; 8 weeks old--weights 220 g–300 g] and C57 
black-6 mice [Males; 8 weeks or older – weights 17-30 g]) were anaesthetised with a 
2-3 % mixture of isoflurane (100 % w/w isoflurane liquid, IsoFlo®) and oxygen, 
delivered at a rate of 2 litres per minute.  The animals were shaved in the area of the 
left thigh, and a 1-2 cm incision made along the lateral aspect of mid-thigh. Then, the 
left sciatic nerve was exposed and separated freely from the surrounding tissues.  A 
slit was created in the epineurium and 40 µl of assigned agent (Table 2.1) injected 
under the epineurium.  The sciatic nerve was sectioned transversely approximately 12 
mm distal from the sciatic foramen with microscissors, and the proximal and distal 
sciatic nerve stumps immediately repaired with four 9/0 monofilament polyamide 
Figure 2.1: A: micro-dialysis needle attached to polyethylene tube and syringe 
for injection of agents. B: sciatic nerve repair with 9/0 monofilament polyamide 
sutures (ETHILON*) and immediate epineurial administration of treatment agent.  
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(ETHILON*) epineurial suture knots (Figure 2.1B).  Thereafter, the remaining volume 
of agent (60 µl) was administered intramuscularly around the nerve repair, and the 
surgical site closed in layers with vicryl suture material (6/0, ETHICON®).  At the end 
of the surgical procedure each animal received a subcutaneous injection of 
buprenorphine hydrochloride (Vetergesic [0.05 mg/kg], Ceva).  Animals were allowed 
to recover for either one week, following which, sciatic nerve tissue was harvested for 
immunohistochemical analysis alone (Chapter 3), or six weeks, following which 
animals were subjected to a series of non-recovery electrophysiological recordings 
(described below), and tissues extracted for immunohistochemical analysis (Chapters 
4 and 5).   
2.2.4 Sciatic nerve gap injury model 
YFP-H mice (male or females [≥8 weeks old– weights 17-30 g]) were anaesthetised 
with a 2-3 % mixture of isoflurane (100 % w/w isoflurane liquid, IsoFlo®) and oxygen, 
delivered at a rate of 2 litres per minute.  Under the operating microscope, the area of 
the left mid-thigh was shaved, a 1-2 cm incision made along the mid-thigh, and the left 
sciatic nerve exposed and carefully dissected free from surrounding tissue.  The distal 
end of the nerve was marked by making an epineurial cut with microscissors 
approximately 3 mm central to where it branches into the peroneal, tibial and sural 
nerves.  The proximal end of the sciatic nerve was marked exactly 4 mm distal to the 
distal end to ensure consistency between the animals (Figure 2.2.A).  Before 
sectioning the nerve, each nerve ending received 30 µl of treatment agent.  A 5-minute 
lapse was allowed for the injected solution to diffuse into the nerve tissue and then a 
gap effect of 4 mm created to allow conduit tube insertion.  The two sectioned nerve 
stumps were inserted approximately 0.5 mm into either end of the conduit tube and 
secured with an application of fibrin glue (Figure 2.2.B).   
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Following conduit implantation, the remaining 40 µl of treatment agent was injected 
into surrounding muscle tissues, and the wound closed in layers with vicryl suture (6/0, 
ETHICON®).  A subcutaneous injection of buprenorphine hydrochloride (Vetergesic 
[0.05 mg/kg], Ceva) was administered at the end of the surgical procedure.  Animals 
were allowed to recover for 5 weeks, during which time animals were assessed for 
locomotion function (gait assessment - described below).  At the end of the recovery 
period animals underwent a series of non-recovery electrophysiological recordings 
(described below), after which tissues were extracted for immunohistochemical 
analysis and axonal tracing (Chapter 6).   
 
 
 
 
 
 
 
 
 
Figure 2.2: A: measurement of nerve segment with graph paper. B: nerve 
conduit repair in 4 mm gap defect of sciatic nerve.  
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2.2.5 Functional assessment of sciatic nerve regeneration 
2.2.5.1 Gait assessment (Cat-Walk system)  
In animals (YFP-H mice) receiving the nerve conduit implantation, locomotor function 
was evaluated prior to electrophysiological recordings (described below), using 
CatWalk system® (Noldus technology, Netherlands) and gait assessment.  Described 
previously by Ngeow et al (2011b), the system incorporates software which helps to 
detect natural gait parameters including; paw print area and intensity which can be 
measured from each run an animal makes across the walking corridor (Deumens et 
al., 2007).  The corridor system consists of a glass floor and a fluorescent tube which 
emits white light (Figure 2.3).  Gait assessment was obtained from two runs conducted 
immediately before, and then 1, 2, 3, 4 and 5 weeks after implantation.  The total 
surface areas and intensity of paw prints were sensed and recorded by a video camera 
attached beneath the walking glass plate (Deumens et al., 2007).  Assessment of 
natural gait does have limitations due to variations in walking speed of the animals 
under the experimental condition (Ngeow et al., 2011b).  Thus, to achieve accurate 
assessment, an average value of the two runs of each animal was counted.  
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Figure 2.3: Illustration of CatWalk system® (Noldus technology, Netherlands). 
B:  Examples of records of surface areas of paw prints each time the animal 
crosses the walkway.  Diagram adapted from noldus technology, Netherlands 
(http://www.noldus.com/CatWalk-XT/specifications). 
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2.2.5.2 Electrophysiological recordings 
Animals (YFP-H mice and C57 black-6 mice) were anaesthetised with an 
intraperitoneal (ip) injection of fluanisone (0.8 ml/kg) and midazolam (4 mg/kg).  Here, 
the left sciatic nerve was exposed at the site of repair and released from the underlying 
tissues, and sectioned as far distally as possible.  Proximally, the nerve was sectioned 
close to the sciatic foramen and raised by a pair of central recording electrodes of 
platinum wire (0.15 mm diameter).  An evoked stimulation across the sciatic nerve was 
delivered from two pairs of distal and proximal electrodes each situated 2 mm distal 
and central to the repaired site.  In the gap repair model, the stimulating electrodes 
were sited close to the conduit edges touching only the nerve tissues.  The surrounding 
skin flaps were raised to create a pool filled with warm liquid paraffin.  The ground 
electrode was positioned on the skin flap proximal to the stimulating and recording 
electrodes. Recording electrodes were connected to a computer where data was 
processed using Spike 2 software (version 5, Cambridge Electronic Design).  An 
illustration of the electrophysiology recording set-up is shown in (Figure 2.4).  The of 
compound action potential (CAP) from the proximal and distal segments was recorded 
from a 10 responses of stimulation along the sciatic nerve.  As in previous study 
recording CAP, 10 Volts for 0.05 milliseconds is considered the maximum stimulus 
intensity which indicate the proportion of myelinated axons that successfully have 
crossed the repaired site (Atkins et al., 2007).  The CAP ratio calculated between the 
responses evoked from proximal or distal to the repair (modulus with distal stimulation 
÷ modulus with proximal stimulation).  The CAP ratio gives an expression of the 
proportion of axons that have crossed the repair site. 
Conduction velocities were also recorded after injury and repair by measuring the 
latency of the earliest component of the CAP evoked by stimulation distal to the 
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repair using the digital storage oscilloscope.  This measurement of conduction 
velocities method was previously validated by Atkins et al. (2007) in comparing 
latencies of the regenerating axons after nerve repair.  
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Figure 2.4: A: Diagram illustrates the arrangement of electrodes for the recording of compound action 
potentials. B:  Examples of compound action potential recordings with electrical stimulation (proximal versus 
distal). C: Recording of compound action potential in direct nerve repair. D: Recording of compound action 
potential in nerve conduit repair. (Figure A and B reproduced with permission from John Wiley and Sons 
and Copyright Clearance Centre). 
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2.2.6 Tissue harvesting, processing and sectioning 
Following one-week recovery (immunohistochemical analysis only) or 
electrophysiology recordings (Chapter 4), animals were perfusion-fixed and tissue 
harvested under non-recovery anaesthesia protocol.  Animals were deeply 
anaesthetised with 0.5 ml of sodium pentobarbital (intraperitoneal injection, 20 % w/v, 
JML), and perfusion-fixed intracardially (via the left ventricle) under a surgical 
microscope, first with 0.2 M perfusion buffer (60 ml in mice and 750 ml in rats), followed 
by 4 % paraformaldehyde in 0.1 M phosphate buffer solution (PBS) (20 ml in mice and 
750 ml in rats).  The left and right sciatic nerves were harvested and a laminectomy 
performed to allow harvesting of the spinal cords.  Tissues were immersed in 4 % 
paraformaldehyde for 4 hours and cryoprotected overnight in 30 % sucrose solution, 
both at 4 °C.  
After completion of the electrophysiology recordings (Chapter 5), animals received a 
0.5 ml (100 mg) intraperitoneal injection of sodium pentobarbital (20 % w/v) whilst 
under deep anaesthesia.  Then the right and left sciatic nerves and spinal cord tissues 
were removed and fixed in 4 % paraformaldehyde for 24 hours, and cryoprotected 
overnight in 30 % sucrose solution, both at 4 °C. Following completion of the 
electrophysiological recordings in the YFP-H mice, the right and left sciatic nerves 
were fixed in situ with 4 % paraformaldehyde for 30 minutes and then tissues mounted 
directly onto slides and stored at 4 °C The spinal cords were harvested following 
laminectomy and processed as described above. 
Before the nerves were frozen down, excessive connective tissues were removed.   
The sciatic nerves were orientated longitudinally on the cryostat chuck, with surgical 
repairs knots facing up, and embedded in Optimal cutting temperature compound 
medium (OCT; Thermo Scientific™).  The meninges surrounding the spinal cords were 
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carefully removed and the cords dissected into three separate sections; cervical, 
thoracic and lumbosacral under a dissecting light microscope.  The spinal cords were 
held in a vertical rostral (top) to caudal (bottom) position on the cryostat chuck, with 
the aid of a section of rubber tubing, which was filled with OCT medium.  The sciatic 
nerves and spinal cords were frozen down to -50 °C freezing temperature using a 
cryostat freezing plate and stored in -80 °C freezer.  Tissues were cut using a cryostat 
(CRYO-STAR HM 560 MV, Microm International, Germany) at optimal cutting 
temperature (-19-23 °C).  The sciatic nerves were sectioned longitudinally at a 
thickness of 14 µm and collected serially onto Poly-D-lysine (PDL, SIGMA) coated 
slides (Figure 2.5).  Three sections, without rolling or orientation distortion were 
collected per slide, and the slides left to air dry for 1 hour, before being stored at -
80 °C, until required for immunohistochemical processing.    
30 µm thick transverse spinal cord sections were cut from the lumbar region block.   
Representative L4 and L5 sections were identified under a light microscope and 12 
sections per animal were collected into a 24-well plate filled with PBS (Figure 2.6).  
The sections were stored at 4 °C fridge before immunostaining. 
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Figure 2.5: Serial collection of nerve tissue sections on PDL coated slides 
during sectioning of sciatic nerve. Sectioning of nerve tissue starts from 
SN.1 to SN.48.  SN: nerve section number.  For each nerve, 3 sections 
were taken across the width of the nerve for analysis. This serial collection 
of sciatic nerve tissues gives representative tissue sample of axons for 
immunostaining.   
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Figure 2.6: Spinal cords sections collected into well plate filled with 
PBS for immunostaining.  
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2.2.7 Immunohistochemistry  
Indirect immunofluorescence immunohistochemistry was employed to label the sciatic 
nerve and spinal cord tissues for macrophages and glial cells 
2.2.7.1 Antibody specificity and pre-absorption controls 
The selection of primary and secondary antibodies for the study of macrophage and 
glial cells labelling was based on their use in previous immunocytochemical studies, 
and protocols developed and tested within the oral neuroscience group laboratory 
(Powis et al. 2012).  The two types of controls conducted for the immunocytochemistry 
in this work were primary and secondary antibody controls.  Pre-absorption of the 
primary antibodies used in these studies was carried out to assess the specificity of 
the primary antibody binding to the antigen.  This procedure involved incubating with 
primary antibody with its specific blocking peptide for 24 hours, before its application 
in the standard immunohistochemical protocol, as described below.  The specificity of 
the secondary antibody to the primary antibody was tested by omitting the primary 
antibodies from the protocol, and applying the secondary antibodies only. 
Omission, and preabsorption of the CD68, IBA-1, and GFAP primary antibodies with 
their respective haptens (Tables 2.2 and 2.3), revealed no positive macrophage or 
glial immunofluorescent labelling in either the sciatic nerve or spinal cord tissues, 
confirming specificity of the antibodies employed in these studies (Figures 2.7-2.11).   
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Table 2.2: Pre-absorption volumes of primary antibodies and their respective peptides 
for macrophage labelling. 
 
 
 
 
 
 
Antibody 
specifity 
Rat sciatic 
nerve 
Type  Total  Used  
Primary  Mouse Anti-rat CD68 
(MCA341GA, BIO RAD) 
0.1 mg/ ml (IgG 
concentration1.0 mg/ml) 
1.5 µl 
(1:1500) 
Secondary  Donkey Anti-mouse CY3 (715-
165-150, Jackson Immuno-
Research Inc) 
0.5 mg/ml at 1.4 mg/ml) 4.5 µl (1:500) 
Blocking 
peptide 
mouse IgG1 negative control 
(MCA1209, BIO RAD) 
0.1 mg/ ml 10 μg (100 µl) 
Antibody 
specifity 
Mouse sciatic 
nerve 
Type  Total  Used  
Primary  Rat anti-mouse CD68 
(MCA1957GA, BIO RAD) 
0.1 mg/ ml (IgG 
concentration 0.5 mg/ml) 
1.5 µl 
(1:1500) 
Secondary  Goat Anti-Rat IgG CY3 (112-
165-167, Jackson Immuno-
Research Inc) 
0.5 mg/ml at 1.4 mg/ml) 4.5 µl (1:500) 
Blocking 
peptide 
rat IgG2a negative control 
(MCA1212, BIO RAD) 
0.1 mg/ ml 10 μg (100 µl) 
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Table 2.3: Pre-absorption volumes of primary antibodies and their respective peptides 
for glial cell labelling. 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Type  Total  Used  
Primary  Goat polyclonal anti-
IBA1 (ab5076) 
100 µg at 0.5 mg/ml 0.48 µl (1:2500) 
Secondary  Donkey anti-goat CY3 
(705-165-147, Jackson 
Immuno-Research Inc) 
1.5 mg/ml 2.4 µl (1:500) 
Blocking 
peptide 
Human IBA1 peptide 
(ab23067) 
100 µg at 1 mg/ml 10 µg (10 µl) 
Antibody Type  Total  Used  
Primary  Rabbit polyclonal anti-
GFAP 
(ab7260) 
50 µg at 0.5 mg/ml 0.6 µl (1:2000) 
Secondary  Donkey anti-rabbit CY3 
(711-165-152, Jackson 
Immuno-Research Inc) 
1.4 mg/ml 2.4 µl (1:500) 
Blocking 
peptide 
Human GFAP peptide 
(ab48665) 
100 µg at 1 mg/ml 10 µg (10 µl) 
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Figure 2.7: Microscopic images illustrating macrophage (CD68) 
antibody specificity and Immunofluorescent labelling in uninjured rat 
sciatic nerve seven days after sciatic nerve exposure. (A) Pre-
absorption of primary antibody with blocking peptide shows negative 
macrophage staining. (B) Application of secondary antibody with 
omission of primary antibody shows negative macrophage staining. (C)  
Application of specific primary and secondary antibodies shows no 
macrophage staining. Scale bar= 100 µm.   
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Figure 2.8: Microscopic images illustrating macrophage (CD68) 
antibody specificity and immunofluorescent labelling in rat sciatic nerve 
seven days after sciatic nerve injury and repair (yellow arrows: repaired 
site). The bright dots indicate active microphages. (A) Pre-absorption of 
primary antibody with blocking peptide shows negative macrophage 
staining. (B) Application of secondary antibody with omission of primary 
antibody shows negative macrophage staining. (C) Application of 
specific primary and secondary antibodies shows positive macrophage 
staining. Scale bar= 100 µm.    
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Figure 2.9: Microscopic images illustrating macrophage (CD68) antibody 
specificity and immunofluorescent labelling in uninjured mouse sciatic nerve. 
(A) Pre-absorption of primary antibody with blocking peptide shows negative 
macrophage staining. (B) Application of secondary antibody with omission of 
primary antibody shows negative macrophage staining. (C) Application of 
specific primary and secondary antibodies shows no macrophage staining. 
Scale bar= 100 µm.   
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Figure 2.10: Microscopic images illustrating macrophage (CD68) antibody 
specificity and immunofluorescent labelling in mouse sciatic nerve six weeks 
after sciatic nerve injury and repair (yellow arrows: repaired site). The bright 
dots indicate active microphages. (A) Pre-absorption of primary antibody 
with blocking peptide shows negative macrophage staining. (B) Application 
of secondary antibody with omission of primary antibody shows negative 
macrophage staining. (C)  Application of specific primary and secondary 
antibodies shows positive macrophage staining. Scale bar= 100 µm. (note: 
intense red dots in A and B images represent sutures materials).  
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Figure 2.11: Microscopic images of spinal cords. Top: Astrocyte (GFAP) labelling in the L4 region of the mouse spinal cord. (A) Pre-
absorption of primary antibody with blocking peptide shows negative astrocyte staining. (B) Application of secondary antibody with 
omission of primary antibody shows negative astrocyte staining. (C) Application of specific primary and secondary antibodies shows 
positive astrocyte staining. Bottom: Microglia (IBA-1) labelling in the L4 region of the mouse spinal cord. (D) Pre-absorption of 
primary antibody with blocking peptide shows negative microglia staining. (E) Application of secondary antibody with omission of 
primary antibody shows negative microglia staining. (F) Application of specific primary and secondary antibodies shows positive 
microglia staining. Scale bar= 25 µm. Blue arrows represent ipsilateral and contralateral horns to the site of nerve injury and repair.  
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2.2.7.2 Macrophage immunohistochemical labelling in the sciatic nerve 
Sciatic nerve sections were stained for pan-macrophage marker CD68.  The 
immunohistochemistry protocols applied for macrophages cell immunolabelling in the 
sciatic nerve for the rats and mice are illustrated in appendix D and E.  
A set of three tissue slides (eg. slide set 1A, 2A, 3A – see Figure 2.5) per animal were 
taken out of the freezer and allowed to air dry for 1 hour, prior to immunohistochemical 
processing.  The slides were placed in a glass staining trough and washed in 
phosphate buffered saline (PBS) containing 0.2 % Triton X-100, for 2 x 10 minutes at 
room temperature on a platform shaker.  Immunostaining of the sciatic nerve tissues 
was achieved by inverting the slides and placing face down on a 24 well plate lid, and 
solutions applied and taken up through capillary action. 
Each slide (a total of three sections) was blocked in 250 µl 20 % normal donkey (017-
000-121, Jackson Immuno-Research Inc) or normal goat serum (S-1000, Vector 
Laboratories) diluted in 0.2 % PBS-T, in a moisture chamber for one hour at room 
temperature.  Following tissue blocking, the sections were incubated with one of the 
primary antibodies mouse anti-rat CD68 (1:1500; MCA341GA; Serotec, Oxford, UK), 
or rat anti-mouse CD68 (1:1500; MCA1957GA; Serotec, UK) diluted in PBST and 5 % 
normal donkey serum, according to the animal species (listed in the Table 2.4), and 
placed in a moisture chamber overnight at 4 °C.  Tissue sections were washed in PBS, 
2 x 10 minutes, and either donkey anti-mouse CY3 (1:500; Jackson Immuno-Research, 
UK) or goat anti-rat CY3 secondary antibody (1:500; Jackson Immuno-Research, UK) 
applied for 90 minutes at room temperature, in a dark environment.  Finally, slides 
were washed in PBS (2 x 10 minutes), mounted in vectashield mounting media (H-
1000, Vector Laboratories) and cover-slipped.  
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2.2.7.3 Glial immunohistochemistry in the spinal cord  
Spinal cord sections were stained for microglial marker IBA-1 and astrocyte marker 
GFAP.  The immunohistochemistry protocols for microglial and astrocytes cells 
immune-labelling is illustrated in appendix F and G.  Preparation of gelatine coated 
slides used in experiments is shown in appendix B. 
Twelve sections per animal from the L4 region were selected for glial cell labelling.  
Spinal cord sections were stained using a free floating technique, carried out in a 24-
well plate.  Each tissue section per well plate, was blocked in 200 µl 10 % normal 
donkey serum (017-000-121, Jackson Immuno-Research Inc) in 0.2 % PBS-T, for one 
hour at room temperature on the platform shaker.  Thereafter, IBA-1 goat polyclonal 
primary antibody (1:2500; Abcam ab5076) or GFAP rabbit polyclonal primary antibody 
(1:2000; ab7260 Abcam), in diluted in PBST and 5 % normal donkey serum was 
applied overnight at 4 °C.  Following 2 x 10 minute washes in PBS, donkey anti-goat 
CY3 secondary antibody (1:500; Jackson Immuno-Research, UK) was applied to IBA-
1 primary labelled sections and donkey anti- rabbit CY3 (1:500; Jackson Immuno-
Research, UK) applied to GFAP primary labelled sections for two hours.  The spinal 
cord tissues were finally washed in PBS 2 x 10 minutes, placed on gelatine coated 
slides, mounted with vectashield and cover-slipped. 
 2.2.8 Image acquisition and analysis of tissues 
The processed sciatic nerve and spinal cord tissues were examined using a Zeiss 
Axioplan 2 fluorescence microscope (D-7082, Carl Zeiss, Germany) with Qimaging 
Retiga 1300R camera (MC 100, Carl Zeiss, Germany), fitted with filters to view 
fluorescent markers FITC (green fluorescence emitted at 490-500 nm maximum 
excitation wavelength) and Cy3 (red fluorescence emitted at 550-570 nm maximum 
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excitation wavelength).  Fluorescent images were acquired using Image Pro-Plus 
software (Version 5; Media Cybernetics, Bethesda, MD), and immunofluorescent 
labelling analysed qualitatively and quantitatively.  
Image processing of macrophage labelling in the sciatic nerve 
Images of three sections of the injured sciatic nerve per animal were captured using 
the x10 objective, for qualitative and quantitative analysis of CD68 staining.  The 
percentage area of positively stained tissue, 1.5 mm either side of the repair site, as 
represented by suture material, was included in the measured area of interest (Figure 
2.12). To quantify the percentage area of macrophage CD68 labelling, Image-Pro Plus 
v.7 software was used. The area of interest highlighted by drawing green line to 
exclude epineurium. The levels of immunoreactivity of the cells were determined, by 
selecting thresholding of images to detect labelled structures and determine the 
percentage area fraction covered (Figure 2.13). Then, images brightness and contrast 
were adjusted to make the images similar to that observed in the fluorescent 
microscope. Each reading was taken three times, and the mean was taken. 
Image processing of glial cell labelling in spinal cord 
Images of three stained spinal cord sections per animal were captured using the x10 
objective for qualitative analysis and x40 objective for quantitative analysis of 
astrocytes and microglial immunoreactivity in the lumbar spinal cord (L4 region). The 
percentage area of GFAP and IBA-1 labelling was measured as ratio in ipsilateral 
versus contralateral sides in the dorsal and ventral horns, per animal (Figure 2.14). 
To quantify the percentage area of Iba-1 and GFAP labelling, Image-Pro Plus v.7 
software was used. The percentage area of glial labelling calculated by selecting area 
of interest and then activation areas highlighted by pink, while the remaining areas 
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would be highlighted by yellow (Figure 2.15). The brightness and contrast of the 
images were adjusted to make the images similar to that observed in the fluorescent 
microscope. Each reading was taken three times, and the mean was taken.   
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Figure 2.12: Microscopic images illustrating areas of interest 
measured and exclusion of epineurium, for quantitative analysis of 
percentage area of CD68 staining in sciatic nerve. The bright dots 
indicate active microphages. Yellow arrow indicated repaired site 
(suture materials). Scale bar= 100 µm.   
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Figure 2.13: Analysis of a proximal part of the injured sciatic nerve and area of 
interest highlighted by drawing green line to exclude epineurium. A) The 
activation area (the bright dots). B) Highlighted activation area (area of 
interested by pink) and grey background area. The ratio of activation area 
(pink) to the selected area (grey) is calculated. Scale bar= 100 µm. 
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Figure 2.14: Microscopic images of spinal cord sections illustrating areas measured for quantitative 
analysis of percentage area of IBA-1 (A) and GFAP (B) glial cell labelling. white arrows indicated 
corresponding areas of interest and showing hypertrophied and amoeboid glial cells.  Scale bar= 
25 µm. 
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Figure 2.15: Analysis of a region of spinal cord. A) The activation area (the bright dots). 
B) Highlighted activation area (area of interested by pink) and background (yellow). The 
ratio of activation area (pink) to the entire picture (yellow) is calculated. Images showing 
hypertrophied and amoeboid glial cells.  Scale bar = 25 µm. 
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2.2.9 Axon tracing 
YFP-H mice were used for assessment of nerve regeneration following nerve injury 
and repair was based on a method described by Harding et al. (2014) and Pateman 
et al. (2015).  YFP-H mice express a yellow fluorescent protein in their neurons which 
enables direct tracing of individual axons following nerve repair.  The method 
measures sprouting index (SI), functional axon tracing and indicates the level of axon 
disruption across the conduit repair. 
Images were captured by a laser scanning confocal microscope (Zeiss LSM510).  
Stacks of optical slices 10 μm thick were taken through the entire thickness of the 
nerve.  Thereafter, for analysis the individual profile of each regenerating axons was 
reconstructed using Adobe Photoshop. 
A reference point was determined by a line perpendicularly drawn across the nerve 
image starting at the interface of the proximal stump with the conduit repair (0.0 mm 
interval) (Figure 2.14).  An additional point before the first interval was marked at -0.5 
mm (uninjured region).  Further intervals were determined on the nerve image from 
0.0 mm to 4.0 mm.   
The first parameter, sprouting Index was determined by counting the number of axons 
at each interval and dividing the axon number at -0.5 mm.  An average value was used 
to minimise the estimation error.    
Secondly, functional axon tracing was used to determine the percentage of axons that 
had successfully crossed the entire length of the conduit repair.  A minimum of 75 % 
of the counted axons at each interval were traced in a backward direction either to the 
proximal stump or to the point of branching (Figure 2.15). Then, tracing was 
undertaken at all preceding intervals in turn to allow the percentage of axons from the 
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start interval represented at each interval to be calculated.  Axons that successfully 
regenerated along entire conduit repair length were counted and the percentage of 
axons at all intervals was determined.   
The third parameter is axon disruption pattern which has been correlated with low 
recovery of nerve function.  Axons disruption primarily occurs shortly after the joining 
of the proximal stump conduit repair which was predetermined from the 0.0 mm to 1.5 
mm intervals as described by Harding et al. (2014) and Pateman et al. (2015).  Axons 
were typically traced across this region and their length measured to determine the 
average axon length as a proportion of the distance (i.e. 1.5 mm) (Figure 2.16).   
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Figure 2.16: Confocal fluorescent microscopic image illustrates axons tracing from 4.0 mm interval position 
back to 0.0 mm. For sprouting index analysis, the images were marked at approximate 0.5 mm intervals 
originating from the point proximal nerve conduit interface to the point where axons had entered the distal 
nerve ending, with one additional interval marked at -0.5 mm prior to the first interval which represent 
uninjured axons. The number of axons at each interval were counted and the number of axons at each 
interval were divided by the number of axons counted at the -0.5 mm interval to give a sprouting index.  
Scale bar= 1.0 mm. 
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Figure 2.17: Confocal fluorescent microscopic image illustrates axon tracing from 4.0 mm intervals back to 
0.0 mm to calculate percentage of axons crossed repair without branching or joining previously traced axons 
as highlighted with yellow circles.  Axon tracing methods using Adobe Photoshop performed from the final 
interval back along the conduit repair to the first interval or a branch point with a previously traced axon, 
with a minimum of 75 % of the axons present traced.  Scale bar= 1.0 mm. 
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Figure 2.18: Confocal fluorescent microscopic image to determine an 
average increase in axon length (highlight axons disruption pattern). Traced 
axons from the 1.5 mm interval back to the 0.0 mm interval were measured 
and compared to the direct distance between intervals (An average 
increase in traced axon length between the 0.0 mm and 1.5 mm intervals 
was considered indicative of axon disruption between the central nerve end 
and conduit repair).  Scale bar= 1.0 mm. 
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2.2.10 Poly-caprolactone conduit preparation, in vitro and ex vivo testing 
Poly-caprolactone conduits used for this work were fabricated by Jonathan Field (PhD 
student) into 3-dimensional structures using microstereolithography in the laboratory 
of Dr. Fred Claeyssens at the University of Sheffield.  Using microstereolithography 
conduits of 1 mm internal diameter, 250 μm wall thickness and 5 mm in length were 
manufactured for evaluation of axon regeneration in the sciatic nerve injury model in 
YFP- transgenic mice (Figure 2.17).   
In vitro and ex vivo testing of Poly-caprolactone as a nerve guidance conduit were 
carried out by Dr. Christopher Pateman in the laboratory of Professor John Haycock 
at the University of Sheffield (Pateman et al., 2014).  This revealed that cultured 
neuronal and DRG cells align along the topographical parallel channels which 
potentially enhances cellular adhesion and neurite outgrowth on the PCL surface.  In 
addition, the grooves or channels act as a guide directing regeneration from the 
proximal toward the distal nerve end segment when used in vivo (Pateman et al., 2014).   
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Figure 2.19: (A and B) Scanning electron microscopy images of PCL nerve 
guidance conduit. (C) An image of PCL nerve guidance conduit of 5 mm length. 
(D) Implantation of PCL nerve conduit for sciatic nerve in repair. 
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2.3 Sample size calculation  
Calculation of sample sizes for this work was performed using Biomath online statistic 
package provided by division of Biomathematics/Biostatistics at Columbia University 
Medical Centre (http://www.biomath.info/power/index.html).  Outcome measures 
considered in this research were based on results from previous experiments carried 
out in our laboratory (Ngeow et al., 2011b, and Pateman et al., 2015). 
Sample size calculations were undertaken for different outcome measures using a 
power of 80 % and significance level (alpha) of 0.05 (two-tailed) and these measures 
are described below.  The sample size chosen in Chapter 3 in the initial study was 
based on previous nerve injury and repair studies carried out by Atkins and colleagues 
(2006).  Atkins et al. (2006) examined the hypothesis that the application of a scar-
preventing agent to a nerve repair site would enhance function and regeneration of 
nerve axons fibres following administration of a scar reducing agent (TGF-b1 and 
TGF-b2) after repair.  Out of 18 adult Sprague-Dawley rats, 6 animals acted as sham-
control and the remaining 12 animals had their nerve sectioned and immediately 
repaired, with six receiving an anti-scarring agent.  Data from this study revealed that 
the mean percentage of collagen fibres was not significantly different from that in the 
sham controls (3.45 %, p =0.15; Kruskal-Wallis multiple comparisons test), while CAP 
ratio was significantly reduced following administration of TGF-b1 and TGF-b2 (0.23, 
p =0.042). Sample size of studies in Chapters 4, 5 and 6 were calculated on standard 
deviations extracted from the initial and previous work in related studies (Ngeow et al., 
2011b, and Pateman et al., 2015).  Sample size calculation to detect significant 
differences between two groups for several parameters were measured using a power 
of 80% and significance level (alpha) of 0.05 (two-tailed).  
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The main parameters measured revealed the following information to determine the 
number of subjects to be studied; 
A) Percentage of CD68 area staining at site of nerve injury and repair 
The mean value of CD68 percentage area staining of two groups (for example; sterile 
water versus IL-1 cytokine antagonist) used from the initial study, were 22.6 % and 
17.08 %.  Using the mean standard deviation of 3.90 %, the difference of 5 % between 
the two treatments would be detected with groups of 9 animals (unpublished data from 
Chapter 3). 
B) The extent of axon regeneration across the repaired site after nerve injury 
The mean value of axon regeneration of 0.45 % and 0.29 % as shown by compound 
action potential ratio between two groups were extracted from previous work (Ngeow 
et al., 2011b).  Using the mean standard deviation of 0.113 %, the difference of 0.16 % 
between the two treatments would be detected with groups of 9 animals. 
c) Percentage of paw print areas following recovery of nerve injury and repair 
The mean value of paw print areas of 0.74 % and 0.24 % as shown by gait analysis 
between two groups were taken from previous work (Ngeow et al., 2011b).  Using the 
mean standard deviation of 0.353 %, the difference of 0.49 % between the two 
treatments would be detected with groups of 9 animals. 
D) Extent of axon sprouting profile in nerve conduit guidance repair 
The values of sprouting index (170.4 % vs 145.4 %), functional tracing (49.9 % vs 
49.2 %) and axon disruption (21.5 % vs 11.4 %) between the two groups was shown 
by assessment of axon sprouting profile in nerve conduit repair in YFP-H mouse model 
(Pateman et al., 2015).  Using the mean standard deviations of 17.67 %, 0.494 % and 
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7.14 %, the differences of 25 %, 0.69 % and 10 %, for sprouting index, functional axon 
tracing and axon disruption between the two treatments would be detected with groups 
of 9 animals. 
Detectable differences with reasonable effect size would be achievable with sample 
sizes of   9 subjects, however, sample size in each treatment group is increased by 
10 % to account for any attrition such as failed repairs or death of animals.  Final 
adjusted sample size was 10 animals in each experimental group.  
 
2.4 Statistical analysis  
Statistical analysis was performed using GraphPad Prism7 (GraphPad Software, Inc, 
USA).  In the initial study, multiple comparisons of immunohistochemical data between 
groups were performed using Dunn's-Kruskal-Wallis multiple comparisons test to the 
difference in mean percentage area of CD68 immunoreactivity in the sciatic nerve 
tissues of all experimental groups.  Differences between groups were considered 
significant if p≤ 0.05.  In Chapters 4,5 and 6, statistical comparisons in 
immunohistochemistry and electrophysiology recordings and the average axon length 
were performed using a two-tailed t-test.  In addition, two-way repeated measures 
ANOVA was used for comparison between the groups to detect any difference in 
sprouting index and functional axon tracing and changes in gait parameters in Chapter 
6.  Quantitative data are expressed as mean ± SEM. Statistical significance between 
the groups was established if p≤ 0.05. Data in graphs are presented as mean ± SEM. 
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CHAPTER 3 
Peripheral application of cytokines antagonist at the site 
of nerve injury and repair: preliminary immune- 
modulation response in peripheral nerve injury 
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3.1 Introduction 
 Nerve injury and repair often results in a functional recovery that is rarely satisfactory 
and often incomplete.  Therefore, it is essential to understand the complex sequence 
of events and processes that follow nerve injury (Rodríguez et al., 2004; Stefano et al., 
2013).   
It is well documented that the inflammatory changes occurring in an injured peripheral 
nerve are regulated by the release of endogenous cytokines (Fregnan et al., 2012; 
Bastien and Lacroix, 2014), which are crucial to Wallerian degeneration (WD) and 
consequent neural regeneration.  These include; IL-1 and TNF-α, cytokines and 
opposing anti-inflammatory cytokines such as IL-10.  The regulation of these cytokines 
has been demonstrated to be vital to neuronal axon healing and the regeneration 
process (Fregnan et al., 2012; Bastien and Lacroix, 2014). 
After peripheral nerve injury, pro-inflammatory cytokines are upregulated in the first 
phase of WD promoting the recruitment of macrophages and other immune cells.  In 
addition, anti-inflammatory cytokines such as IL-10 are upregulated helping to reduce 
the initial inflammatory response (Taskinen, 2000; Gaudet et al., 2011).  Consequently, 
anti-inflammatory cytokine action helps to accelerate the end of the degeneration 
stage and initiate the regeneration and healing phase to establish the recovery 
process of injured peripheral nerves. 
It is generally agreed that cells such as Schwann cells and macrophages play a crucial 
part during Wallerian degeneration (Fregnan et al., 2012; Bastien and Lacroix, 2014).  
These cells clear degenerated material by phagocytosis and additionally, produce 
several cytokine mediators and neurotrophic factors that support nerve cell 
regeneration.  It has been suggested that pro-inflammatory cytokines IL-1 and TNF-α, 
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are expressed as proactive proteins which are then split into their active form to 
regulate the immune inflammatory response by activation of networks of other 
cytokines and neurotrophic factors.  Moreover, these pro-inflammatory cytokines 
produce their effects by acting on receptors that are expressed either on neurons or 
other neighbouring cells (Thacker et al., 2007; Fregnan et al., 2012; Bastien and 
Lacroix, 2014).  
TNF-α acts on TNF-R1 and -R2 receptors which are both expressed on glial cells and 
neurons.  After constriction nerve injury it was observed that, TNF-α expressed at an 
injury site played a significant role in the nerve degeneration and regeneration process 
by regulating the recruitment of macrophages, and subsequent production of 
inflammatory cytokines such as IL-1 (Sommer et al., 2001; George et al., 2005). 
Several in vivo and in vitro studies have investigated the role of TNF-α following 
peripheral nerve injury.  Knockout studies demonstrate that following sciatic nerve 
injury, mice lacking TNF-α protein displayed poorer functional nerve recovery, due to 
impaired cell infiltration and delayed myelin material clearance at the time of 
regeneration of damaged axons (Nadeau et al., 2011).  Other studies have reported 
that TNF-α injections are associated with the development of neuropathic pain (Kato 
et al., 2009; Kato et al., 2010), and these in vivo studies revealed the direct effect of 
TNF-α antagonist (Etanercept) on attenuating pain-related behaviour in a dose-
dependent regime after crush sciatic model of nerve injury.  This highlights the critical 
role that TNF-α plays in direct chemoattraction of immune cells and the development 
of neuropathic pain following peripheral nerve injury. 
IL-1 cytokine is an important pro-inflammatory cytokine that exists in two forms (IL-1 α 
and IL-1 β) with different biological effects at a cellular level (Fregnan et al., 2012; 
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Bastien and Lacroix, 2014).  It is well documented, that after nerve injury, levels of IL-
1 are rapidly upregulated by Schwann cells as they lose contact with their 
corresponding axons, and IL-1 upregulation is involved in the development of 
neuropathic pain following peripheral nerve injury (Sommer et al., 2001; Ren and 
Torres, 2009).  IL-1 acts by binding to the IL-1 receptor accessory protein (IL-1 RAcP) 
of IL-1RI which has been proposed to stimulate surrounding glial cells and 
subsequently sensitize central neurones (Wolf et al., 2006; Bastien and, Lacroix, 2014). 
Therefore, it appears that IL-1 cytokine is a key mediator in the interaction between 
microglia and neurones, and blocking the action of its IL-1 receptor 1(IL-1R1) has been 
considered as a therapeutic approach in preventing development of neuropathic pain 
(Sommer et al., 2001; Ren and Torres, 2009). 
Lastly, IL-10 a powerful anti-inflammatory cytokine, is produced by many different cell 
types including macrophages, T cells, mast cells and fibroblasts (Gaudet et al., 2011; 
Bastien and Lacroix, 2014).  It has been observed that IL-10 plays a vital role in 
regulating production of the pro-inflammatory cytokines and subsequent 
downregulation of recruitment of immune cells following peripheral nerve injury 
(Gaudet et al., 2011; Bastien and Lacroix, 2014; Kwilasz et al., 2015).  Several 
signalling pathways have been suggested to enhance or suppress IL-10 transcription 
which include MAPK and NFkB in immune cells.  It is known that IL-10 acts through 
its 1L-10 receptor-1 (1L-10R1) that is expressed on the surface of immune cells, and 
as a result reduces the immune inflammatory response and resultant tissue damage.  
In addition, this anti-inflammatory cytokine is believed to exert a neuroprotective 
function centrally by decreasing glial cell activity and promoting neuronal cells survival 
after injury (Gaudet et al., 2011; Bastien and Lacroix, 2014; Kwilasz et al., 2015).  After 
injury, it has been shown that expression of IL-10 is upregulated within a few hours 
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and peaks at 7 days, following macrophage infiltration at the site of injury (Taskinen et 
al., 2000).  There is clear evidence that administration of IL-10 at the time of nerve 
repair reduced as fibrous tissue formation at the site of nerve injury and repair and, 
showed better regeneration in comparison to control groups (Atkins et al., 2007).   
3.2 Aim and objectives 
The aim of this study was to investigate the effects of novel pro-inflammatory cytokine 
interleukin-1 antagonist (Anakinra), and anti-inflammatory cytokine IL-10 and 
combination of TNF-α antagonist (Etanercept) and anti-inflammatory cytokine IL-10, 
on inflammatory reaction at the site of peripheral nerve injury, in order to establish their 
possible contribution to the reduction or prevention of neuropathic pain, and determine 
their potential effects on nerve regeneration. 
3.3 Hypothesis 
Application of anti-inflammatory agents at the time of nerve repair may reduce 
inflammation at the repair site and subsequently prevent development of neuropathic 
pain. 
 
3.4 Materials and methods 
Chapter 2 details the experimental materials, anaesthesia and methods employed in 
this series of experiments.  A schematic overview of the experimental design of this 
study is shown in Figure 3.1.  
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Figure 3.1: Illustration of the experimental design, investigating the effect of a range 
of anti-inflammatory cytokines in an in vivo model of sciatic nerve injury and repair. 
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Experimental groups 
A total of thirty male Sprague Dawley rats (8 weeks old--weights 220 g–300 g) were 
used in this study.  Animals are divided into five groups.  In four groups, animals 
received sciatic nerve injury and repair and were randomly assigned different 
treatments:  Interleukin-1 antagonist (n=6), Interleukin-10 treatment (n=6), 
combination treatment (IL-10 and TNF-α antagonist) (n=6) and sterile water (n=6).  
The fifth group of animals acted as sham controls and had their sciatic nerves exposed 
and dissected free (n=6).  Preparation and concentration of treatment agents is 
detailed in Chapter 2, section 2.2.2. 
Briefly, the animals were anaesthetized with 2-3 % isoflurane administrated at a rate 
of 2 litres per minute, and the left sciatic nerve exposed.  40 µl of assigned treatment 
agent was injected under the epineurium, and the nerve sectioned and immediately 
repaired.  60 µl of the remaining treatment agent was injected intramuscularly around 
the nerve repair, and the wound layers closed with 4/0 vicryl sutures.  The animals 
received a subcutaneous injection of buprenorphine (0.05 mg/kg) and were left to 
recover for a period of seven days.   
Following a recovery period of seven days, the animals were anaesthetised by 
intraperitoneal injection of 0.5 ml of sodium pentobarbital (20 % w/v) and perfusion-
fixed intracardially.  The left sciatic nerves were removed and post fixed in 4 % 
paraformaldehyde for 4 hours and stored overnight in 30 % sucrose overnight.  The 
nerves were frozen down, sectioned longitudinally at a thickness of 14 µm and serially 
collected onto PDL coated slides.  The sections were incubated with primary antibody 
raised in mouse against rat CD68, which was visualised with a fluorescent secondary 
antibody donkey anti-mouse CY3 (described in section 2.2.7.2).  
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Images of three non-overlapped nerve sections were captured using the x20 objective, 
and an area of interest traced and analysed 1.5 mm either side of the repair site, as 
previously described in Chapter 2.   
To quantify the percentage area of macrophage CD68 labelling, the area of interest 
highlighted, and immunoreactivity of the cells were determined by selecting 
thresholding of images to detect labelled structures (See Chapter 2, section 2.2.8). 
Each reading was taken three times, and the mean was taken. 
The investigator analysing the specimens was blinded to treatment received in order 
to avoid experimental bias. 
Multiple comparisons of data between the experimental groups were performed using 
Dunn's-Kruskal-Wallis multiple comparisons test to compare the difference in mean 
percentage area of CD68 immunoreactivity in the sciatic nerve tissues of all 
experimental groups. Differences between groups were considered significant at p< 
0.05.  Statistical analysis was performed using Microsoft Excel 2010 and GraphPad 
Prism7 (GraphPad Software, Inc, USA).  
 3.5 Results 
Qualitative Observations 
The primary antibody specificity was tested and detailed in Chapter 2; section 2.2.7.1. 
The results confirmed that pre-absorption of mouse anti-rat CD68 with its respective 
antigen, and omitting it from the staining protocol, showed no positive CD68 labelling 
in the control and injured and repaired sciatic nerve tissue.    
The width of the sciatic nerve in all injured animals appeared to be significantly greater 
than that in the sham-control group (Figure 3.2 and 3.3).  Seven days following the 
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sciatic nerve transection and repair there was abundant positive CD68 macrophage 
labelling across the breadth of the injury site, particularly around the repair sutures, 
with less immunoreactivity evident either distal or proximal to the repaired site (Figure 
3.2, A).  
 
 
 
 
 
 
 
Figure 3.2:  Immunofluorescent images illustrates macrophage 
infiltration and CD68 immunoreactivity in sciatic nerve following 
injury and repair.  A: Montage of four images of an injured and 
repaired rat sciatic nerve (yellow arrow indicate repair site).  B: Image 
of an uninjured rat sciatic nerve. Scale bar= 100 µm.  
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Figure 3.3: Immunofluorescent images illustrating macrophage infiltration and 
immunofluorescent CD68 expression in sciatic nerve, 7 days following peripheral nerve 
injury and repair, and following administration of different treatments (Bright dots 
indicate active microphages).  A: Sham. B: sterile water. C: IL-1 antagonist. D: IL-10. 
E: Combination.  Immunoreactive labelling for CD68 macrophage marker was 
observed in all repair groups (yellow arrows indicate repair site). Scale bar = 100 µm. 
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Quantitative Observations 
Seven days following sciatic nerve injury and repair, immunoreactive labelling for 
CD68 macrophage marker was observed in all 5 groups of animals.  Levels of CD68 
labelling appeared low at the site of nerve injury and repair 7 days following application 
of IL-1 antagonist and IL-10 compared to the other groups (Figure 3.3). Quantitative 
analysis revealed that groups injected with sterile water (p=0.006; 22.6 (-19.17); 
Dunn's-Kruskal-Wallis multiple comparisons test) or combination treatment drugs 
(p=0.009; 22.08 (-18.58), Dunn's-Kruskal-Wallis multiple comparisons test), had a 
significant increase in macrophage expression at the injury site compared to the sham 
group (3.5) (Figure 3.4).  However, following administration of IL-10 (p=0.990; 18.33 
(-14.83); Dunn's-Kruskal-Wallis multiple comparisons test) or IL-1 antagonist (p=0.990; 
17.08 (-13.58), Dunn's-Kruskal-Wallis multiple comparisons test), macrophage 
immunoreactivity at the site of repair was not significantly different to the sham group 
(Figure 3.4).  Overall, the mean macrophage labelling following epineurial 
administration of IL-10 and IL-1 antagonist treatment were not different from the sham 
group, 7 days following nerve injury and repair.   
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Figure 3.4: Percentage area of CD68 immunoreactivity in the sciatic nerve, 7 
days following peripheral nerve injury and repair, and following administration of 
treatment.  Data are expressed as the means. (*: p<0.05, ns: p>0.05). 
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3.6. Discussion 
The study provided preliminary data on the effect of peripheral application of anti-
inflammatory cytokines at the site of sciatic nerve injury and repair.  Peripheral 
application of IL-1 antagonist (Anakinra) and anti-inflammatory IL-10 at the time of 
nerve injury and repair it was observed that macrophage reactivity was not different to 
the sham group, but in the sterile water and combination treatment groups 
macrophage reactivity was greater than the sham group.  TNF-α antagonist has been 
investigated by Dr. Simon Atkins and Dr. Emma Bird in the oral neuroscience group 
at the University of Sheffield (Unpublished data).  They studied the effect of TNF-α 
antagonist on the ectopic neural activity seven days after nerve injury and repair.   So, 
TNF-α antagonist as single treatment was not included in this experiment.   
The experiments demonstrated that although there was a demonstrable increase in 
the mean percentage area staining for macrophages in the IL-1 antagonist and IL-10 
group it was not significantly different to the sham controls.  However, the mean 
percentage area staining for macrophages was significantly higher in the sterile water 
and combination group.  These findings suggest IL-1 cytokine antagonist and anti-
inflammatory IL-10 may play a role in limiting macrophage recruitment in peripheral 
nerve injury.  Furthermore, it would appear that a combination of IL-10 and TNF-α 
antagonist showed no significant reduction in the mean percentage area staining for 
macrophages.  It also suggests IL-1 antagonist may be more effective at reducing 
macrophages numbers than TNF-α antagonist or IL-10 alone.  This may indicate their 
possible contribution to the reduction or prevention of neuropathic pain, and potential 
effects on nerve regeneration. 
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The exact role these inflammatory mediators play in peripheral nerve injury is not 
completely understood, however there is ample evidence suggesting that their overall 
function may be involved in suppressing abnormal nociceptive signals primarily 
through the suppression of recruitment and activation of immune cells, as well as 
reduction of the effects of pro-inflammatory cytokines pooling at an injury site and in 
the CNS (Thacker et al., 2007; Gaudet et al., 2011; Bastien and Lacroix, 2014). 
Following peripheral nerve injury, there is a slow process of degeneration initiated at 
severed segments of the peripheral nerve (Gaudet et al., 2011).  Initially the distal 
segment swells and then later disintegration of their myelin sheet commences, with 
the proximal segment showing a reduction in diameter of nerve fibres (Johnson et al., 
2005).  The neuronal response to injury begins with a rapid division of Schwann cells 
which subsequently regulate degeneration and regeneration processes of severed 
neuronal axons by expression of neurotrophic molecules including nerve growth factor 
(NGF) and pro-inflammatory cytokines (Osbourne, 2007).  After complete transection 
of the sciatic nerve, a severe inflammatory reaction ensues and promotes recruitment 
of immune inflammatory cells and proliferation of fibroblasts and scar tissue formation 
at the injury site (Thacker et al., 2007).  Inflammatory cells including neutrophils and 
mast cells, infiltrate the site of nerve injury seven days’ post injury and begin their 
phagocytosis and release of inflammatory mediators (Perkins and Tracey, 2000).  
These observations may explain, in part, the increase seen in the width of the sciatic 
nerve after injury, in our studies. 
Following peripheral nerve injury, the recruitment of non-neuronal cells including 
macrophages, is considered to play an important part in the regeneration process of 
sectioned nerves (Gaudet et al., 2011).  Macrophages enter the severed segments 
between days 4 to 7 after injury and clear the axon and myelin debris within two weeks 
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(Stoll and Müller, 1999).  Our findings showed large numbers of macrophages invading 
the sciatic nerve as shown by positive CD68 marker immunofluorescent labelling 
which was marked across the injury site, particularly at the repair site. 
In vivo studies have revealed that application of IL-1 antagonist, or neutralizing 
antibodies to TNF-α in a rodent sciatic nerve neuropathy model, attenuates pain-
associated behaviours and this was confirmed by immunohistochemical analysis of 
macrophage immunoreactivity at site of nerve repair (Sommer et al., 1999; Schäfers 
et al., 2001).  Data from this study showed that seven days following sciatic nerve 
injury and epineurial repair, and peripheral administration of IL-1 antagonist (Anakinra), 
CD68 macrophage labelling was not significantly different when compared to sham 
controls.  This is consistent with previous immunohistochemical reports where reduced 
TNF immunoreactivity and macrophage infiltration was observed at the site of nerve 
injury following epineurial application of anti-IL-1R1 in a chronic constriction model of 
peripheral neuropathy (Sommer et al., 1999).  Furthermore, in a mouse IL-1R1 
knockout model, low levels of neutrophil and macrophage infiltration were associated 
with reduced pain-related behaviours and improved functional recovery of peripheral 
nerves (Nadeau et al., 2011).  
Pro-inflammatory cytokines that are produced by immune cells 2-3 days following 
peripheral nerve injury, are responsible for the first stage of the healing process, 
inducing degeneration and clearing of debris at the site of injury.  At this stage, these 
anti-inflammatory cytokine mediators are highly expressed by resident and infiltrating 
cells which regulate the inflammatory response following nerve damage.  Peripheral 
administration of IL-10 immediately after nerve injury, has been reported to reduce 
macrophage activation and decreased production of inflammatory cytokines (Taskinen 
et al., 2000).  In this experiment, IL-10 treated animals showed non-significant levels 
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of macrophages labelling when compared to sham nerves.  In contrast, the effect of 
combined treatment of IL- 10 and TNF-α antagonist was insignificant, and it is possible 
that the dose of combination treatment was ineffective to reduce immune response at 
the site of nerve injury and repair.  Although the current results showed short term 
downregulation of the immune inflammatory response at the site of peripheral nerve 
injury and repair, further research is necessary to investigate the long-lasting effects 
associated with cytokine-based therapy on functional regeneration and establish their 
role as neuropathic pain -targeted therapy in peripheral nerve injuries. 
3.7 Summary 
In summary, it is evident from the literature that the immune inflammatory cell 
response regulates pathways between the neurones at the levels of peripheral and 
central nervous system regions, by the production of inflammatory cytokines which are 
considered to play an important role in neuropathic pain development.  Moreover, 
there is significant evidence that pro-inflammatory cytokines produced at a site of 
nerve injury may stimulate central sensitization and produce hyperalgesia due to 
increased ectopic neuronal activity, subsequently leading to the development of 
neuropathic pain (Ren and Torres, 2009).  Therefore, selectively targeting peripheral 
cytokine signalling at the time of nerve repair, may influence signalling regulatory 
molecules that are responsible for initiation and maintenance of neuropathic pain. 
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CHAPTER 4 
Interleukin-1 cytokine antagonist reduces the immune 
inflammatory response and promotes axon regeneration 
after peripheral nerve injury and repair 
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4.1 Introduction 
Interleukin-1 cytokine is considered a key pro-inflammatory cytokine mediator which 
plays an important role in the axonal healing process after nerve injury.  More 
specifically, IL-1 is considered a principal chemoattractant to macrophages at the site 
of nerve injury and involved in the regulation of nerve growth factor (NGF) synthesis, 
and so indirectly promotes axonal sprouting and growth (Brown et al., 1991; Burnett 
and Zager, 2004; Gaudet et al., 2011).  Interleukin-1 cytokine exists in two forms; IL-
1α, and IL-1β.  As previously stated, IL-1α and IL-1β exhibit similar molecular structure 
and bind to IL-1R1, but induce different responses (Bastien and Lacroix, 2014). 
The pro-inflammatory cytokine IL-1 acts by the binding to the IL-1 receptor accessory 
protein (IL-1acp) of IL-1RI to promote signal transductions which orchestrate the 
nociceptive signalling pathway after nerve injury, in both the spinal cord and peripheral 
nerves (Bastien and Lacroix, 2014).  The recombinant form of IL-1RA (Anakinra) is 
widely used in the treatment of many inflammatory conditions, such as rheumatoid 
arthritis, and more recently recognized as a therapeutic approach in the treatment of 
neuropathic pain and promoting nerve regeneration after nerve injury (Richards and 
McMahon, 2013; Bastien and Lacroix, 2014). 
Following peripheral nerve injury, IL-1 is believed to induce pain sensitivity and 
maintain this nociceptive response through the process of peripheral and central 
sensitization although these mechanisms are still not fully understood (Marchand et 
al., 2005; Wolf et al., 2006).  Moreover, IL-1 cytokine antagonists have shown to induce 
central inhibition of mechanical allodynia and lower the pain threshold.  As a 
consequence, this might reduce spontaneous ectopic firing and the development of 
abnormal behavioural symptoms such as hyperalgesia and allodynia (Sweitzer et al., 
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2001; Sommer et al., 2001; Ren and Torres, 2009).  Another possible suggestion 
regarding the initiation of central sensitization and neural plasticity is increased glial 
cell interactions with neural pain circuits secondary to an influx of pro-inflammatory 
cytokines such as IL-1 (Taves et al., 2013).  The effect of recombinant IL-1 cytokine 
antagonist application reveals important mechanisms that are likely to suppress 
peripheral and central neurone sensitization involved in the initiation of neuropathic 
pain (Schäfers et al., 2001; Sommer et al., 2004; Wolf et al., 2006; Ren and Torres, 
2009). 
IL-1 is known to induce glial cell phenotypic changes following intrathecal injection, 
resulting in the expression of several inflammatory mediators which act in the 
recruitment and infiltration of immune cells (Mika et al., 2013).  Additionally, activation 
of microglial and astrocytes in the dorsal and ventral horns of the spinal cord, in 
response to peripheral nerve damage has been observed several weeks following 
injury.  This glial activation has been widely implicated in the development of 
neuropathic pain (Hansen and Malcangio, 2013, Mika et al., 2013).  IL-1 released from 
activated microglia has been proposed to induce hyper excitability of dorsal horn 
neurones and activation of nearby glial-like cells and thus mediate nociceptive 
changes by modulation of the excitatory and inhibitory neurotransmissions processes 
through NMDA receptor activity in dorsal horn of the spinal cord (Zhang et al., 2008; 
Taves et al., 2013). 
It has been shown that there is a positive correlation between increased recruitment 
of macrophages and functional recovery of axon following peripheral nerve injury 
(Brown et al., 1991; Nadeau et al., 2011).  In several transgenic and knockout mice 
models, depletion of IL-1R1 and TNFR1 signalling was associated with reduced 
infiltration of macrophages as well as reduced mechanical hyperalgesia and 
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diminished functional recovery of peripheral nerves after injury (Brown et al., 1991; 
Nadeau et al., 2011). Therefore, targeting the entire IL-1 cytokine profile might be 
critical for axonal regeneration and reduce neuropathic pain.   
Overall, there is substantial evidence that IL-1 plays a vital role in promoting axon 
growth and neurones excitability at the site of peripheral injury and in the spinal cord. 
Furthermore, IL-1’s activation of immune cells provides a supplementary source for its 
continued production which could perhaps increase pain sensitivity. 
4.2 Aim and objectives 
The aim of this study was to investigate the effect of IL-1 cytokine antagonist on the 
inflammatory immune response and nerve regeneration, 6 weeks following peripheral 
nerve injury and repair.  More specifically; to determine the effect of IL-1 cytokine 
antagonist on macrophage infiltration at the site of nerve injury and repair, and on glial 
activation in the dorsal and ventral horns of the spinal cord.  In addition, to study the 
effect of IL-1 cytokine antagonist on axonal regeneration 6 weeks following peripheral 
nerve injury and repair.   
4.3 Hypothesis 
The application of IL-1 cytokine antagonist, peripherally at the site of nerve injury and 
repair will reduce immune cell reactivity, and spinal glial cell activation, thus potentially 
reducing neuropathic pain, and improve functional recovery. 
4.4 Materials and methods 
Chapter 2 details the experimental materials, anaesthesia and methods employed in 
this series of experiments.  All treatments received by animals were randomised and 
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investigators performing the experiments and analysis of result were blinded.  A 
schematic overview of the experimental design of this study is shown in Figure 4.1.  
 
 
 
 
 
 
 
 
Figure 4.1: Illustration of the experiment design, investigating the effect of IL-1 
antagonist in an in vivo model of sciatic nerve injury and repair. 
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Experimental groups 
A total of 20 male C57 black-6 mice (8 weeks or older – weights 17-30 g) were used 
in this study.  In the present work, a sample size calculation suggested that minor 
differences (5 %) in the extent of axon regeneration by electrophysiology recording 
and percentage area staining of macrophage marker, would be detected with a sample 
size of 10 animals in each group. Animals were randomly allocated to either treatment 
group IL-1 cytokine antagonist (n=10), or sterile water group (n=10).  Preparation and 
concentration of IL-1 cytokine antagonist (10 mg/100 μl) is detailed in Chapter 2, 
section 2.2.2.   
Briefly, the animals were anaesthetised with 2-3 % of isoflurane and oxygen (2 litres 
per minute), the left sciatic nerve exposed and 40 µl of treatment agent injected under 
the epineurium. The sciatic nerve was sectioned transversely and immediately 
repaired with four 9/0 monofilament polyamide (ETHILON*) epineurial suture knots 
(Figure 2.1B).  Thereafter, the remaining 60 µl of treatment agent was injected 
intramuscularly around the nerve repair, and the wound closed in layers with vicryl 
suture material (6/0).  Postoperative analgesia was maintained with a subcutaneous 
injection of single dose of opioid analgesic (0.05 mg/kg buprenorphine hydrochloride) 
and the animals were allowed to recover for a period of 6 weeks.  
In this experiment additional sham group (n=10) from previous work in the Oral 
neuroscience group is included to explain difference between treatment groups under 
the investigation.  Sterile water is considered as negative control and sham not 
included initially due to the ethical issue in accordance with the UK Home Office 
Animals (Scientific Procedure) Act 1986.   
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Functional assessment of nerve function recovery 
Six weeks following sciatic nerve transection and repair, animals were anaesthetised 
with an intra-peritoneal injection of intravenous fluanisone (0.8 ml/kg) and midazolam 
(4 mg/kg).  The left sciatic nerve was exposed and a pair of central recording 
electrodes applied to the nerve (platinum wire 0.15 mm diameter).  An evoked 
stimulation across the sciatic nerve was delivered from two pairs of distal and proximal 
electrodes, each situated 2 mm either side of the repair site (Figure 2.4).  Data was 
recorded and stored using Spike 2 software (version 5, Cambridge Electronic Design, 
UK).  The CAP ratio calculated between the responses evoked from proximal or distal 
to the repair (modulus with distal stimulation ÷ modulus with proximal stimulation) were 
compared between the experimental groups, IL-1 cytokine antagonist and sterile water 
groups, from an average of 10 responses to stimulation along the sciatic nerve.  In 
addition, conduction velocities were recorded by measuring the latency of the earliest 
component of the CAP evoked by stimulating the regenerated segment of the sciatic 
nerve. This recording would include both the proximal and the regenerated 
components of the nerve. 
Tissue sectioning and immunohistochemistry analysis 
Following completion of the electrophysiology recordings, animals received a 0.5 ml 
intraperitoneal injection of sodium pentobarbital (20 % w/v) and perfusion-fixed 
intracardially.  The left sciatic nerves and spinal cord tissues were harvested, post 
fixed in 4 % paraformaldehyde for 4 hours and stored overnight in 30 % sucrose.  The 
tissues were frozen down and sectioned as described previously (Chapter 2, section 
2.2.6).   
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Staining and analysis of macrophage labelling in the sciatic nerve 
Three slides (9 nerve sections) per animal were washed in phosphate buffered saline 
(PBS) containing 0.2 % Triton X-100, for 2 x 10 minutes, and then incubated overnight 
with a monoclonal antibody raised in rat against mouse CD68 (macrophage marker).  
Fluorescent macrophage labelling was visualised with goat anti-rat CY3 secondary 
antibody. For full details see Chapter 2, section 2.2.7. 
Images of three sciatic nerve sections were captured using the x10 objective and the 
percentage area of CD68 positively stained tissue, 1.5 mm either side of the repair 
site, measured (Figure 2.12).  To quantify the percentage area of macrophage CD68 
labelling, the area of interest highlighted, and immunoreactivity of the cells were 
determined by selecting thresholding of images to detect labelled structures (See 
Chapter 2, section 2.2.8). Each reading was taken three times, and the mean was 
taken. 
Staining and analysis of glial labelling in the spinal cord 
Twelve sections from the L4 region were selected per animal and processed for 
fluorescent immunohistochemistry microglial (IBA-1) and astrocyte (GFAP) labelling.  
Free floating sections were blocked in in 200 µl 10 % normal donkey serum and 
incubated with a polyclonal antibody to IBA-1 raised in goat, or a polyclonal antibody 
to GFAP raised in rabbit, and respective secondary antibodies donkey anti-goat CY3 
or donkey anti- rabbit CY3. For full details see Chapter 2, section 2.2.7. 
Three images per animal, representative of dorsal and ventral horn regions, were 
captured at x5 objective for qualitative analysis and at x40 objective for quantitative 
analysis.  Glial cell activation was interpreted by an increase in the number 
(proliferative changes) and complexity of the cells morphology (phenotypic alteration) 
152 
 
such as enlarged cell bodies and thicker processes in the dorsal and ventral spinal 
horns.  The percentage area of glial labelling calculated by selecting area of interest 
and then activation areas highlighted by pink, while the remaining areas would be 
highlighted by yellow (See Chapter 2, section 2.2.8). Each reading was taken three 
times, and the mean was taken.  The ratio of glial cell reactivity was determined by 
measuring and comparing the ratio of positive labelling between the ipsilateral and 
contralateral sides, in both the dorsal and ventral horn regions 
Statistical comparisons were performed using t-test (Two-tailed). Quantitative data 
was expressed as mean values ± SEM. Differences between groups were considered 
significant at p<0.05.  Statistical analysis was performed using Microsoft Excel 2010 
and GraphPad Prism7 (GraphPad Software, Inc, USA).   
4.5 RESULTS 
4.5.1 Functional analysis 
Following 6 weeks of recovery, electrophysiological studies were carried out to 
determine the efficacy of IL-1 cytokine antagonist on neuronal axon regeneration by 
recording a series of compound action potential after sciatic nerve injury and repair.   
Compound action potentials (CAP) 
CAPs were recorded from the sciatic nerve evoked by stimulation at the proximal and 
distal sides of the nerve repair using a stimulus of 10 Volts (Figure 4.2).  In the 
uninjured sham group, the mean CAP ratio was 0.89 (SEM± 0.0793), indicating that 
higher compound action potentials were evoked by stimulation at the distal site. 
The ratio of CAP from proximal and distal stimulation were compared between the 
experimental groups. The mean CAP ratio for the IL-1 cytokine antagonist group was 
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0.5950 (SEM ± 0.0656), while the mean CAP ratio for the sterile water group was 
0.5338 (SEM ± 0.0766). 
The CAP ratio in the IL-1 cytokine antagonist group was not statistically significantly 
different from the CAP ratio in the sterile water, 6 weeks following sciatic nerve injury 
and repair (p=0.550, two-tailed t-test) (Figure 4.3).   
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Figure 4.2:  Calculation of CAP ratio as evoked by stimulation proximal and distal 
to the repair site, respectively. 
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Figure 4.3: Comparison of mean compound action potential (CAP) amplitude 
ratios between experimental groups (Data expressed mean ± SEM; ns: p>0.05). 
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Conduction velocities 
Assessment of the regeneration rates of repaired nerve fibres were compared by 
recording the conduction velocities six weeks after sciatic nerve injury and repair in 
both experimental groups (Figure 4.4).   
Six weeks after recovery, the mean conduction velocities between the groups was not 
statistical significant differences (p=0.056, two-tailed t-test).  The conduction velocity 
of the fastest axons in the sham controls was 53.3 m s-1 (SEM± 4.371). The 
conduction velocities were significantly slower in all the nerve repair groups.  Although 
the conduction velocity was marginally higher in the IL-1 antagonist group when 
compared to the sterile water group, this was not statistical significant; 34.34 ms-1 
(SEM ± 2.739) and 27.26 ms-1 (SEM ± 2.123) respectively.   
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Figure 4.4: Mean conduction velocities of experimental groups (Data 
expressed mean ± SEM; ns: p≥0.05). 
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4.5.2 Immune cells fluorescent labelling 
Immunohistochemical analysis was carried out to determine the effect of peripherally 
applied IL-1 cytokine antagonist, at the time of nerve repair, in a clinically relevant 
model of peripheral nerve injury and repair.  Qualitative and quantitative assessment 
of expression of CD68 (macrophage marker), GFAP (astrocyte label) and IBA-1 
(microglial marker) was carried out to determine the change in immune and glial cell 
response, at nerve injury site and in the dorsal and ventral horns of the spinal cord.  
The primary antibody specificity was tested and detailed in Chapter 2; section 2.2.7.1. 
The result of testing the primary antibody specificity in mouse sciatic nerve and spinal 
cord tissues is shown in Figures 2.9, 2.10 and 2.11. 
CD68 macrophage labelling following sciatic nerve injury and repair 
Qualitative Observations  
Six weeks following sciatic nerve injury and repair CD68 macrophage labelling was 
present across the breadth of the injury site, in both experimental groups.  
Immunofluorescent labelling was particularly intense around the repair site and less 
immunoreactivity observed either distal or proximal to the repair site (Figure 4.5).   
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Figure 4.5: Immunofluorescent images illustrate macrophage infiltration and CD68 immunoreactivity in sciatic nerve 6 weeks 
following nerve injury and repair (yellow arrows: repaired site).  A: Sterile water treatment group.  B: IL-1 antagonist treatment.  
The bright dots indicate active microphages. Low macrophages immunoreactivity across the repair site in the IL-1 antagonist 
group when compared to the sterile water group. Scale bar= 100 µm. 
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Quantitative Observations 
Six weeks following sciatic nerve injury and repair, there was a significant reduction in 
CD68 macrophage immunoreactivity at the site of nerve repair, in animals treated with 
IL-1 cytokine antagonist compared with the sterile water treatment group (p= 0.0268, 
two-tailed t-test) (Figure 4.6).  The mean expression of macrophage labelling was 
statistically lower in the IL-1 cytokine antagonist treated C57- black-6 mice (21.96 ± 
2.959) compared with those receiving sterile water (36.25 ± 5.193). 
 
 
 
 
 
  
 
Figure 4.6: Quantification of CD68 macrophage labelling in the sciatic nerve six 
weeks following nerve injury and repair (Data expressed mean ± SEM;  : p 
<0.05). 
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IBA-1-microglia labelling following sciatic nerve injury and repair 
Qualitative Observations 
Qualitative analysis of the spinal cord sections revealed a similar pattern of distribution 
of IBA-1 microglia labelling in the two experimental groups; sterile water and IL-1 
antagonist, six weeks following sciatic nerve injury and repair.  Clusters of reactive 
microglial cells with long and branching processes were present, with high levels of 
IBA-1 present in the dorsal horns in both experimental groups (Figure 4.7).  
Furthermore, there appeared to be reduced activation of microglial cells in ventral 
horns in the IL-1 antagonist group (Figure 4.7). 
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Figure 4.7: Immunofluorescent images of microglia (IBA-1) labelling in the spinal cord 6 weeks following nerve 
injury and repair. (A) Sterile water group. (B) IL-1 antagonist group.  White arrows indicate corresponding areas of 
interest and showing hypertrophied and amoeboid active glial cells.  Scale bar = 25 µm. 
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Quantitative Observations 
Quantitative analysis revealed there was no significant statistical difference in the 
mean ratio of IBA-1 expression in ipsilateral versus contralateral sides in the dorsal 
horn region of the spinal cord (p= 0.780, two-tailed t-test), following treatment with IL-
1 antagonist (1.453 ± 0.1004) when compared to animals treated with sterile water 
(1.416 ± 0.0804) (Figure 4.8). 
However, there was a significant statistical difference in the mean ratio of microglia 
labelling in ipsilateral versus contralateral sides in the ventral horn region of the spinal 
cord (p= 0.022, two-tailed t-test), following treatment with IL-1 antagonist (1.229 ± 
0.0737) compared to animals treated with sterile water (1.448 ± 0.0492) (Figure 4.8). 
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Figure 4.8: Quantification of the ratio of microglial activation (IBA-1 marker) in 
the ipsilateral and contralateral dorsal and ventral horns of the spinal cord, six 
weeks following peripheral nerve injury and repair. (Data expressed mean ± 
SEM;  : p <0.05, ns: p>0.05). 
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GFAP astrocyte labelling following sciatic nerve injury and repairs 
Qualitative Observations 
Six weeks following sciatic nerve injury and repair, there was a marked expression of 
astrocyte activation and morphological changes, as indicated by GFAP 
Immunofluorescent labelling, in the dorsal and ventral horns of the spinal cord (Figure 
4.9).  High levels of expression of astrocyte reactivity, with pronounced branching of 
processes was observed in dorsal horn regions in both experimental groups, which 
was accompanied by a reduced activation of astrocytes in the ventral horns (Figure 
4.9). 
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Figure 4.9: Immunofluorescent images of astrocytes (GFAP) labelling in the spinal cord 6 weeks following nerve 
injury and repair. (A) Sterile water group. (B) IL-1 antagonist group.  White arrows indicate corresponding areas 
of interest and showing hypertrophied and amoeboid active glial cells.  Scale bar = 25 µm. 
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Quantitative Observations 
Six weeks following nerve injury and repair, quantitative analysis revealed no 
significant statistical difference in the mean ratio of astrocytes labelling using GFAP 
immune marker in ipsilateral versus contralateral sides in the dorsal horn region of the 
spinal cord (p= 0.139, two-tailed t-test), after treatment with IL-1 antagonist (1.313 ± 
0.1251) as compared to animals treated with sterile water (1.555 ± 0.0958) (Figure 
4.10). 
Result of quantitative analysis also shows a statistical difference in the mean ratio of 
astrocytes cells labelling in ipsilateral versus contralateral sides in the ventral horn 
region of the spinal cord (p= 0.039, two-tailed t-test), following treatment with IL-1 
antagonist (1.165 ± 0.0565) as compared to animals treated with sterile water (1.607 
± 0.1928) (Figure 4.10). 
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Figure 4.10: Quantification of the ratio of astrocyte activation (GFAP marker) in 
the ipsilateral and contralateral dorsal and ventral horns of the spinal cord, six 
weeks following peripheral nerve injury and repair. (Data expressed mean ± SEM; 
 : p <0.05, ns: p>0.05).  
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4.6 Discussion 
Data from this study indicate an effect of IL-1 cytokine antagonist treatment at the time 
of peripheral nerve injury.  Mice treated with IL-1 cytokine antagonist following 
peripheral nerve repair showed a significantly reduced immune cell reactivity at the 
injury site, and corresponding L4 ventral horn when compared to the sterile water 
group. Peripheral application of IL-1 antagonist reduced immune inflammatory 
response but did not significantly improve functional recovery as measured by CAP 
and conduction velocities in this experiment.   
The degeneration process in a distal nerve segment is completed seven days after 
nerve injury, and the high levels of IL-1 activity seen in the degenerating segment, 
mediate axon disintegration, and are also likely to be associated with maintaining NGF 
synthesis at the site of nerve repair and macrophage infiltration (Ide, 1996, Navarro et 
al., 2007; Gaudet et al., 2011).  Therefore, a therapeutic approach aimed at blocking 
IL-1 receptors may be more likely to succeed without interfering with the critical 
process of regeneration and achieve functional improvement if applied continually or 
in combination with other anti-inflammatory factors after nerve repair to enhance 
neuronal axons regeneration capability. 
Recruitment of macrophages into severed nerve fibres at the site of injury is vital to 
the cellular events that follow nerve injury (Johnson et al., 2005, Gaudet et al., 2011).  
However, this involves various cell functions including; myelin material clearance and 
production of neurotrophic factors and cytokines.  These cells usually infiltrate the site 
of nerve injury by 2 to 3 days, and contribute to the initial IL-1 production which is 
derived from other cells including Schwann cells.  Previous studies show that, IL-1 
activity is involved in the signalling pathway that mediates the inflammatory response, 
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which is responsible for repair mechanism in nerve tissues (Navarro et al., 2007; 
Gaudet et al., 2011).  Hence, it may also have some positive effects on the process of 
nerve regeneration after nerve repair. 
Peripheral nerve injury is associated with a rapid increase in IL-1 levels, which in turn 
induces NGF synthesis to promote axonal survival and out growth in the severed nerve 
segment (Brown et al., 1991).  In our therapeutic approach studies, epineurial 
administration of IL-1 cytokine antagonist, down regulated the immune response but 
did not promote functional recovery after sciatic nerve injury.    Although macrophage 
immunoreactivity was reduced at the site of nerve repair, the dose of IL-1 cytokine 
antagonist appears to be insufficient to promote axon regeneration, as indicated by 
low axonal regeneration potential.  However, this may have been due to the possibility 
that the axons did not reach their maturation stage, low number of sprouting axons, or 
scar tissue formation.  After severe nerve injury, axons can grow haphazardly to form 
a neuroma, which may result in some degree of irreversible blockage of electric nerve 
conductions distal to the site of nerve injury (Gunasekera et al., 2011).    
Considering previous evidence on the correlation between severity of nerve injury, 
immune inflammatory activity and axonal response to injury, we investigated the 
effects of IL-1 signalling activity at the site of sciatic nerve injury and repair.  When we 
blocked the IL-1RI activity with Anakinra in the periphery, the levels of immune cell 
reactivity was down regulated, proving its therapeutic efficacy as previously described 
in preclinical studies (Perkins and Tracey, 2000; Zuo et al., 2003, Thacker et al., 2007).  
Moreover, pre-treatment with IL-1 cytokine antagonist has been also shown to 
diminish onset of pain-related behaviours in peripheral nerve injury in rodents 
(Schäfers et al., 2001; Sweitzer et al., 2001; Sommer et al., 2004).  Therefore, it is 
likely that the therapeutic regime we applied was partially effective in reducing the 
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persistent expression of IL-1 at the site of nerve injury, as indicated by decreased 
immune cell expression in peripheral nerves, six weeks after nerve repair.  It is also 
reasonable to speculate that the Schwann cell myelination process is either impaired 
or delayed in severe injury which is known to regulate functional regeneration of axons 
during the regeneration process. 
IL-1 cytokine is believed to be associated with early stages of peripheral nerve 
regeneration and in our experiment, Anakinra did not alter the levels of IL-1, but 
instead competed with its receptors.  In our experiment no difference was recorded in 
CAP ratio and this may be due to scar tissue formation or that the IL-1 cytokine 
antagonist dose is suboptimal.  While it was possible to obtain CAP of regenerating 
fibres, greater accuracy could possibly be obtained by direct measurement of electrical 
nerve fibres at different time intervals which could accurately predict functional 
recovery by reducing bias in regeneration contributed by different nerve fibres.  In the 
comparisons between the uninjured sham controls and the nerve repair groups, the 
result showed that the CAPs were always smaller after repair. This might have resulted 
from a reduction in the number and/or size of regenerated axons in the distal stump. 
Conduction velocity, conduction of nerve electricity, is a validated method to 
discriminate nerve fibre maturation, in which the heavily myelinated and largest 
diameter axons will conduct faster than those less myelinated with smaller diameter 
(Atkins et al., 2007).  The conduction velocity of all of the repaired groups was 
significantly slower than for the sham uninjured at 6 weeks following nerve injury and 
repair.  
Data from our study did not show difference in electric nerve conduction between the 
IL-1 cytokine antagonist and sterile water group, which may be due to Anakinra dose 
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or recovery time after nerve repair.  Also, it is possible to speculate that axonal 
maturation occurred at a slow rate and this was shown by the similar conduction 
velocities ratio between the two groups.  Moreover, severe nerve injury such as 
neurotmesis is another limiting factor of nerve fibre regeneration, due to formation of 
scar tissue and inappropriate guiding of the growth pathway.  The rate of regeneration 
could be hindered after injury where the process of regeneration is slow and delayed, 
and Schwann cell tube lamina require greater time to establish the growth cone 
guidance signals to achieve or promote connection and healing. 
In our investigation, epineurial administration of IL-1 antagonist reduced the immune 
inflammatory response but did not significantly improve functional recovery after 
sciatic nerve sectioning and repair.  The effects of Anakinra did not significantly 
enhance regeneration in this experiment.  However, the present therapeutic regime 
allows us to target the immune reaction and we found that mice receiving Anakinra at 
the time of nerve repair, showed lower levels of CD68 immune positive cells, 6 weeks 
following nerve injury and repair.  Targeting IL-1 signals is considered one therapeutic 
approach in reducing pain due to its anti-inflammatory effects.  On the other hand, 
Anakinra did not improve axons regeneration and this opposing outcome may be 
related to the degree and timing of inflammation, as severity of inflammation may 
reduce neural survival.  Moreover, several studies reported that immediate and 
subsequent administration of IL-1 antagonist contributed to successful functional 
regeneration and survival (Schäfers et al., 2001; Sweitzer et al., 2001; Sommer et al., 
2004).  Therefore, it’s important to control inflammation to ensure that it occurs in 
appropriate degree and at correct time and IL-1 may play an important role in this 
process in peripheral nerve injury. 
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In the spinal cord, the over expression of IL-1 cytokine induces activation and 
phenotypic changes of microglia and astrocytes (Mika et al., 2008; Mika et al., 2013, 
Pilat et al., 2015).  It is well documented that injury to peripheral nerves is associated 
with phenotypic changes of glial cells in central sensory in the spinal cord (superficial 
and deep laminae I and II) (Eriksson et al.,1993; Taves et al., 2013).    Previous studies 
using specific glial marker (OX-42) to highlight the response of glial cells in different 
sensory territories in response to peripheral nerve injuries, have revealed high levels 
of OX-42 pan-glial markers expression which indicate increased cell immunoreactivity.  
In addition, these studies reported that glial cells exhibited morphological changes 
similar to the qualitative results observed in the present experiment.  These phenotypic 
changes include observable morphological features in this work highlighting the glial 
cells role in neurone excitability which trigger chronic pain behaviours following 
peripheral nerve injuries (Eriksson et al.,1993; Beggs et al., 2007; Taves et al., 2013).  
It has been postulated that sensitization of spinal neurones contribute to glial activation, 
partly by receptor stimulation on neurones in the spinal cord which further activate 
microglial cell and promote production of pro-inflammatory cytokines, and these 
effects are blocked by pan-glial inhibitors such as interleukin-1 receptor antagonist 
and soluble tumour necrosis factor receptor antagonist (Mika et al., 2008; Mika et al., 
2013; Pilat et al., 2015).  However, our experiment showed reduced expression of glial 
markers in spinal ventral horns as opposed to the dorsal spinal region 6 weeks 
following epineurial injection of IL-1 antagonist at the time of sciatic nerve injury and 
repair.  Since these markers mainly reflect the stages of their activation in response to 
continuous stimulus as a result of nerve injury, this would need further investigation at 
stages of nerve regeneration and different time periods after injury and repair. 
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4.7 Summary 
Anakinra is recombinant human interleukin-1 receptor antagonist and its effectiveness 
has been described in many clinical trials in the treatment of chronic neuropathies.  
Furthermore, administration of IL-1 receptor antagonist has shown to reduce 
neuropathic pain in pre-clinical studies.  In this experiment, epineurial injection of 
Anakinra did show reduced macrophage immunoreactivity, 6 weeks after sciatic nerve 
injury and repair.  In addition, the dose regime may be ineffective in this experiment to 
have a compound effect on nerve regeneration and reducing pain markers 
simultaneously.  However, Interleukin-1 receptor antagonist is unlikely to reduce pain 
behaviours as a single therapeutic approach.  In such conditions, the use of either 
combination antibodies or continuous administration to compete with IL-1R1 activity, 
to reduce nerve apoptosis and promote axonal regeneration, along with blockage of 
inflammatory mediators to reduce nerve fibre nociception that leads to pain 
hypersensitivity and long- persisting pain state, may have greater effect. 
Direct assessment of functional regeneration using electrophysiology to monitor the 
growth of axons after six weeks did not directly differentiate the rate of growth between 
the two experimental groups.  Further experiments are required to test functional 
assessment of regenerating fibres at different time intervals along with different doses 
of Anakinra, and the consideration of continuous drug delivery approach at the site of 
nerve injury and repair.  Finally, the dose of Anakinra administered epineural after 
nerve repair, appeared to show reduced inflammation locally as well as glial activation 
in the spinal cord.  Hence this may be a potential therapeutic drug for reducing 
neuropathic pain following peripheral nerve injuries.  
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CHAPTER 5 
Effect of combination of TNF-α antagonist and IL-10 on 
inflammation and neural regeneration in peripheral nerve 
injury 
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5.1 Introduction 
Peripheral nerve recovery following severe nerve injury is never complete even when 
a nerve repair is achieved by direct anastomosis of nerve segments.  This has been 
attributed to the disruption and subsequent disintegration of axon-Schwann cell unit 
(Rodríguez et al., 2004; Navarro et al., 2007; Li et al., 2014). 
It has been shown that modulating the immune response at the axonal level following 
peripheral nerve injuries promote axon growth and improve functional regeneration 
after nerve repair (Thacker et al., 2007; Bastien and Lacroix, 2014; Wood and 
Mackinnon, 2015).  Extensive evidence clearly demonstrates the contribution of 
immune cells in tissue damage and regeneration, and activation of cytokines in the 
development of neuropathic pain following nerve injury (Thacker et al., 2007; Bastien 
and Lacroix, 2014; Wood and Mackinnon, 2015).  The effect of cytokine proteins, TNF-
α and IL-10 has been discussed previously in Chapter 1, section 1.3.4 and 1.4.2.  
These cytokines have been shown to influence immune cell infiltration at the site of 
nerve injury and targeting these cytokines has been of much interest in nerve injury 
models.  TNF-α and IL-10 cytokines are thought to contribute to the process of 
degeneration and regeneration by acting via different sets of specific Toll-like 
receptors (TLRs) expressed on various cell types including neurons (Thacker et al., 
2007; Bastien and Lacroix, 2014).   
TNF-α is an important pro-inflammatory cytokine which is expressed following 
peripheral nerve injury and believed to induce ectopic neuronal discharge and 
subsequently initiate neuropathic pain (George et al., 2005, Kato et al., 2009, Kato et 
al., 2010).  Several studies have investigated the modulation of pro-inflammatory TNF-
α cytokines following peripheral nerve injury and repair by using TNF-α antagonist 
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(Etanercept).  It has been shown that local application of Etanercept at time of nerve 
repair is associated with reduced immunoreactivity of macrophages and this effect 
further suppressed pain related-behaviours.  In addition, Etanercept enhanced the rate 
of growth and regeneration process of damaged neuronal axons (Kato et al., 2009; 
Kato et al., 2010).  
The anti-inflammatory cytokine, IL-10 is greatly implicated in controlling the 
inflammatory immune response (Morris et al., 2014; Bastien and Lacroix, 2014; 
Kwilasz et al., 2015).  IL-10 is also thought to be involved in neural regeneration by 
regulating other pro-inflammatory cytokines expression during process of 
degeneration of severed axons.  Following peripheral nerve injury, IL-10 receptor 
activation leads to the inhibition of TNF-α and promotes release of endogenous anti-
inflammatory mediators such as soluble TNFRs and IL-1 receptor antagonist (Wagner 
et al., 1998; Sakalidou et al., 2011).  Because of its anti-inflammatory function, local 
application of IL-10 after nerve injury has been shown to reduce the inflammatory 
response and prevent development of neuropathic pain mediated by TNF-α 
expression (Wagner et al.,1998).  Moreover, peripheral application of IL-10 at time of 
nerve repair has accelerated functional recovery and this was attributed to decreased 
amount of scar tissue formation at the site of nerve repair (Atkins et al., 2007; 
Sakalidou et al., 2011). 
Hence, combination therapy of IL-10 and TNF-α antagonist (Etanercept) might 
achieve maximal effect in suppressing the process that initiates inflammatory 
response and thus reduces tissue damage.  Furthermore, this creates a strong rational 
for testing this combination in enhancing functional nerve regeneration following 
peripheral nerve injuries.  Synergistic effects of IL-10 and Etanercept have not 
previously been reported as a combination treatment in peripheral nerve injury.  
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However, previous reports of single therapy of either TNF-α antagonist and IL-10 have 
been criticized regarding the side effect and long-term bioavailability, respectively.  
This synergistic effect of drugs combination might provide better nerve regeneration 
and limit single drug inefficacy and dosing side effects of monotherapy use at time of 
nerve repair. 
5.2 Aim and objectives 
The aim of this study was to investigate the effect of combination of IL-10 and TNF-α 
antagonist on the inflammatory immune response and nerve regeneration, 6 weeks 
following peripheral nerve injury and repair.    More specifically; to determine the effect 
of combination of IL-10 and TNF-α antagonist on macrophage infiltration at the site of 
nerve injury and repair, and on glial activation in the dorsal and ventral horns of the 
spinal cord.  Furthermore, this study aimed to assess the effect of combination of IL-
10 and TNF-α antagonist therapy on functional nerve regeneration 6 weeks following 
peripheral nerve injury and repair.  
5.3 Hypothesis 
Combined application of IL-10 and TNF-α antagonist, peripherally at the site of nerve 
injury and repair will reduce immune cell reactivity, and spinal glial cell activation, thus 
potentially reducing neuropathic pain, and improve functional recovery. 
5.4 Materials and methods 
Chapter 2 details the experimental materials, anaesthesia and methods employed in 
this series of experiments.  All treatments received by animals were randomised and 
investigators performing the experiments and analysis of result were blinded.  A 
schematic overview of the experimental design of this study is shown in Figure 5.1. 
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Figure 5.1: Illustration of the experimental design, investigating the effect of 
combined IL-10 + TNF-α therapy in an in vivo model of sciatic nerve injury and 
repair. 
  
180 
 
Experimental groups 
A total of 20 male C57 black-6 mice (8 weeks or older – weights 17-30 g) were used 
in this study.  In this study, a sample size calculation suggested that minor differences 
(5 %) in the extent of axon regeneration by electrophysiology recording and 
percentage area staining of macrophage marker can be detected with a sample size 
of 10 in each group.  Animals were randomly allocated to either combined application 
of IL-10 and TNF-α antagonist (n=10) or sterile water group (n=10).  Preparation and 
concentration of IL-10 (125 ng/100 µl) and TNF-α (0.15 mg/100 µl) antagonist is 
detailed in Chapter 2, section 2.2.2.   
Briefly, the animals were anaesthetised with 2-3 % of isoflurane and oxygen (2 litres 
per minute).  The left sciatic nerve was exposed, 40 µl of treatment agent injected 
under the epineurium, and the sciatic nerve sectioned transversely and immediately 
repaired with four 9/0 monofilament polyamide (ETHILON*) epineurial suture knots 
(Figure 2.1B).  The remaining 60 µl of the treatment agent was injected intramuscularly 
around the nerve repair, and the wound closed in layers with vicryl suture material 
(6/0).  Postoperative analgesia was maintained with a subcutaneous injection of single 
dose of opioid analgesic (0.05 mg/kg buprenorphine hydrochloride) and the animals 
were allowed to recover for a period of 6 weeks.   
In this experiment additional sham group (n=10) from previous work in the Oral 
neuroscience group is included to explain difference between treatment groups under 
the investigation.  Sterile water is considered as negative control and sham not 
included initially due to the ethical issue in accordance with the UK Home Office 
Animals (Scientific Procedure) Act 1986.   
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Functional assessment of nerve function recovery 
Six weeks following sciatic nerve transection injury and repair, animals anaesthetised 
with an intra-peritoneal injection of intravenous fluanisone (0.8 ml/kg) and midazolam 
(4 mg/kg).  The left sciatic nerve was exposed and a pair of central recording 
electrodes applied to the nerve (platinum wire 0.15 mm diameter).  An evoked 
stimulation across the sciatic nerve was delivered from two pairs of distal and proximal 
electrodes, each situated 2 mm to the repaired site (Figure 2.4).  Data was recorded 
and stored using Spike 2 software (version 5, Cambridge Electronic Design, UK).  The 
CAP ratio calculated between the responses evoked from proximal or distal to the 
repair (modulus with distal stimulation ÷ modulus with proximal stimulation). were 
compared between the experimental groups, from an average of 10 responses to 
stimulation along the sciatic nerve.  In addition, conduction velocities were recorded 
by measuring the latency of the earliest component of the CAP evoked by stimulating 
the regenerated segment of the sciatic nerve. This recording would include both the 
proximal and the regenerated components of the nerve.  
Tissue sectioning and immunohistochemistry analysis 
Following completion of the electrophysiological recordings, animals received a 0.5 ml 
(100 mg) intraperitoneal injection of sodium pentobarbital (20 % w/v) whilst under deep 
anaesthesia.  Then the right and left sciatic nerves and spinal cord tissues were 
removed and fixed in 4 % paraformaldehyde for 24 hours, and cryoprotected overnight 
in 30 % sucrose solution, both at 4 °C.  The tissues were frozen down and sectioned 
as described previously (Chapter 2, section 2.2.6).   
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Staining and analysis of macrophage labelling in the sciatic nerve 
Three slides (9 nerve sections) per animal were washed in phosphate buffered saline 
(PBS) containing 0.2 % Triton X-100, for 2 x 10 minutes, and then incubated overnight 
with a monoclonal antibody raised in rat against mouse CD68 (macrophage marker).  
Fluorescent macrophage labelling was visualised with goat anti-rat CY3 secondary 
antibody. For full details see Chapter 2, section 2.2.7. 
Images of three sciatic nerve sections were captured using the x10 objective, for 
qualitative and quantitative analysis of CD68 staining.  The percentage area of 
positively stained tissue, 1.5 mm either side of the repair site, as represented by suture 
material, was included in the measured area of interest (Figure 2.12).  
To quantify the percentage area of macrophage CD68 labelling, the area of interest 
highlighted, and immunoreactivity of the cells were determined by selecting 
thresholding of images to detect labelled structures (See Chapter 2, section 2.2.8). 
Each reading was taken three times, and the mean was taken. 
Staining and analysis of glial cells in the spinal cord 
Twelve sections from the L4 region were selected per animal and processed for free 
floating immunohistochemical processing for microglial marker (IBA-1) and astrocytes 
marker (GFAP) labelling.  Sections were blocked in in 200 µl 10 % normal donkey 
serum and incubated with a polyclonal antibody to IBA-1 raised in goat, or a polyclonal 
antibody to GFAP raised in rabbit, and respective secondary antibodies donkey anti-
goat CY3 or donkey anti- rabbit CY3.   For full details see Chapter 2, section 2.2.7. 
Three images per animal, representative of dorsal and ventral horn regions, were 
captured at x5 objective for qualitative analysis and at x40 objective for quantitative 
analysis.  Glial cell activation was interpreted by an increase in the number 
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(proliferative changes) and complexity of the cells morphology (phenotypic alteration) 
such as enlarged cell bodies and thicker processes in the dorsal and ventral spinal 
horns.  The percentage area of glial labelling calculated by selecting area of interest 
and then activation areas highlighted by pink, while the remaining areas would be 
highlighted by yellow (See Chapter 2, section 2.2.8). Each reading was taken three 
times, and the mean was taken.   
The ratio of glial cell reactivity was determined by measuring and comparing the ratio 
of positive labelling between the ipsilateral and contralateral sides, in both the dorsal 
and ventral horn regions.  
 Statistical comparisons were performed using t-test (Two-tailed).  Quantitative data 
was expressed as mean ± SEM and differences between groups were considered 
significant at p<0.05.  Statistical analysis was performed using Microsoft Excel 2010 
and GraphPad Prism7 (GraphPad Software, Inc, USA).  
5.5 RESULTS 
5.5.1 Functional analysis 
Following 6 weeks of recovery, electrophysiological studies were carried out to 
determine the efficacy of combined application of IL-10 and TNF-α antagonist on 
neuronal axon regeneration by recording a series of CAP after sciatic nerve injury and 
repair.   
Compound action potential (CAP) 
Assessment of nerve function recovery was determined by recording CAP of nerve 
fibres proximal and distal to the site of nerve injury and repair six weeks following 
repair (Figure 5.2).  In the uninjured sham group, the mean CAP ratio was 0.89 (SEM± 
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0.79), indicating that higher compound action potentials were evoked by stimulation at 
the distal site.  Statistical analysis revealed that the combined treatment group had 
significant grater CAP ratio (0.525 [SEM± 0.05288] versus the sterile water group 
(0.2578 [SEM± 0.04633]; p= 0.001, two-tailed t-test) (Figure 5.3).  
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 Figure 5.2: Calculation of CAP ratio as evoked by stimulation proximal and distal 
to the repair site, respectively. 
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Figure 5.3: Comparison of mean compound action potential (CAP) amplitude ratios 
between experimental groups (Data expressed mean ± SEM;   : p=0.001). 
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Conduction velocities  
Six weeks following sciatic nerve injury and repair, no significant difference in distal 
conduction velocities were seen between the two experimental groups (p=0.599, two-
tailed t-test).  The conduction velocity of the fastest axons in the sham controls was 
60.70 m s-1 (SEM± 3.529). The conduction velocities were significantly slower in all 
the nerve repair groups.  The conduction velocities were slow in all experimental 
groups (Figure 5.4).  The mean conduction velocity in the combination treated group 
was 28.3 ms-1 (SEM± 2.729), whereas in the sterile water group the mean conduction 
velocity was 26.41 ms-1 (SEM± 2.252). 
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Figure 5.4: Mean conduction velocities of experimental groups (Data expressed 
mean ± SEM; ns: p>0.05). 
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5.5.2 Immune cells fluorescent labelling 
Immunohistochemical analysis was carried out to determine the effect of peripherally 
applied combination treatment of IL-10 and TNF-α antagonist, at the time of nerve 
repair, in a clinically relevant model of peripheral nerve injury and repair.  Qualitative 
and quantitative assessment of expression of CD68 (macrophage marker), GFAP 
(astrocyte label) and IBA-1 (microglial marker) was carried out to determine the 
change in immune and glial cell response, at the nerve injury site and in the dorsal 
and ventral horns of the spinal cord.   
CD68 macrophage labelling following sciatic nerve injury and repair 
Qualitative Observations  
Six weeks following sciatic nerve injury and repair immunoreactivity for CD68 
macrophage labelling was present in both groups of animals; combined treatment and 
sterile water.  CD68 labelling was intense and highly expressed around the site of 
sciatic nerve repair, compared with less immunoreactivity observed either distal or 
proximal to the repaired site (Figure 5.5).   
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Figure 5.5: Immunofluorescent images illustrate macrophage infiltration and CD68 immunoreactivity in sciatic nerve 6 weeks 
following nerve injury and repair. (yellow arrows: repaired site).  A: Combination treatment group.  B: Sterile water group.  The 
bright dots indicate active microphages.  Low macrophages immunoreactivity across the repair site in the combination group when 
compared to the sterile water group. Scale bar= 100 µm. 
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Quantitative Observations 
Quantitative image analysis of macrophage infiltration revealed a statistically 
significant difference in the levels of expression between the two experimental groups 
(p= 0.014, two-tailed t-test) (Figure 5.6).  The mean percentage area of CD68 labelling 
following nerve repair and epineurial injection of combination agent was 16.12 (± 2.155) 
compared with those which received sterile water injection, where the mean 
percentage area of CD68 labelling was 27.78 (± 3.735). 
 
 
 
 
 
 
Figure 5.6: Quantification of CD68 macrophage labelling in the sciatic nerve six 
weeks following nerve injury and repair (Data expressed mean ± SEM;  : p <0.05). 
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IBA-1-microglia labelling following sciatic nerve injury and repair 
Qualitative Observations 
Qualitative analysis indicated that fluorescent IBA-1 microglia labelling was present in 
the dorsal and ventral horn regions of spinal cords taken from both experimental 
groups, and clusters of reactive microglial cells were present, exhibiting long and 
branching processes.  Initial observations suggested that IBA-1 levels in the dorsal 
horns appeared to be higher in animals receiving sterile water compared with 
combined treatment agent, but IBA-1 labelling levels appears similar in the ventral 
horns in both experimental groups (Figure 5.7).   
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Figure 5.7: Immunofluorescent images of microglia (IBA-1) labelling in the spinal cord 6 weeks following nerve injury and 
repair. (A) Sterile water group. (B) Combination group.  White arrows indicate corresponding areas of interest and showing 
hypertrophied and amoeboid active glial cells.  Scale bar = 25 µm. 
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Quantitative Observations 
Six weeks following nerve injury and repair, quantitative image analysis revealed a 
higher level of IBA-1 microglial activation in mice-treated with sterile water compared 
with those mice treated with combination agent of IL-10 and TNF-α antagonist, at the 
time of sciatic nerve repair.  Statistical analysis revealed a significant difference in the 
mean ratio of IBA-1 microglial marker labelling in ipsilateral versus contralateral sides 
in the dorsal horn region of the spinal cord (p= 0.023, two-tailed t-test), following 
combined treatment (1.351 ± 0.1013) compared with sterile water treatment (1.966 ± 
0.2276) (Figure 5.8). 
There was no significant difference in the levels of IBA-1 microglial labelling in 
ipsilateral versus contralateral sides in the ventral horn of the spinal cord between the 
groups (p= 0.927, two-tailed t-test) (Figure 5.8).  The ratio of IBA-1 positive cells in 
mice treated with combination agents was 1.542 (± 0.1815) compared with those 
treated with sterile water,1.561 (± 0.0961), six weeks after nerve injury and repair. 
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Figure 5.8: Quantification of ratio of microglial activation (IBA-1 marker) in ipsilateral 
versus contralateral dorsal and ventral horns six weeks following peripheral nerve 
injury and repair. (Data expressed mean ± SEM;  : p <0.05, ns: p>0.05). 
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GFAP astrocyte labelling following sciatic nerve injury and repairs 
Qualitative Observations 
A similar pattern of astrocyte (GFAP) activation and changes in morphology were 
observed in the spinal cord sections, as were seen in microglia (IBA-1) activation, six 
weeks following sciatic nerve injury and repair (Figure 5.9).  
High levels of GFAP immunoreactivity with pronounced branching of astrocyte 
processes was observed in the dorsal horns of the sterile water group.  This was 
accompanied by high GFAP labelling in ventral horns in both experimental groups 
(Figure 5.9).  
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Figure 5.9: Immunofluorescent images of astrocytes (GFAP) labelling in the spinal cord 6 weeks following nerve injury 
and repair. (A) Sterile water group. (B) Combination group. White arrows indicate corresponding areas of interest and 
showing hypertrophied and amoeboid active glial cells. Scale bar = 25 µm. 
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Quantitative Observation 
Quantitative analysis of astrocyte GFAP labelling, revealed a significant difference in 
levels of expression in ipsilateral versus contralateral sides in the dorsal horn region 
of the spinal cord (p= 0.022, two-tailed t-test) between the two treated groups, six 
weeks following of sciatic nerve injury and repair (Figure 5.10).   The mean ratio of 
astrocyte labelling was lower in mice treated with combination agents (1.273 ± 0.06635) 
compared with mice treated with sterile water (1.572 ± 0.0997) at time of sciatic nerve 
repair.    
In contrast, but similar to IBA-1 microglial labelling, there was no significant difference 
in astrocyte labelling in ipsilateral versus contralateral sides in the ventral horns 
between the two groups (p= 0.774, two-tailed t-test) (Figure 5.10).  The mean ratio of 
astrocyte immunoreactivity in combination group was 1.451 (± 0.1582) compared with 
1.389 (± 0.1427) in the sterile water group. 
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Figure 5.10: Quantification of ratio of astrocyte activation (GFAP marker) in ipsilateral 
versus contralateral dorsal and ventral horns six weeks following peripheral nerve injury 
and repair. (Data expressed mean ± SEM;  : p <0.05, ns: p>0.05). 
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5.6 Discussion 
These findings support the role of anti-inflammatory IL-10 cytokine and TNF-α 
antagonist as key modulators involved in the response to nerve injury.  Administration 
of a combined treatment of IL-10 cytokine and TNF-α antagonist at time of nerve repair 
showed significantly improved nerve regeneration.  Furthermore, a significant 
reduction in inflammatory markers at the site of nerve repair was seen, as was a 
decrease in glial activation in the dorsal horn of the spinal cord. 
Electrophysiological analysis was chosen as a key evaluation of functional nerve 
regeneration in this sciatic nerve injury and repair model.  The result showed that the 
CAP was always higher in the uninjured sham and the nerve repair groups, when 
compared the repair groups.  This difference in the CAP might have resulted from a 
reduction in the number and/or size of regenerated axons in the distal stump after 
nerve injury and repair. 
CAP ratio was significantly higher in combination treated animals compared with those 
in the sterile water group, suggesting a larger proportion of axons regenerated 
successfully across the repaired site (Ngeow et al., 2011b).  It is possible combined 
application of IL-10 cytokine and TNF-α antagonist was effective in reducing fibrous 
tissue formation and subsequently improved nerve fibres regeneration, but 
histomorphometric analysis is essential to further assess this (Atkins et al., 2007; 
Sakalidou et al., 2011).  However, assessment of conduction velocities did not show 
any difference in conduction speed between the experimental groups.  Peripheral 
administration of combination therapy at time of nerve repair did not improve 
conduction speed and, moreover, it is more likely that axons matured at slow rates in 
both sensory and motor fibres within the sciatic nerve.  This is consistent with previous 
studies that have reported enhanced recovery of nerve function, suppression of local 
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inflammation and reduction of scar tissue formation subsequently following application 
of either IL-10 cytokine or TNF-α antagonist, following peripheral nerve injury and 
repair (Atkins et al., 2007; Kato et al., 2010). 
In our study, combined epineurial administration of IL-10 cytokine and TNF-α 
antagonist immediately after nerve repair reduced immune cell infiltration at the site of 
nerve injury and repair, compared with animals receiving sterile water treatment.  The 
combination therapy appears to regulate the immune cell activity, which may possibly 
prevent development of neuropathic pain following peripheral nerve injury.  Previous 
studies reported that local application of TNF- antagonist Etanercept after sciatic 
nerve injury was associated with downregulation of inflammatory cytokines that 
mediate onset of neuropathic pain.  Moreover, application of Etanercept was thought 
to support the rate of growth, and regeneration process of injured axons (Sommer et 
al., 2001; Kato et al., 2009; Kato et al., 2010). 
It is well documented that IL-10 regulates production of pro-inflammatory cytokines, 
including TNF-α at the site of nerve injury, and subsequently suppresses sensitization 
and plasticity of neurons in the spinal cord (2014; Morris et al., 2014; Kwilasz et al., 
2015).  There is clear evidence that IL-10 functionally inhibits signalling pathways that 
contribute to immune cell chemotaxis and associated cellular events during Wallerian 
degeneration (Morris et al., 2014; Kwilasz et al., 2015).  Here, combined therapy of IL-
10 and TNF-α antagonist exerted a reduction of immune cell reactivity locally, and 
furthermore centrally in the spinal cord – indicated in our study, by reduced glial cell 
marker IBA-1 and GFAP immunoreactivity. 
The precise role of pre-treatment of the injured peripheral nerve at the time of nerve 
repair with combination therapy has not previously been explored.  However, the 
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current results suggest that combined epineurial application of IL-10 and TNF-α 
antagonist could suppress nociceptive pain signals largely through suppressing 
production of pro-inflammatory cytokines.  In addition, this approach possibly reduces 
activation of immune cells at the injury site as well as in the sensory areas in the spinal 
dorsal horns regions. 
The contribution of glial cells, microglia and astrocytes, to the development of 
neuropathic pain after nerve injury has largely been investigated using different glial 
inhibitors (interleukin-1 receptor antagonist and soluble tumour necrosis factor 
receptor antagonist) that were applied intrathecal at the site of spinal cord injury 
(Sweitzer et al., 2001; Mika et al., 2013).  These inhibitors were shown to inhibit pain 
related mechanisms through reduced glial cell activation (Sweitzer et al., 2001; 
Zelenka et al., 2005; Kato et al., 2009; Hansen and Malcangio, 2013).  However, these 
inhibitors reduced pain hypersensitivity immediately after nerve injury, but had no 
additive effect unless continuous application was delivered using special cutaneous 
pump for several weeks post injury.  In our study, combined epineurial administration 
of IL-10 cytokine and TNF-α antagonist was the first to report and reduced glial cell 
activation shown by reduced IBA-1 and GFAP cell labelling in the dorsal horns of the 
spinal cord.  It is possible that a combined IL-10 and TNF-α antagonist therapeutic 
approach interferes in the early stages of healing with signals that activate glial cells, 
and produces long lasting anti-inflammatory effects with a single injection that possibly 
suppresses pain related mechanisms, thus preventing the development of neuropathic 
pain.  
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5.7 Summary 
The present study demonstrated that the effect of immediate combination therapy of 
IL-10 and TNF-α antagonist enhanced some aspects of nerve regeneration after nerve 
injury and repair.  In addition, this therapeutic approach has resulted in a suppressed 
immune inflammatory response locally at the site of nerve injury, and centrally in the 
spinal dorsal horns.  It should be highlighted that combined therapy of IL-10 and TNF-
α antagonist appears to have a synergistic effect on the regeneration process without 
compromising immune cell function and subsequent healing process of the injured 
peripheral nerve.  Although, the current combination therapy based method produced 
recognized long lasting anti-inflammatory effects, further research is necessary to 
optimise its therapeutic effect and tolerability, in the consideration for its targeted 
therapeutic approach in the management of neuropathic pain following peripheral 
nerve injury. 
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CHAPTER 6 
Repair of peripheral nerve injury with gap defect using 
poly-carprolactone conduit and TNF-α antagonist 
 
 
This study was undertaken in collaboration with my colleague Emad Albadawi (PhD 
student).  I am grateful for his contribution in this study by carrying out conduit 
implantations and axon tracing techniques.  Poly-caprolactone conduits used for this 
work were fabricated by Jonathan Field (PhD student) in the laboratory of Dr. Fred 
Claeyssens at the University of Sheffield.   
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6.1 Introduction 
It has been long established that adequate restoration of function following peripheral 
nerve injury is clinically challenging.  This is more apparent in nerve injuries where 
there is a ‘gap deficit’.  Poor outcome in repairing nerve tissue across a defect may be 
related to undue tension where there has been an attempt at direct surgical 
anastomosis of nerve stumps.  Therefore, other treatment modalities have been 
advocated such as an autologous nerve graft where the nerve gap defect is too long 
and does not permit direct nerve repair.  However, this type of repair is infrequently 
used due to restricted availability and morbidity associated with donor nerve tissue 
(Stefano et al., 2013).  As a result, more work is being undertaken on developing novel 
biologically engineered tissues or materials that could functionally substitute nerve 
tissue (Johnson et al., 2005).  Other challenges of neural tissue regeneration may be 
related to invasion of scar tissue, and limited angiogenesis and revascularization 
which are required to enhance neurogenesis and support axon regeneration (Johnson 
and Soucacos, 2008; Cattin et al., 2015). 
During the reparation phase of a damaged peripheral nerve, the Schwann cell-basal 
lamina promote and guide axon growth, however, segmental nerve tissue loss has a 
detrimental effect of loss of axon growth potential and guidance across the gap defect.  
Therefore, nerve conduit guidance (NCG) provides an artificial means of guiding and 
supporting nerve growth, enhancing nerve regeneration and neurogenesis (Johnson 
and Soucacos, 2008; Chiono and Tonda-Turo 2015). 
There are several types of NCG materials that have been used for repair of peripheral 
nerve injuries including biological (nerve autograft and autologous collagen) and 
synthetic (lactate polymer) nerve guides based on their ability to support axon growth 
206 
 
and prevent fibrous tissue invasion (Johnson et al., 2005; Johnson and Soucacos, 
2008; Nan et al., 2012; Wood and Mackinnon, 2015).   
Despite advancements in microsurgical replacement techniques, the misdirection of 
regenerating axons still provides a hindrance to fulfilling the aim of complete recovery 
of nerve function after nerve repair (Ichihara et al. 2008; Johnson and Soucacos 2008; 
Muheremu and Ao, 2015).  In addition, it has been proposed that the NCG properties 
should support Schwann cells to migrate through the conduit without impeding the 
regeneration process.  As a result, the NGC architecture should promote axonal 
regeneration in order to stimulate Schwann cells to migrate and enhance neuronal 
regeneration (Ichihara et al., 2008; Johnson and Soucacos, 2008; Muheremu and Ao, 
2015).  Several methods have been advocated to construct synthetic nerve conduit to 
replicate critical elements of regenerative environment during healing of damaged 
axons. Recently, Pateman et al (2015) developed microstereolithography method in 
the laboratory of Dr. Fred Claeyssens at the University of Sheffield.  This method which 
is a new innovative 3D printing process that uses a laser source of A 405 nm.  Briefly, 
the method involves object designing using optical laser beam, photosolidifcation of 
photocurable resin and finally custom conduit guidance printing (Pateman et al., 2015). 
An overview of evidence available from experimental evaluation of poly-caprolactone 
(PCL) conduits in peripheral nerve repair, indicate that they are able to support axonal 
growth across a nerve defect and enhance nerve regeneration (Bertleff et al. 2005; R 
H Shin et al. 2009; Allodi et al. 2012).  
Bertleff et al. (2005) compared the recovery of sensory function following traumatic 
hand injuries using a biodegradable PCL and repair a gap of 8 mm or more.  Their 
study showed that recovery of sensation in the nerve conduit repair group was 
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considered at least as good as in the direct repair group and, thus PCL conduit is 
considered suitable for the repair of nerve gap defect up to 20 mm without tension.   
Another study conducted by Shin et al. (2009) evaluated functional and 
histomorphological outcomes following conduit implantation of three synthetic 
materials (collagen, PCL and PGA) and nerve autograft in repairing a10 mm gap 
defect of sciatic nerve in a rodent model.  After 12 weeks, there were no significant 
difference observed in compound muscle action potentials as shown by 
electromyographic measurements, and the percentage of axon counts between the 
autograft and synthetic conduit repairs.  Furthermore, there were no differences in 
mean myelin thickness between the experimental groups.  In addition, results showed 
that PCL and collagen conduits remained structurally stable with optimum results, 
whereas PGA conduits degraded quickly, and established that PCL conduits can be 
used to repair 10 mm sciatic nerve gap defect with better functional outcome similar 
to the autograft repair, as compared to other synthetic conduit guidance materials.  
Several studies investigated nerve regeneration following repair of gap defects using 
either a biodegradable PCL conduit or an autologous nerve graft in rodent models 
(Den Dunnen et al., 1996; Reid et al., 2013).  It has been reported that using a 
biodegradable PCL for repair is associated with faster nerve regeneration and is 
qualitatively better than using an autologous nerve graft (Den Dunnen et al., 1996).  
However, histomorphometric analysis did not show a significant difference in pattern 
and distribution of myelinated fibres between these two repair groups and results 
revealed similar numbers of axons in the distal stumps and equivalent re-innervation 
rate of end organ muscle and skin (Reid et al., 2013).   
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There is sufficient evidence that inflammatory cytokines such as TNF-α, produced by 
immune cells, have a detrimental effect on axonal regeneration, by upregulating the 
immune reaction following nerve injury (Gaudet et al., 2011; Bastien and Lacroix, 2014; 
Wood and Mackinnon, 2015).  Although the precise effect of TNF-α is not completely 
understood, there is convincing evidence to support the fact that appropriate targeting 
of TNF-α receptors improves regeneration as well as nerve function and suppresses 
pain related behaviours (Liefner et al., 2000; Iwatsuki et al., 2013; Kato et al., 2010). 
Moreover, epineurial applications of TNF-α antagonist have been shown to inhibit 
immune cell activity and down regulate inflammation following peripheral nerve injury 
(Liefner et al., 2000; Iwatsuki et al., 2013; Kato et al., 2010). 
6.2 Aim and objectives 
The aim of this study was to investigate the effect of poly-carprolactone conduit and 
TNF-α antagonist (Etanercept) on the inflammatory immune response and nerve 
regeneration, 5 weeks following peripheral nerve injury and repair.  More specifically; 
to determine the effect of TNF-α antagonist on glial activation in the dorsal and ventral 
horns of the spinal cord, and establish the effect of poly-carprolactone conduit and 
TNF-α antagonist (Etanercept) on axonal regeneration and gait movement, 5 weeks 
following peripheral nerve injury and repair.   
6.3 Hypothesis 
The implantation of PCL-based conduits with administration of TNF-α antagonist 
(Etanercept) peripherally at the site of nerve injury and repair will reduce the immune 
cell reactivity, and spinal glial cell activation, thus potentially reducing neuropathic pain, 
and improve functional recovery. 
 
209 
 
6.4 Materials and methods 
Chapter 2 details the experimental materials, anaesthesia and methods employed in 
this series of experiments.  All treatments received by animals were randomised and 
investigators performing the experiments and analysis of result were blinded.  A 
schematic overview of the experimental design of this study is shown in Figure 6.1. 
 
 
 
 
 
 Figure 6.1: Illustration of the experimental design investigating the effect of poly-
carprolactone conduit and TNF-α antagonist (Etanercept) on the inflammatory 
immune response and nerve regeneration in an in vivo model of sciatic nerve 
injury and repair. 
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Experimental groups  
A total of 20 thy-YFP mice either male or females (≥8 weeks old– weights 17-30 g) 
were used in this study.  For this study, a sample size calculation suggested that minor 
differences (5 %) in the extent of axon regeneration assessed by electrophysiological 
recording, functional axon tracing and gait analysis outcome can be detected with a 
sample size of 10 in each group.  Animals were randomly allocated to either treatment 
groups: PCL conduit repair and Etanercept treatment (n=10) or PCL conduit repair 
with sterile water (n=10). Preparation and concentration of TNF-α (0.15 mg/100 µl) 
antagonist is detailed in Chapter 2, section 2.2.2.  
Briefly, the animals were anaesthetised with 2-3 % of isoflurane and oxygen (2 L/min). 
The left sciatic nerve was exposed and 30 µl of treatment injected into either side of 
the segments (the proximal and distal) where the 4 mm defect would be created (see 
Chapter 2, section 2.2.4).  A 5 mm PCL conduit was implanted and the two sectioned 
nerve stumps were inserted approximately 0.5 mm into either end of the conduit tube 
and secured with an application of fibrin glue (Figure 2.2).  Following conduit 
implantation, the remaining 40 µl of the treatment agent was injected intramuscularly 
into surrounding muscle tissues, and the wound closed in layers with vicryl suture (6/0, 
ETHICON®).  A subcutaneous injection of buprenorphine hydrochloride (Vetergesic 
[0.05 mg/kg], Ceva) was administered at the end of the surgical procedure, and 
animals allowed to recover for 5 weeks. 
In this experiment additional sham group (n=10) from previous work in the Oral 
neuroscience group is included to explain difference between treatment groups under 
the investigation.  Sterile water is considered as negative control and sham not 
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included initially due to the ethical issue in accordance with the UK Home Office 
Animals (Scientific Procedure) Act 1986.   
Functional assessment of nerve function recovery 
Gait analysis 
As previously described in Chapter 2, section 2.2.5.1, gait assessment is acquired by 
use of CatWalk system that incorporates automated software analysis of natural gait 
parameters. Briefly, paw prints obtained from runs which were conducted immediately 
before (baseline) and then at weeks 1, 2, 3, 4 and 5 after nerve conduit repair. An 
average value of the two runs of each animal was counted   
Electrophysiology 
Electrophysiological recording is detailed in Chapter 2; section 2.2.5.1.  For non-
recovery electrophysiological recordings, animals anaesthetised with an intra-
peritoneal (ip) injection of intravenous fluanisone (0.8 ml/kg) and midazolam (4 mg/kg).  
The sciatic nerve of left leg was exposed and a pair of central recording electrodes 
applied to the nerve (platinum wire 0.15 mm diameter).  An evoked stimulation across 
the sciatic nerve was delivered from two pairs of distal and proximal electrodes, each 
sited close to the conduit edges touching only the nerve tissues.  Data was recorded 
and stored using Spike 2 software and the CAP ratio calculated between the 
responses evoked from proximal or distal to the repair (modulus with distal stimulation 
÷ modulus with proximal stimulation). were compared between the experimental 
groups, from an average of 10 responses to stimulation along the sciatic nerve.  In 
addition, conduction velocities were recorded by measuring the latency of the earliest 
component of the CAP evoked by stimulating the regenerated segment of the sciatic 
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nerve. This recording would include both the proximal and the regenerated 
components of the nerve.  
Axon tracing 
Axon tracing measures the sprouting Index (SI), the number of individual axons that 
have crossed the defect and the level of axon disruption across the initial portion of 
the conduit repair.  As previously stated (see Chapter 2, section 2.2.9), a reference 
line was drawn across the junction of central nerve segment and conduit edge and 
established as 0.0 mm interval and then subsequent intervals determined in forward 
direction at length of 0.5 mm up to 4.0 mm distal to the interface of axons and conduit 
edge.  
The SI was determined by counting the number of axons at each interval and dividing 
by the axon number at the -0.5 mm interval (see Chapter 2, section 2.2.9).  An average 
value was used to minimise the estimation error.  Functional axon tracing is used to 
determine the percentage of axons that have successfully reached each interval 
across the nerve gap defect.  Next axons were traced and the length measured from 
point 0.0 mm to 1.5 mm to determine the average axon length as proportion of the 
distance (i.e. 1.5 mm) (see Chapter 2, section 2.2.9).   
Tissue sectioning and immunohistochemistry analysis 
Following completion of the electrophysiology recordings, animals received a 0.5 ml 
intraperitoneal injection of sodium pentobarbital (20 % w/v) and the spinal cord tissues 
was removed and fixed in 4 % paraformaldehyde for 24 hours, and cryoprotected 
overnight in 30 % sucrose solution, both at 4°C.  The spinal cords were frozen down 
and sectioned as previously described (Chapter 2, section 2.2.6).   
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Staining and analysis of glial cells in the spinal cord 
Twelve sections from L4 region were selected per animal and stained for microglial 
marker (IBA-1) and astrocyte marker (GFAP) using free floating technique.  Sections 
were blocked in in 200 µl 10 % normal donkey serum and incubated with a polyclonal 
antibody to IBA-1 raised in goat, or a polyclonal antibody to GFAP raised in rabbit, and 
respective secondary antibodies donkey anti-goat CY3 or donkey anti- rabbit CY3. 
Tissues were then mounted onto gelatine-coated slides and cover slipped with 
vectashield.  For full details see Chapter 2, section 2.2.7. 
Images of three immunostained sections, representative of dorsal and ventral horn 
regions, per animal, were captured at x40 objective for quantitative analysis and at x5 
objective for qualitative analysis.  Glial cell activation was interpreted by an increase 
in the number (proliferative changes) and complexity of the cells morphology 
(phenotypic alteration) such as enlarged cell bodies and thicker processes in the 
dorsal and ventral spinal horns.   
The percentage area of glial labelling calculated by selecting area of interest and then 
activation areas highlighted by pink, while the remaining areas would be highlighted 
by yellow (See Chapter 2, section 2.2.8). Each reading was taken three times, and the 
mean was taken.  The ratio of glial cell reactivity was determined by measuring and 
comparing the ratio of positive labelling between the ipsilateral and contralateral sides, 
in both the dorsal and ventral horn regions.  
Statistical comparisons of CAP, conduction velocity and glial cell labelling were 
performed using t-test (Two-tailed).  Quantitative data was expressed as mean ± SEM.  
Two-way repeated measures ANOVA was used for comparison between the groups 
to detect any difference in sprouting index and functional axon tracing and gait 
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parameters.  Differences between groups were considered significant at p<0.05.  
Statistical analysis was performed using Microsoft Excel 2010 and GraphPad Prism7 
(GraphPad Software, Inc, USA).   
6.5 RESULTS 
Five weeks following conduit implantation, the sciatic nerve had regenerated through 
the conduit in 8 out of 20 mice (four in each group).  The remaining 12 mice where 
their nerves had failed to regenerate due to technical failure as conduit become 
separated from either the proximal or the distal end were excluded from further 
analysis.   
6.5.1 Functional analysis 
6.5.1.1 Gait analysis of paw print intensity and total paw print area 
Analysis of changes in gait movement is considered an effective method to analyse 
function after peripheral nerve repair, and is assessed by measuring paw print intensity 
and surface area.  
Paw print intensity 
Immediately after the nerve injury and repair there was dramatic drop of the left paw 
print intensity in both groups.  The TNF-α antagonist group had 60 % of the 
preoperative paw print intensity after one week (Figure 6.2), whilst the sterile water 
had 50 % of preoperative paw print intensity at this time point, although this difference 
was not statistically significant (p= 0.999, two-way repeated measures ANOVA).  The 
results obtained at weeks 2 and 3 showed that there was a significant difference 
between the left paw print intensity in the TNF-α antagonist group when compared to 
the sterile water group (week 2, p= 0.0333; week 3, p= 0.0372, two-way repeated 
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measures ANOVA).  In the TNF-α antagonist group, the left paw print intensity had 
recovered to 70 % of the preoperative value at week 2 and week 3 in comparison to 
the sterile water group where intensity remained at 50 % of preoperative values.  
Furthermore, the TNF-α antagonist group showed reduction in function at week 4 and 
5, but remained slightly above the sterile water group (week 4, p=0.999; week 5, 
p=0.999, two-way repeated measures ANOVA).   
However, the print intensity of the right paw (uninjured side) were reduced compared 
to preoperative value, and become indistinguishable from week 1 as no significant 
differences was registered between the experimental groups during the study (week1, 
p=0.877; week 2, p=0.998; week3, p=0.999; week 4, p=0.789; week 5, p=0.939, two-
way repeated measures ANOVA) (Figure 6.3). 
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Figure 6.2:  The mean intensity of the left paw print as a percentage of the preoperative 
value (100 %) for each group at each time point of function assessment. : p <0.05). 
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Figure 6.3:  The mean intensity of right paw print as a percentage of the preoperative 
value (100 %) for each group at each time point of function assessment.  
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Total paw print area 
The percentages of total print area of the left paw (injured side) were negatively 
affected in both groups when compared to baseline values (Figure 6.4).  At week 1 
and week 2 assessment, the TNF-α antagonist group had 60 % of preoperative value 
of total paw print area, and the sterile water had 40 % of preoperative value of total 
paw print area this time point, but not significant (week 1, p= 0.139; week 2, p=0.166, 
two- way repeated measures ANOVA).  However, the value of total print area of the 
left paw was significantly different between the experimental groups at week 3 
assessment (p= 0.0252, two-way repeated measures ANOVA) and analysis shows 
that the TNF-α antagonist repair group had a significantly greater left paw print area 
as compared to the sterile water group.  Moreover, changes in gait function as shown 
by variation in values of total paw print area at weeks 4 and week 5 showed no 
significant difference between groups at these time points (week 4, p= 0.1612; week 
5, p= 0.4972, two-way repeated measures ANOVA).  
The values of total print area of the right paw (uninjured side) were reduced as 
compared to the preoperative values in both groups at week 1 assessment (Figure 
6.5).  By week 2 of gait assessment the TNF-α antagonist had a total paw print area 
slightly greater than the sterile water group but this was not statistically significant (p= 
0.742, two-way repeated measures ANOVA).  Once more, there were transient 
changes in gait function for the rest of assessment period at week 3,4 and 5 and results 
did not reveal any difference between treatment groups (p= 0.999, two-way repeated 
measures ANOVA).   
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Figure 6.4:  The mean total area of left paw print as a percentage of the preoperative value 
(100 %) for each group at each time point of function assessment.  : p <0.05). 
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Figure 6.5:  The mean total area of the right paw print as a percentage of the preoperative 
value (100 %) for each group at each time point of function assessment.  
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6.5.1.2 Electrophysiology analysis 
Following 5 weeks of recovery, electrophysiological studies were carried out to 
determine the efficacy of poly-carprolactone conduit and TNF-α antagonist 
(Etanercept) on neuronal axon regeneration by recording a series of a compound 
action potential after sciatic nerve injury and repair.   
Compound action potentials (CAP) 
The CAP ratio in the uninjured sham group was 0.89 (SEM± 0.79), indicating that 
higher compound action potentials were evoked by stimulation at the distal site.  The 
ratio of CAP from the proximal and distal segment was compared between the 
experimental groups and whilst data show some indication of better regeneration of 
nerve fibres in animals receiving TNF-α antagonist treatment, compared with receiving 
sterile water, the results were not statistically significant (p=0.313, two-tailed t-test) 
(Figure 6.6).  In the TNF-α antagonist group, the mean CAP ratio was 0.4895 (SEM± 
0.1371), while the mean CAP ratio for the sterile water group was 0.311 (SEM± 0.104) 
(Figure 6.7). 
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Figure 6.6: Calculation of CAP ratio as evoked by stimulation proximal and distal to 
the repair site, respectively. 
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Figure 6.7: Comparison of mean compound action potential (CAP) amplitude ratios 
between experimental groups (Data expressed mean ± SEM; ns: p>0.05). 
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Conduction velocities  
The conduction velocity of the fastest axons in the sham controls was 60.70 m s-1 
(SEM± 3.529). The conduction velocities were significantly slower in all the nerve 
repair groups.  The results revealed no significant difference in the conduction 
velocities attained by stimulating distal nerve fibres in both groups (p= 0.777, two-tailed 
t-test) (Figure 6.8). The mean conduction velocities in the sterile water group were 
14.1 ms-1 (SEM± 2.896), whereas in the TNF-α antagonist group the mean conduction 
velocities were 15.5 ms-1 (SEM± 3.931).    
 
 
 
 
 
 
  
Figure 6.8: Mean conduction velocities of experimental groups, 5 weeks following 
conduit implantation (Data expressed mean ± SEM; ns: p>0.05). 
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6.5.1.3 Axon tracing 
Five weeks following sciatic nerve repair, only 8 out of 20 mice (four in each group) 
their nerves successfully regenerated as the conduits did not dislodge or separate 
from the proximal or distal never end and the remaining were excluded from further 
analysis.   
Qualitative Observations 
Morphological assessment of axonal regeneration across a 4 mm gap following 5 
weeks of PCL nerve conduit repair of sciatic nerve showed a difference in the pattern 
of axon growth between the groups.  More, specifically, axonal sprouting was more 
organized in the TNF-α antagonist group as compared to the sterile water group at the 
start of axonal regeneration within the conduit (0.0 mm interval) (Figure 6.9).   
Thereafter, as axons enter the conduit and progressed towards the distal nerve 
segment they showed more uniform pattern of regeneration through the conduit after 
5 weeks of nerve injury and repair in all experimental groups. 
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Figure 6.9: Confocal fluorescent microscopic images of Thy-1-YFP-H nerve conduit repair with intervals marked from 4.0 mm interval 
position back to 0.0 mm (start) interval. (A) TNF-α antagonist group. (B) Sterile water group.  In all of the repair groups, there is an 
area of disrupted axons shown around the proximal nerve ending-conduit interface, with axons then becoming more organised once 
had crossed the conduit and entered the distal nerve stump.  TNF-α antagonist group typically appeared to have less axon sprouting 
at the join between proximal nerve end and conduit than the sterile water repairs.  In the sterile water group axons typically were 
disrupted and disorganised upon regenerating out from the proximal transected segment, whilst in the TNF-α antagonist group axons 
regenerating through the PCL conduits tended to be more densely arranged than axons with greater organisation pattern. Scale bar= 
1.0 mm.  
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Quantitative Observations 
Sprouting index 
The results obtained show that at 0.5 mm, axonal sprouting was significantly less in 
the TNF-α antagonist group (p=0.010, two-way repeated measures ANOVA) (Figure 
6.10).  The sprouting index was lower in the TNF-α antagonist group compared to the 
sterile water group at 0.5 mm interval into the conduit (41 % versus 69 %).   
 
 
 
Figure 6.10: Sprouting index values for each 0.5 mm interval. Data expressed mean 
± SEM;  : p <0.05).   
228 
 
Functional axon tracing   
Regenerated axons were traced across the repair site to determine the proportion of 
axons that had successfully regenerated across the distal nerve segment (4.5 mm 
interval) through the conduit 5 weeks after nerve injury and repair (Figure 6.11).  When 
comparing the proportion of regenerated axons, the results showed that 30 % of axons 
in the TNF-α antagonist group, compared to 24 % of axons in the sterile water group, 
reached the last distal point at interval 4.5 mm, but this was not statistically significant 
(p=0.999, two-way repeated measures ANOVA).  Furthermore, comparing overall 
axon proportions from the 0.0 mm interval, almost 60-70 % of axons in the TNF-α 
antagonist and the sterile water groups failed to regenerate across the repaired site. 
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Figure 6.11: Percentages of axons that successfully had reached the distal segment 
from the repair start point (0.0 mm interval) (Data expressed mean ± SEM; ns: p>0.05).  
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Axon disruption  
Axonal disruption mostly occurs shortly after joining of the proximal stump with the 
conduit repair and predetermined between 0.0 mm and 1.5 mm intervals as described 
in Chapter 2, section 2.2.9.  When comparing the length of regenerated axons across 
repair site between 0.0 mm and 1.5 mm intervals there was significant reduction in the 
level of axonal disruption in the TNF-α antagonist group as compared to the sterile 
water group (7.288 [SEM±0.656] versus 12.36 [SEM±1.981]; p=0.039, two-tailed t-test) 
(Figure 6.12).   
 
 
 
 
Figure 6.12: Axon disruption across the initial 1.5 mm of nerve conduit repair (Data 
expressed mean ± SEM;  : p <0.05).   
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6.5.2 Immune cells fluorescent labelling 
The qualitative and quantitative assessment of immune cell expression of IBA-1 
(microglial marker) and GFAP (astrocyte label) was carried out to determine the 
change in immune cell response, in the dorsal and ventral horns of the spinal cord.   
IBA-1-microglia labelling following sciatic nerve injury and repair 
Qualitative Observations 
Five weeks following sciatic nerve injury and repair, and conduit implantation, clusters 
of IBA-1 immunofluorescent reactive microglial cells with long and branching 
processes were observed in the dorsal horns of animals receiving sterile water 
treatment (Figure 6.13).  This was accompanied by dense microglial activation in 
ventral horns in both experimental groups (Figure 6.13).  
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Figure 6.13: Immunofluorescent images of microglia (IBA-1) labelling in the spinal cord, 5 weeks following conduit 
implantation. (A) Sterile water group. (B) TNF-α antagonist group.  White arrows indicate corresponding areas of 
interest and showing hypertrophied and amoeboid active glial cells. Scale bar = 25 µm. 
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Quantitative Observations 
Five weeks following nerve injury and conduit implantation and repair, statistical 
analysis revealed a significant difference in IBA-1 microglial marker labelling in 
ipsilateral versus contralateral sides in the dorsal horns between the two experimental 
groups (p= 0.030, two-tailed t-test) (Figure 6.14).  The mean ratio of IBA-1 fluorescent 
labelling in ipsilateral and contralateral sides in the dorsal horn after five weeks of 
injury in the TNF-α antagonist group was 1.28 (SEM± 0.0697), compared with those 
treated with sterile water,1.505 (SEM± 0.0388).   
The quantitative analysis of IBA-1 microglial labelling in the ventral horn of the spinal 
cord did not show any difference between the groups (p= 0.866, two-tailed t-test) 
(Figure 6.14).  The mean ratio of IBA-1 positive cells in ipsilateral versus contralateral 
sides in the ventral horns in mice treated with TNF-α antagonist was 1.32 (SEM± 
0.0393) whereas those treated with sterile water was 1.333 (SEM± 0.0590).  
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Figure 6.14: Quantification of ratio of microglial activation (IBA-1 marker) in ipsilateral 
versus contralateral dorsal and ventral horns five weeks following peripheral nerve injury 
and conduit implantation. (Data expressed mean ± SEM;  : p <0.05, ns: p>0.05). 
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GFAP astrocyte labelling following sciatic nerve injury and repairs 
Qualitative Observations 
Astrocyte activation and morphological changes observed in the spinal cord sections, 
five weeks following nerve injury and conduit implantation, were similar to changes 
seen in microglia activation (Figure 6.15).  
Qualitative analysis of the spinal cord sections in the lumbar-4 region, showed high 
levels of immunofluorescent astrocyte labelling, with pronounced branching of 
processes, in dorsal horns in the sterile water group.  Moreover, there was also high 
GFAP labelling in the ventral horns in both experimental groups (Figure 6.15).  
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 Figure 6.15: Immunofluorescent images of astrocyte (GFAP) labelling in the spinal cord, 5 weeks following conduit 
implantation. (A) Sterile water group. (B) TNF-α antagonist.  White arrows indicate corresponding areas of interest 
and showing hypertrophied and amoeboid active glial cells. Scale bar = 25 µm. 
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Quantitative Observation 
Quantitative analysis of GFAP astrocyte labelling in the L4 region of the spinal cord, 
revealed a significant difference in the ratio of expression in ipsilateral versus 
contralateral sides in the ventral horns between the two treated groups, five weeks 
following sciatic nerve injury and conduit implantation (p= 0.022, two-tailed t-test) 
(Figure 6.16).    
The mean ratio of astrocyte labelling was lower in dorsal horns of mice treated with 
TNF-α antagonist 1.218 (SEM± 0.0666) compared with mice treated with sterile water 
(1.465 [SEM± 0.0457]) at time of sciatic nerve repair.  In contrast, there was no 
significant difference in the ratio of astrocytes labelling in ipsilateral versus 
contralateral sides in the ventral horns between the two groups (p= 0.389, two-tailed 
t-test) (Figure 6.16).  The mean ratio of astrocyte immunoreactivity in the TNF-α 
antagonist group was 1.163 (SEM± 0.0466) compared with mice treated with sterile 
water at time of nerve repair the cell labelling was 1.23 (SEM± 0.0559).   
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 Figure 6.16: Quantification of ratio of astrocyte activation (GFAP marker) in ipsilateral 
versus contralateral dorsal and ventral horns five weeks following peripheral nerve 
injury and conduit implantation. (Data expressed mean ± SEM;  : p <0.05, ns: p>0.05). 
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6.6 Discussion 
This study demonstrated that sciatic nerve repair with a poly-carprolactone (PCL) 
conduit and TNF-α antagonist (administrated at the time of repair) resulted in a 
demonstrable increase in CAP ratio, compared with PCL conduit repair and sterile 
water, however these results were not significant.  In addition, there were 
improvements in gait movements, axonal regeneration, and the axons appeared to 
have less disrupted growth.  Furthermore, there was a significant reduction in glial 
markers, centrally, in the spinal cord.  Five weeks following sciatic nerve repair, only 
8 out of 20 mice (four in each group) their nerves successfully regenerated as the 
conduits did not dislodge or separate from the proximal or distal nerve end and the 
remaining were excluded from further analysis.   
Gait analysis is increasingly used as another a means of evaluating functional nerve 
recovery in rodent models of peripheral nerve injury and repair (Deumens et al., 2007; 
Deumens et al., 2010; Ngeow et al., 2011b).  In this study, the assessment of gait 
function showed a similar pattern of functional recovery across the experimental 
groups during the study period.  In addition, analysis of gait movements (intensity and 
total paw print area) revealed a sharp decline one week after conduit implantation 
compared to baseline values, which was followed by some improvement, when treated 
with TNF-α antagonist.  However, improvements in gait movement were significantly 
evident in intensity and total paw print area at week 2 and 3 week after nerve injury 
and repair.  This improvement possibly due to the effect of TNF-α antagonist on the 
axon regeneration rate at early time following nerve injury and repair.  This effect was 
also reported by Ngeow et al (2011) following epineurial injection of Mannose-6-
Phosphate after sciatic nerve repair in mice. 
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In general, the pattern of nerve function recovery was consistent with those expected 
as a consequence of nerve injury, and as previously reported by Ngeow et al (2011b).  
Ngeow et al (2011b) described gait analysis of gait movements using the catwalk 
system to assess motor and sensory recovery 12 weeks following sciatic nerve injury 
and repair in mice.  Their study showed a sharp decline in paw print area up to 3 weeks 
after nerve injury and repair and limited improvement was observed over the study 
period.   In our experiment the recovery period was five weeks and this showed an 
immediate a drop of gait function one week after nerve injury and repair.  However, 
significant improvement were recorded at weeks 2 and 3, but a decline in function was 
seen again during the reminder of the study period at weeks 4 and 5.  The decline in 
gait function in this experiment as well as those reported by Ngeow et al (2011b) may 
be due to development of some degree of neuropathic pain which prevented animals 
from using their injured paw. Analysis of gait function parameters such as intensity 
and total paw print area is highly sensitive and potentially valuable for assessment of 
nerve regeneration as a measurement of functional recovery of peripheral nerve after 
injury. 
Five weeks following nerve conduit repair and administration of TNF-α antagonist, a 
greater CAP ratio was observed, but was not significant.  In the comparisons between 
the uninjured sham controls and the nerve repair groups, the result showed that the 
CAPs were always smaller after repair. This might have resulted from a reduction in 
the number and/or size of regenerated axons in the distal stump. 
A similar finding was observed following epineurial injection of IL-1 cytokine antagonist 
6 weeks after nerve injury and repair (Chapter 4).  The results did show a better CAP 
ratio, which was not significant, and it is possible that axons had similar regeneration 
rate.  Although the experiment recorded the CAP following nerve injury and repair, it 
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may be possible that the TNF-α antagonist dose was not optimal to enhance 
regeneration of the repaired nerves.  The conduction velocity of all of the repaired 
groups was significantly slower than for the sham uninjured at 5 weeks following nerve 
injury and repair.  In addition, conduction velocities showed reduced propagation of 
electrically evoked action potentials which may be due to axons having regenerated 
at a slow rate.  
A few studies have reported the use of axon tracing to evaluate functional regeneration 
after nerve injury and repair.  Axon tracing assesses sprouting Index (SI), the number 
of individual axons successfully crossed the defect and the level of axon disruption 
across the initial portion of the conduit repair (Harding et al., 2014; Pateman et al., 
2015), which was adopted for this study.   In our experiment sprouting index were high 
at 0.0 mm interval and thereafter began to fall to their lowest values at intervals 4.0 
mm and 4.5 mm, indicating a similar pattern of axonal regeneration through the conduit 
as axons reached the distal nerve end, in both groups.  In mice receiving TNF-α 
antagonist treatment, there was a reduced axon disruption possibly indicating a better 
recovery of nerve function with less scar tissue formation.  In addition, axons 
regenerating through the PCL conduit appeared to have more organized growth as 
opposed to the sterile water group.  These observations possibly related to a reduction 
in scarring.  A similar result to Pateman et al. (2015), their study showed less disrupted 
axon growth following both poly-ethylene glycol (PEG) conduit implantation as 
compared to nerve graft repair.  In addition, their study did not show any difference in 
axon SI or unique axon tracing and they speculated this attributed to the conduit 
biocompatibility and internal structural support between nerve segments.   
It has been proposed that the development of neuropathic pain after nerve injury is 
associated with sensitization of spinal neurones, partly by glial activation and 
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production of pro-inflammatory cytokines which stimulate neurones in the spinal cord, 
and these effects are blocked by pan-glial inhibitors (interleukin-1 receptor antagonist 
and soluble tumour necrosis factor receptor antagonist) that were applied intrathecal 
at the site of spinal cord injury (Sweitzer et al., 2001; Mika et al., 2008; Mika et al., 
2013; Pilat et al., 2015).  These inhibitors were shown to inhibit pain related 
mechanisms through targeting molecules critical for glial cell activation in peripheral 
nerve injury, including c-JUN and p38 MAPK pathways (Sweitzer et al., 2001; Zelenka 
et al., 2005; Kato et al., 2009; Hansen and Malcangio, 2013).   
In our study, epineurial injection of TNF-α antagonist at the time of conduit implantation 
was associated with downregulated glial cells immunoreactivity as well as reduced 
glial cells labelling of their respective markers in the dorsal regions of the spinal cord.  
This was also observed following epineurial injection of TNF-α antagonist and possibly 
related to the synergistic effect of the treatment applied on the immune inflammatory 
response.  However, epineurial injection of IL-1 antagonist did show reduced glial cells 
immunoreactivity in the ventral horns of the spinal cord and it is not clear whether the 
this related to the early effect of treatment or the dose was suboptimal to abolish glial 
cells activation after 6 weeks of nerve injury and repair.  In agreement with others, the 
current observation shows that TNF-α antagonist therapeutic approach interferes in 
the early stages with signals that activate glial cells, and produces long lasting anti-
inflammatory effects with a single injection that possibly suppresses pain related 
mechanisms, thus preventing the development of neuropathic pain.  
6.7 Summary 
Data from this study demonstrated that the use of PCL nerve conduit with 
administration of TNF-α antagonist promoted more organized growth pattern of 
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regenerated axons.  In addition, it showed early improvements in functional recovery 
as well as reduced glial markers in the dorsal spinal horns five weeks after of nerve 
injury and conduit implantation.   
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CHAPTER 7 
General discussion 
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7.1 Introduction  
The aim of this chapter is to discuss the results described in previous sections.  In 
addition, it will also highlight consideration of assessment methods and any potential 
future work.  Finally, this section will draw the conclusion of the key findings from the 
work contained within this thesis. 
7.2 The effect of cytokines therapy on inflammatory response  
Macrophage immunoreactivity in peripheral nerve injury 
The IL-1 antagonist, TNF-α antagonist and the anti-inflammatory cytokine IL-10 
demonstrated variable effects on the abundance of macrophage immunoreactivity 
seven days and six weeks following sciatic nerve injury and repair. 
An epineurial injection of IL-10 and IL-1 cytokine antagonist reduced macrophages 
immunoreactivity at the site of nerve injury and repair which was not significantly 
different when compared to the sham group (see Chapter 3).  In contrast, the 
combination of IL-10 and TNF-α antagonist was associated with an increased 
expression of CD68 macrophage labelling as compared to the sham group, seven 
days following sciatic nerve injury and repair (see chapter 3).    Although this was a 
short term follow up, the effect of combined treatment of IL- 10 and TNF-α antagonist 
was expected to down regulate macrophage immunoreactivity, but this was not 
observed in this experiment.  However, it may be possible that the dose used for the 
combination of IL- 10 and TNF-α antagonist was not optimal to reduce macrophage 
immunoreactivity at the site of nerve injury and repair.   
In Chapter 4 and 5, the results showed that both IL-1 cytokine antagonist and a 
combination of IL-10 and TNF-α antagonist applied at the time of nerve repair 
significantly reduced macrophage immunoreactivity as seen by macrophage labelling, 
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6 weeks following nerve injury and repair (see chapter 4 and 5).  Previous studies 
reported that injection of either IL-1 or TNF-α antagonist contributed to reduction of 
pain related behaviours and subsequent successful functional nerve regeneration 
(Schäfers et al., 2001; Sweitzer et al., 2001; Sommer et al., 2004).  This effect was 
thought to be contributed to by downregulating macrophage immunoreactivity and 
controlling the degree of immune inflammatory response at appropriate time following 
nerve injury and repair.   
There is also clear evidence that the anti-inflammatory cytokine IL-10 regulates the 
production of pro-inflammatory cytokines and the combined treatment of IL-10 and 
TNF-α antagonist possibly exerts a synergistic effect on reducing macrophage 
immunoreactivity (Gaudet et al., 2011; Morris et al., 2014).  Although this was 
opposing to the effect shown at short term follow up, this needs further work to explore 
anti-inflammatory effect of this therapeutic approach by investigating different 
therapeutic dose at different recovery periods of time following nerve repair. 
Glial activation in peripheral nerve injury 
Peripheral injection of IL-1 cytokine antagonist and combination treatment of IL-10 and 
TNF-α antagonist all showed significant reduction in microglial and astrocytes 
activation as well as diminished glial cells labelling of its respective immune marker in 
the dorsal and ventral horns of the spinal cord.  Similar to previous studies, nerve injury 
induced dense activation and phenotypic changes of microglia and astrocytes and 
increased expression of their respective immune markers (Mika et al., 2008; Mika et 
al., 2013, Pilat et al., 2015).  
Six weeks following epineurial administration of IL-1 cytokine antagonist reduced glial 
cell immunoreactivity was seen in the ventral horns, but not in the dorsal horns of the 
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spinal cord (see chapter 4). This may reflect different stages of glial cells activation in 
response to continuous stimulus as a result of nerve injury, and this would need further 
exploring. 
The combined effect of IL-10 and TNF-α antagonist on immune response has not 
previously been explored (see Chapter 5).  However, this therapeutic approach 
possibly exerted beneficial effect by downregulating glial cells reactivity as shown by 
less IBA-1 and GFAP cells labelling in the dorsal horns of the spinal cord.  Previous 
studies have investigated the role of glial cells, microglia and astrocyte, using different 
glial inhibitors (Sweitzer et al., 2001; Mika et al., 2008; Mika et al., 2013).  These 
studies showed that intrathecal administration of glial inhibitors such as interleukin-1 
receptor antagonist and soluble tumour necrosis factor receptor antagonist at the site 
of spinal cord injury diminished pain-related behaviours.  Our experiment first to record 
the effect of peripheral application of combined treatment of IL-10 and TNF-α 
antagonist at the site of nerve injury and repair (see chapter 5).  In agreement with 
these studies, it is possible the effect contributed by downregulating glial cells 
activation and produced long lasting anti-inflammatory effect following peripheral 
nerve injury and repair. 
These findings provide supplementary evidence that the key cytokines molecules of 
IL-1, TNF-α and anti-inflammatory IL-10 influence the regenerative process and 
subsequent functional recovery of injured and repaired peripheral nerves.   
7.3 The effect of cytokines therapy on nerve regeneration 
Electrophysiological analysis 
The electrophysiological recordings did not show improvement in nerve regeneration 
as shown by low compound action potential (CAP) and conduction velocity following 
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epineurial injections of either TNF-α antagonist or IL-1 cytokine antagonist 5 or 6 
weeks after nerve injury and repair (see Chapter 4 and 6).  These measures remained 
low and intraneural scaring at the repair site may have influenced this outcome. It is 
also possible that the dose used in these studies was not optimal to enhance 
regeneration of the repaired nerves. This needs further investigation, including 
different doses at different recording and recovery periods for assessment of nerve 
regeneration.  
There is clear evidence that anti-inflammatory IL-10 cytokine can overcome scar tissue 
formation and this intervention eventually improved functional nerve regeneration by 
significant remodelling of collagen fibres formation.  By considering results from Atkins 
et al., work (2007), a significant correlation was noted between the degree of scarring 
and improvement in CAP ratio which predicted that a low level of scar formation was 
associated with better regeneration of repaired nerves.  The result supports the 
observation following combined epineurial administration of IL-10 and TNF-α 
antagonist at time of nerve repair.  This was possibly associated with low propensity 
for scarring by acting as anti-scarring agents and possibly reduced endogenous 
constrain to regenerating axons.  Certainly, it is possible that scar remodelling 
improved the recovery of nerve action potential propagation which has contributed to 
the difference between the groups at six weeks post injury and repair.  Besides, the 
efficiency of optimal administration of IL-1 and TNF-α antagonist suggest that a single 
dose was useful to suppress the inflammation, but was also associated with some 
improvement in nerve regeneration.  It is seemed likely that the dose of these agents 
was less optimal and may be that an insufficient concentration contributed to the 
outcome. 
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Gait function analysis 
The pattern of recovery of paw prints in the last experiment was consistent with 
previous studies in nerve injuries and repairs described by Ngeow et al. (2011b).   
The recovery of gait function in this experiment showed limited improvement, with the 
TNF-α antagonist group only reaching to 58 % of the preoperative value at week 5 
after nerve repair.  However, epineurial injection of TNF-α antagonist at the time of 
nerve conduit repair did show a significant difference in paw print intensities at the 
earlier time point, particularly at week 2 and in the total paw print area values at week 
3 postoperatively when compared to the sterile water treatment.  In this respect, this 
may have occurred due to early the effect of TNF-α antagonist which possibly 
increased the rate of axon regeneration following nerve injury and repair.  Although, 
the recovery period in our experiment was shorter (5 weeks), assessment of gait 
function using the catwalk system was similar to those seen by Ngeow et al. (2011b) 
and the limited improvements was attributed to the lack of motivation or increased 
anxiety level of the animals due to the development of some degree of neuropathic 
pain following sciatic nerve injury and repair.  Moreover, it has also been claimed that 
the walking speed affect gait parameters in the dynamic and stance phase (Ngeow et 
al., 2011b).  Taken together, these results suggest that the analysis of paw print 
variables using the catwalk system is important and can provide more useful outcome 
measures of functional recovery of sensory and motor nerve fibres.  
Axon tracing 
Axon tracing is based on measuring the sprouting Index, the number of individual 
axons that have crossed the defect and the level of axon disruption across the initial 
portion of the conduit repair.   
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The results only showed a significant difference in the axon count and sprouting index 
that occurred at the start of axon regeneration in mice treated with TNF-α antagonist 
when compared to those treated with sterile water, 5 weeks following nerve injury and 
repair.  However, the lowest sprouting index level was observed at the 0.5 mm interval 
following nerve conduit repair with TNF-α antagonist treatment when compared to the 
sterile water group.  The difference observed may be related to a reduction in scar 
tissue and this could have contributed to the reduced level of axon disruption, but this 
was not confirmed histologically.  The production of scar tissue may be influenced by 
the early effects of the TNF-α antagonist.  Moreover, no further difference was 
observed in the axons proportion as they extended toward the distal segment of the 
repair as shown by the axon tracing either after epineurial injection of TNF-α 
antagonist or sterile water treatment, and this indicates that a low proportion of axons 
crossed the full defect.  In our experiment (see Chapter 6), peripheral application of 
TNF-α antagonist at the time of repair was associated with reduced axon disruption 
when compared to the sterile water treatment and this could indicate a better recovery 
of nerve function with less scar tissue formation.  In a study conducted by Pateman et 
al.  (2015) axon length analysis was used to indicate axonal disruption at the early 
stage of regeneration.  They demonstrated mice that had received poly-ethylene glycol 
(PEG) conduit implantation had less disrupted axon growth when compared to nerve 
graft repair.  
7.4 Methodological consideration 
Several methods have been described in the literature that are considered as objective 
and quantitatively measure the extent of nerve regeneration, and these includes 
electrophysiological recordings, axon tracing, functional gait analysis, and 
immunohistochemistry studies of immune cells activity and their related markers.   
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Besides, these methods allowed for a wide assessment of nerve function and 
assessed variable parameters that could correlate to one another to show 
improvements in nerve function.  
Electrophysiology recordings 
Electrophysiological recordings of evoked nerve action potentials provide an objective 
measures of nerve integrity and this method has been frequently used for assessment 
of nerve regeneration following nerve injuries in preclinical research (Atkins et al., 2007; 
Ngeow et al., 2011a).  Although sensory function is the most studied outcome measure 
in preclinical research, this work recorded evoked CAP following stimulation of 
successfully regenerated fibres across the repair.  The nerve was stimulated on either 
side of the repair site with electrical pulses of maximum recommended intensity that 
provoke a nerve response.  Thereafter, CAP ratio allowed comparisons between the 
groups to reduce interpretation bias of only recording distal segment stimulation.  The 
conduction velocity of regenerated fibres is determined by measuring the latency of 
the early part of CAP of nerve fibres population which is responsible for the majority 
of fast firing response during stimulation of the distal nerve segment. 
Gait analysis 
Assessment of gait dynamics are considered sensitive and quantitatively reliable for 
evaluation of return of both sensory and motor function in rodent following successful 
regeneration of nerve fibres after injury and repair (Deumens et al., 2007; Ngeow et 
al., 2011b).  The method of gait analysis is based on the measurements of paw prints 
obtained during the stance phase in which the hind limb contacts the walkway screen 
glass which is considered sensitive measure of assessment of nerve regeneration.  
However, gait analysis has been disputed because the data obtained cannot be 
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correlated with other outcome measures (Deumens et al., 2007; Ngeow et al., 2011b).  
Additionally, the accuracy of gait analysis has been challenged because the paw print 
parameters are affected by the animals walking speed.  As a result, to reduce 
variability of interpretation, an average values of paw print parameters were taken to 
achieve a representative paw print reading from each experimental group.   
Axon tracing 
This method is considered essential to complement the outcome measures of the 
electrophysiological recordings and gait analysis (Sabatier et al., 2008; Harding et al., 
2014; Pateman et al., 2015).  Although this method is valuable, it is demanding as 
there are species dependent variations in axons numbers from one nerve to another 
due to the inherent variability in anatomical component or axon numbers within the 
nerve trunk.  It has also been criticized as being more time consuming to perform and 
subjective in its interpretation, because no formal functional assessment can be 
conducted (Sabatier et al., 2008; Harding et al., 2014; Pateman et al., 2015).  Although 
this method is still evolving it has potential to reduce inaccuracies associated with 
computerized system analysis.  Besides, this method provides a more rapid 
assessment of results and accurate interpretation of sample morphology which will 
present more reliable and reproducible findings. 
Immunochemistry analysis 
Immunochemistry is considered valuable for the assessment of expression levels of 
immune cells markers at the site of nerve injury and centrally in the spinal cord.  In 
addition, assessment of macrophage immunoreactivity and glial activation can 
contribute to the assessment of nerve recovery and regeneration as these cells and 
their respective markers are upregulated in the injury related response of damaged 
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axons during degeneration and the healing process following peripheral nerve injury 
(Eriksson et al., 1993; Taves et al., 2013).  However, for accurate experimentation of 
primary and secondary antibody labelling appropriate negative controls were 
performed for this work and incorporated into the relevant staining protocol to count 
for variation in results between the experimental groups (Chapter 2; section 2.2.6.1).  
In addition, accurate analysis of sections need appropriate and consistent selection of 
tissues to render the sample more representative in order to reduce bias during 
interpretations. 
7.5 Future perspectives 
Comprehensive investigation of nerve regeneration in peripheral nerve injuries  
Driven by the observed results in this work further study is essential to assess potential 
nerve regeneration following application of different novel cytokines agents.  It is also 
vital to apply different dosage concentration and timings to assess obstacles to 
recovery of nerve function using histomorphometric and functional methods.   
Gait analysis is considered an objective measure and likely to be subject to excess 
variability between gait movement parameters.  However, precise quantification of 
functional loss using several paw print parameters such as percentage of toe spread 
and paw angle to measure functional recovery and to understand adaptive activity 
associated with gait movement, will enable more accurate assessments to monitor 
functional recovery. 
Nerve conduit repair improvement  
Future in vitro and in vivo experiments will be valuable to assess any potential 
improvements in the PCL conduit model as an alternative means for repairing 
damaged peripheral nerves.  It would also sensible to increase the number of 
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experimental subjects along with the use of several outcome measures over different 
recovery periods to fully investigate peripheral nerve regeneration.  The next important 
step is to use different method such as histomorphometric, and immunohistochemistry 
to investigate the comprehensive profile of immune cells activity as well as assess 
recovery of nerve function. 
7.6 Conclusion 
Recovery of peripheral nerve function is limited, and the outcome is usually associated 
with significant morbidity following nerve injury. Hence, novel therapeutic agents, 
including IL-1 antagonist, and TNF-α antagonist and anti-inflammatory IL-10 cytokine 
represent new treatment modalities that have shown considerable promise for 
improving nerve regeneration capacity.  Moreover, combining different therapeutic 
agents to attain complementary molecular targeting approaches following suitable 
repair strategies in peripheral nerve injuries has shown some promise.  This line of 
experimental research could provide new insight into the clinical benefit through the 
development of successful therapeutic strategies to prevent neuropathic pain 
development, enhance nerve fibre regeneration and improve functional recovery 
following peripheral nerve injury. 
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Appendices 
The following appendices contains laboratories related techniques including slide 
preparation, tissue cutting and immunostaining technique which were used in this 
research experiments.   
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APPENDIX A 
Preparation of Poly-D-lycine hydrobromide (P1149, 10mg vial PDL, SIGMA) slides 
used in the experiments. 
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APPENDIX B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation of gelatine coated slides used in free-floating sections technique. 
268 
 
APPENDIX C 
Preparations of most commonly used solutions in the experiments. 
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APPENDIX D 
Primary and secondary antibodies staining protocols for rat sciatic nerve tissues 
(three slides per animal) 
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APPENDIX E 
Primary and secondary antibodies staining protocols for mouse sciatic nerve tissues 
(three slides per animal). 
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APPENDIX F 
Microglial labelling protocols for mouse spinal cords (six spinal cord tissues per 
animal). 
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APPENDIX G 
Astrocytes labelling protocols for mouse spinal cords (six spinal cord tissues per 
animal). 
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